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ABSTRACT OF DISSERTATION 
 
 
 
DEVELOPMENT AND PRECLINICAL EVALUATION OF LONG-LASTING 
COCAINE HYDROLASES FOR COCAINE OVERDOSE AND COCAINE USE 
DISORDER TREATMENT 
 
Cocaine is a plant-based illicit drug commonly involved in substance use disorder. 
Although cocaine overdose and cocaine use disorders cause adverse health consequences 
to individuals and the economic burden on their family and society, there are no FDA (Food 
and Drug Administration) approved medications for treatment. Recently, it has been 
recognized that delivery of cocaine hydrolase (CocH) is a promising therapeutic strategy. 
Human butyrylcholinesterase (hBChE), the primary enzyme involved in cocaine 
metabolism in human, have advantages over other candidates for the development of CocH. 
Previous studies in our laboratory have designed and characterized hBChE mutants that 
have ~4,000-fold improved catalytic efficiency against naturally occurring (-)-cocaine as 
compared to the wild-type hBChE. Besides the catalytic efficiency, the biological half-life 
is another essential factor that influences the desired therapeutic value in the long-term 
treatment of cocaine use disorder. In order to provide prolonged effects to reduce 
administration frequency in clinical use, efforts have been made to increase the retention 
time of CocHs in blood circulation by fusing CocHs with other thermostable proteins or 
their mutants, including human serum albumin (Albu) or the Fc region of the human IgG 
(Fc). 
In this dissertation, we demonstrated the clinical potential and the benefits of long-
lasting CocHs for cocaine overdose treatment. We used rodent models to show the ability 
of AlbuCocH1 to block or reverse manifestations of toxic effects of cocaine. In addition, a 
concomitant LC-MS/MS-based analysis was conducted to investigate the pharmacokinetic 
profile of a lethal dose of cocaine with the presence of AlbuCocH1. These experimental 
data demonstrated AlbuCocH1 as an effective cocaine detoxification agent by accelerating 
the metabolism of cocaine. 
In order to examine the potential therapeutic value of Fc-fused CocHs in the 
treatment of cocaine use disorder, we conducted a series of behavioral experiments in rats 
to evaluate the effectiveness and duration of Fc-fused CocHs in blocking or attenuating 
cocaine-induced psychostimulant and discriminative stimulus effects. In addition, the 
 
 
 
intravenous self-administration model was used to investigate the long-term effectiveness 
of Fc-fused CocHs in blocking or attenuating the reinforcing effects of cocaine. It has been 
shown that a single dose of E30-6-Fc (3 mg/kg) was able to effectively alter the cocaine 
dose-response curve and attenuate the reinforcing efficacy of cocaine for at least a month 
in both male and female rats. 
In summary, AlbuCocH1 (TV-1380), which failed to meet the primary efficacy 
endpoint in clinical trials for facilitating abstinence in cocaine-dependent subjects with a 
weekly dosing schedule (due to the short biological half-life), is more suitable to be 
developed as a cocaine detoxification agent. On the contrary, the newly designed Fc-fused 
CocH (e.g. CocH3-Fc, E30-6-Fc) with higher catalytic efficiency and longer biological 
half-life will be beneficial for long-term abstinence management in cocaine-dependent 
individuals. 
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1. Chapter One: Introduction 
1.1. Cocaine 
Cocaine is a natural alkaloid abstracted from the leaves of the Erythoxylum coca 
plant (E. coca), a bush that grows in the mountain region of Latin America. Cocaine is a 
powerful psychostimulant and highly addictive drug. Once consumed by humans, cocaine 
interacts with multiple crucial proteins, especially monoamine reuptake transporters, to 
induce a series of physiological and psychotic effects, which would eventually lead to 
intoxication and chronic abuse disorder. Cocaine abuse is a worldwide social and public 
health problem. However, there are no FDA approved medications for the treatment so far.   
In this chapter, the pharmacokinetic and pharmacodynamics properties of cocaine, 
the acute and chronic toxicity associated with cocaine use, and the medications under 
development for cocaine overdose and cocaine use disorder treatment will be reviewed.  
1.1.1. History of cultural use and medical use 
The coca leaf has been used, chewed and sucked, for over a millennium since 
ancient Indian discovered its origin and superpower. Initially, chewing of coca had been 
reserved for the noble class and was usually associated with religious activity. Later, its 
use became more widespread. Indians used it as a food substitute to overcome hunger, a 
tool to stay warm, and a medicine to treat disease by shaman. In 16th century, when the 
Spanish conquered the Incas, coca use was banned initially. However, Spaniards soon 
found coca kept their Indian slaves worked harder in the mines. They abolished the ban 
and began systematic cultivation of the plant (1). Coca was not able to become popular in 
the Europe at that time, since its effects in the dried leaves decayed over long-term ocean 
voyage, as well as the coca plant was difficult to grow in the European climate (2). 
Cocaine, the major chemical constituent of the coca leaf, was isolated in the 1850s 
by the efforts of German chemists - Friedrich Gaedcke and Albert Niemann. Over the next 
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two to three decades, people believed cocaine had powerful positive effects. Sigmund 
Freud, a Viennese neurologist and the founder of psychoanalysis, was no doubt an 
enthusiastic supporter of cocaine. In 1884, he published a medical analysis of cocaine – 
“Uber Coca” (3). He identified cocaine as a central nervous system stimulant and an agent 
that leads to euphoria, using himself as subject. He also advocated the therapeutic value of 
cocaine, including in the treatment of morphine addiction. However, a number of other 
adverse consequences were observed soon. Karl Koller, an ophthalmologist, explored 
cocaine as a local anesthetic in eye surgery (3). This led to the only pharmaceutical use of 
cocaine remaining to today. 
At the same time, cocaine was also popular in the United States. It has been added 
as an ingredient in Coca Cola and many patent medicines. Physicians prescribed coca and 
cocaine products for a variety of illnesses. It was not until the early 20th century that people 
realized the disastrous effects of cocaine. In 1914, 46 out of 48 states had laws restricting 
the distribution or sale of coca and cocaine. Currently, cocaine is listed as Schedule II as a 
drug with an acceptable medical use, but with a high potential for abuse as well (4). A 4% 
cocaine chloride topical solution is indicated for the induction of local anesthesia of the 
mucous membranes when performing diagnostic procedures and surgeries on or through 
the nasal cavities in adults (5).  
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Figure 1-1. Timeline of major discoveries and policy changes related to cocaine. 
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1.1.2. Mechanism of action 
Cocaine exerts its major physiological functions through inhibition of monoamine 
reuptake transporters, including dopamine reuptake transporter (DAT), serotonin reuptake 
transporter (SERT), and norepinephrine reuptake transporter (NET). Reuptake transporters 
are essential membrane proteins to recycle and maintain a low extracellular concentration 
of the neurotransmitters in the nervous system. By blocking reuptake transporters, cocaine 
causes accumulation of neurotransmitters in the synaptic cleft, resulting in prolonged 
activation of postsynaptic receptors. In vivo studies have shown that cocaine has inhibition 
constants (Ki values) of 0.14, 0.64, and 1.6 M at the SERT, DAT, and NET, respectively 
(6).  
Cocaine also binds to two classes of neurotransmitter receptors, including 
muscarinic acetylcholine receptors (mAChRs) and sigma receptors. In rats, cocaine inhibits 
mAChRs in heart and brain with a higher affinity at M2 receptors than at M1 receptors (7).  
In addition, evidence shows that cocaine also binds to human mAChRs (8).  Sigma 
receptors are expressed in numerous regions in the brain and suggested to contribute to the 
delusions and psychoses induced by certain drugs (9). It has been found that cocaine binds 
to sigma receptors with a Ki value (6.7 ± 0.3 µM) compatible with a blood concentration 
reported to produce psychosis in human volunteers (10). It has also been proposed that the 
psychotomimetic effects of cocaine may be partially due to its interaction with sigma 
receptors (10). 
In addition, cocaine binds to several voltage-gated ion channels, which contributes 
to its local anesthetic effects. Although there are voltage gated ion channels in nerve and 
cardiac tissue, this interaction is more likely to play a role in the cardiotoxicity of cocaine 
rather than its effects in the CNS (11). Ex vivo studies, using isolated cardiac myocytes, 
have shown that cocaine decreased the inward sodium current by binding with inactivated 
state of sodium channels (12), decreased the outward potassium current by binding to 
cardiac potassium rectifier channels (13), and increased the probability and duration of L-
type calcium channel opening (14). 
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1.1.3. Pharmacokinetics of cocaine 
There are basically two chemical forms of cocaine: base (“crack”) or salt (“cocaine 
hydrochloride”). They contain the same cocaine molecule but differ in physical properties. 
Cocaine base is insoluble in water but melts at 98C, which allows to be smoked (SM). 
Cocaine salt is highly water soluble, which is readily for intravenous injection (IV) or 
insufflation (INS) snorting (15). 
1.1.3.1. Absorption and distribution 
Cocaine is absorbed through the mucous membranes of the nose and mouth, and 
respiratory tracts. Due to the first-pass metabolism, the bioavailability of cocaine after oral 
intake (PO) is only 30-50% in human (16). The bioavailability of cocaine is higher when 
administered via other routes with approximately 90% with SM and 80% with INS (17). 
The administration route of cocaine has an impact on the onset of its action as well. IV and 
SM produce effects almost instantly (within 1 min), whereas INS or PO result in slower 
onset of 5 min or up to 30 min, respectively (17).  
Cocaine (pKa = 8.6) is mainly staying its ionized form in the physiological PH (7.4). 
It distributes to most body organs, including the heart, kidney, adrenals, and liver. Most 
importantly, the high solubility of cocaine in lipids ensures that it crosses the blood brain 
barrier (BBB) to reach the central nervous system (18). PET study indicates that the peak 
concentration of cocaine in basal ganglia after administration of 40 mg cocaine was about 
10 M, which is more than 10-fold higher than peak concentration in the plasma (18, 19) .  
1.1.3.2. Metabolism 
Since cocaine is a diester of the base of ecognine, the major cocaine metabolism 
pathway is enzymatic hydrolysis at either benzoyl ester or methyl ester by the action of 
blood and liver esterases. The metabolic pathways and major metabolites are displayed in 
Figure 1-2. In human, butylcholinesterase (BChE) and liver carboxylesterase 2 (hCE-2) 
catalyze cocaine hydrolysis at the benzoyl ester group (20), producing benzoic acid and 
ecgonine methyl ester (EME).  Liver carboxylesterase 1 (hCE1) catalyzes cocaine 
hydrolysis at methyl ester, producing benzoylecognine (BE) (21). BE and EME are the 
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major metabolites of cocaine under physiological condition in human. Both of them lack 
the psychoactive effects of cocaine. They are not expected to cross BBB (22) and are 
inactive at dopamine transporter (23). 
In addition, a small portion of cocaine undergoes N-demethylation by hepatic P450 
to produce norcocaine, which is an active metabolite of cocaine. Norcocaine binds to 
dopamine reuptake transporter (23) and can readily enter the primate brain (22). However, 
PET study with carbon-11 labeled cocaine revealed that norcocaine does not contribute to 
the subjective effect experienced immediately after IV administration of pharmacological 
active dose of cocaine (22, 24). The formation of norcocaine attributes to the hepatotoxicity 
of cocaine (25).  
In human, the plasma clearance half-life (T1/2) of cocaine is dose dependent (1 - 3 
mg/kg, IV),  ranging from 40 min to 90 min (26). The same study has found that the initial 
plasma concentration of cocaine after 1 mg/kg IV administration is around 550 ng/ml (~ 
1.81 M). In rats, the T1/2 of cocaine is relatively shorter. The T1/2 of cocaine is overall 
close to 13.0  1.5 min with the dose range from 0.5 mg/kg to 3 mg/kg (IV) (27). The same 
study has found that the initial plasma concentration of cocaine after 1 mg/kg IV 
administration is 755  119 ng/ml (2.49  0.39 M). 
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Figure 1-2. Metabolism pathways and major metabolites of cocaine (28).  
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1.1.3.3. Excretion  
Studies showed that only ~1% of the cocaine dose might be excreted unchanged in 
urine. The majority urinary metabolites are BZE (25-40%) and EME (15-25%) (29). 
According to literature, up to 65% of the dose is recoverable in urine by 3 days after cocaine 
use. Therefore, urine is a good specimen to monitor prior cocaine exposure.  
1.2. Cocaine intoxication 
1.2.1. Toxicity of cocaine 
The major toxic effects associated with acute and chronic use of cocaine are 
neurotoxicity and cardiovascular toxicity.  The major mechanisms underlying these toxic 
effects are reviewed below. 
1.2.1.1. Neurotoxicity 
Cocaine abusers present a serial of neurological and cognitive impairments, 
including deficits in cognition, loss of control, impulsiveness, etc. In addition, cocaine 
addicts often suffer from neurological complications, like seizures, cerebral ischemia, 
cerebral hemorrhages and cerebral atrophy (30). The mechanism of neurotoxicity induced 
by acute and chronic use of cocaine is complex and involves various cellular and molecular 
pathways. The major reasons leading to neuronal death includes oxidative stress, 
excitotoxicity, and apoptosis.   
1.2.1.1.1. Oxidative stress  
Oxidative stress describes the unbalance between the production of reactive oxygen 
and nitrogen species (ROS and RNS) and the response of physiological antioxidant 
mechanisms. Oxidative stress plays an important role in the toxic effects of various abuse 
drugs, including cocaine. Cocaine use leads to dysregulation of brain dopaminergic system, 
resulting in increased extracellular DA concentration. Excessive concentration of DA could 
be neurotoxic due to the formation ROS (e.g. H2O2, O2-, OH, and NO3-) during its 
metabolism through auto-oxidation or monoamine oxidase (MAO) action (30). It has been 
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shown that cocaine exposure led to an increase in H2O2 level in the prefrontal cortex (PFC) 
and striatum of rats (31). On the other hand, studies demonstrated that cocaine exposure 
induced changes in activity of major antioxidant enzymes, including catalase, glutathione 
peroxidase, and superoxide dismutase in the cortex and striatum of animals (32). The levels 
of antioxidants, like glutathione and reduced vitamin E (33), were also reported to be 
downregulated upon exposure to cocaine. If the antioxidant system is not able to deal with 
the increased level of ROS, cell death will occur in dopaminergic cells and surrounding 
cells due to oxidation of important cellular macromolecules such as amino acids, 
phospholipids, and nucleic acids (34).  
1.2.1.1.2. Excitotoxicity 
Excitotoxicity means cell death caused by toxic effects of excitatory 
neurotransmitters. Cocaine use results in an increase of extracellular glutamate 
concentration in several brain regions, like the ventral tegmental area (VTA), nucleus 
accumbens (NAc), PFC, and striatum (35). Glutamate triggers the activation of NMDA 
receptors, resulting in an increases in intracellular Ca2+ concentrations. These increases 
lead to activation of Ca2+ dependent enzyme that causes degradation of proteins, 
phospholipids, and nucleic acids, eventually, resulting in neuronal death (36).   
1.2.1.1.3. Apoptosis 
It has been demonstrated that the abused substances, including cocaine, could 
induce neuronal cell death by apoptosis. There are evidences indicating that the cocaine-
induced apoptosis may be mediated by oxidative stress (37) or mitochondrial dysfunction. 
In vivo studies have shown that cocaine could cause biochemical features of apoptosis, like 
activation of caspases, loss of mitochondrial potential, and cytochrome C release (38).  
1.2.1.2. Cardiovascular toxicity 
Cardiac toxicity is the most frequent complication of cocaine use. A large number 
of cardiovascular diseases have been associated with acute or chronic cocaine use, 
including hypertension, acute myocardial ischemia and infarction, cardiac dysrhythmias 
and endocarditis, and so on (39, 40). A large percentage of sudden deaths associated with 
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cocaine use are from cardiac causes. The toxic effects of cocaine on the heart and vascular 
system are attributed to two major pharmacological properties of cocaine.  
1.2.1.2.1. Sympathomimetic effects 
The primary pharmacological property of cocaine is to block the reuptake of 
catecholamines. The accumulation of catecholamines leads to sympathomimetic 
stimulation not only of the central nervous system (CNS) but also of the heart muscle and 
the vascular smooth muscle (41). The increased norepinephrine levels in vascular smooth 
muscle stimulates -adrenergic receptors, resulting in a vasoconstrictor response (41). 
Experiments using preparations without sympathetic innervation show that cocaine may 
be able to induce vasoconstriction via directly increasing calcium flux into smooth muscle 
cells (42). Vasoconstriction eventually leads to an increase in blood pressure and coronary 
vascular resistance. On the other hand, accumulation of catecholamines in the myocardium 
stimulate the -adrenergic receptors, resulting in an increase in heart rate, an increase in 
cardiac automaticity, and possibly other tachyarrhythmias (41). Potentiation of -
adrenergic receptors also causes increases in cAMP level and activation of cAMP-
dependent protein kinase, resulting in increases in calcium levels in the myocardial cells 
(43). Activation of -adrenergic receptors in the heart by cocaine may also contribute to 
higher calcium levels within myocardium (43).  
1.2.1.2.2. Local anesthetic effects 
As mentioned above, cocaine also binds to and blocks several kinds of ion channels. 
Evidence shows that cocaine blocks the fast sodium channel in the myocardium, resulting 
in a depression of depolarization and slowing of conduction velocity. This effect leads to 
an abnormal ECG profile similar to that caused by other type I antiarrhythmic agents (44). 
This local anesthetic and membrane-stabilizing property is responsible for a negative 
inotropic effect of cocaine (41).  
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1.2.2. Prevalence of cocaine overdose 
Cocaine remains among the most common illicit drug associated with visits to 
United States hospital emergency departments (ED). Based on data from the Substance 
Abuse and Mental Health Service Administration (SAMHSA) (45), during 2011, 
approximate half of drug misuse or abuse ED visits involved illicit drugs (1.25 million out 
of 2.5 million). Although the majority (56.3%) of illicit drug ED visits involved multiple 
drugs, cocaine is one of the most commonly involved drugs, with 505,224 ED visits 
(40.3%).  
According to the information collected by National Center for Health Statistics 
(NCHS) at the Center for Disease Control and Prevention (46), among the more than 
64,000 drug overdose deaths estimated in 2016, more than 10,000 overdose deaths 
involved cocaine. From the lowest number in 2010 to 2015, there’s been a 1.6-fold increase 
in the total number of deaths involving cocaine (47). 
1.2.3. Current interventions used in the emergence departments 
The first step management of cocaine overdose in the ED includes physical cooling 
since the toxic effects of cocaine are able to raise core temperature and lead to life-
threatening hyperthermia (48). Medications commonly used following cooling aim to 
reduce the effects of cocaine in the CNS and cardiovascular system (49). All of the 
treatments are only able to reduce/reverse the symptoms caused by cocaine while cocaine 
still existing in the patient’s body.  
1.2.3.1. Benzodiazepines and other GABA-active agents 
Benzodiazepine receptor agonists such as lorazepam, diazepam, and midazolam 
and gamma-aminobutyric acid (GABA) reuptake inhibitors, such as tiagabine, are 
commonly used in the EDs to enhance the inhibitory effects of GABA (49). This type of 
medication leads to sedation and centrally mediated decrease in sympathetic activity. The 
potential adverse effects include over-sedation and respiratory depression associated with 
large and repeated doses (50).  
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1.2.3.2. Calcium channel blocker 
Several classes of calcium channel blockers, including dihydropyridine, 
phenylalkylamine, and benzothiazepine, have been used to reverse cocaine-induced 
increases in systemic vascular resistance and arterial pressure, as well as frequency of 
coronary vasospasm (49). Potential adverse effects are greatest with the dihydropyridine 
agents such as isradipine, nifedipine, nimodipine, and amlodipine since their actions on 
vasodilation and hypotension can lead to reflex tachycardia (51). 
1.2.3.3. Nitric oxide-mediated vasodilators 
Nitric-oxide mediated vasodilators, such as nitroglycerin and nitroprusside, are also 
important agents in treatment of cocaine-associated hypertension, coronary artery 
vasospasm, and chest pain (49). However, these agents may cause hypotension. 
1.2.3.4. Beta-adrenergic receptor and beta/alpha- adrenergic receptor antagonists 
Non-selective 1/2 antagonist, like phentolamine, is recommended as an initial 
treatment for persistent hypertension form cocaine (52). Due to the hyperadrenergic 
symptoms associated with cocaine, non-selective 1/2 antagonist, like propanol, are 
commonly considered to resolve this situation (49). In 1985, a phenomenon of “unopposed 
-stimulation” was reported, showing selective blocking of  receptors may cause a 
paradoxical hypertension in cocaine-positive patient (53). However, reports on large 
number of patients treated with  antagonist after cocaine exposure generally showed 
neutral or beneficial effects on cardiovascular outcomes (40).  Mixed 1/2/1 antagonist, 
like carvedilol and labetalol, also showed beneficial results in studies on their effects on 
cardiovascular symptoms caused by cocaine (49). 
1.3. Cocaine use disorder 
In the DSM-5(54), psychiatric diagnoses of cocaine abuse and cocaine dependence 
are replaced by one diagnosis – cocaine use disorder (CUD). Cocaine dependence is 
approximately comparable to a moderate to severe subtype of CUD, whereas, cocaine 
abuse is equivalent to the mild subtype. 
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1.3.1. Diagnosis and epidemiology 
According to the World Drug Report 2017 (55), cocaine use in terms of annual 
prevalence has remained stable in recent years on a global level, at around 0.4 percent of 
population aged 15-64 years. It is estimated that there are nearly 17 million past-year user 
of cocaine worldwide, with high annual prevalence rates in North America (1.8%), Oceania 
(1.5%), Western and Central Europe (1.1%). The largest number of cocaine user worldwide 
was found in North America (33% of the global total), followed by Western and Central 
Europe (20%) and South America, together with the Caribbean and Central America (17%) 
(55). 
Cocaine use disorder is diagnosed when someone experiences clinically significant 
impairment caused by the recurrent use of cocaine, including health problems, physical 
withdrawal, persistent or increasing use, and failure to meet major responsibilities at work, 
school, or home (15). According to the 2016 National Survey on Drug Use and Health 
(NSDUH) (56), in 2016, the estimate of about 1.9 million people aged 12 or older who 
were current users of cocaine included about 432,000 current users of crack. NSDUH 
respondents who used cocaine or crack in the past 12 months were categorized as having a 
cocaine use disorder if they met the DSM-IV criteria for either dependence or abuse for 
cocaine. About 867,000 people aged 12 or older in 2016 had a cocaine use disorder in the 
past year. This number of people represents 0.3 % of the population aged 12 or older. The 
percentage of the population aged 12 or older with a cocaine use disorder remained stable 
between 2010 and 2016. However, the percentage in 2016 was lower than the percentages 
in 2002 to 2009.  
1.3.2. Neurology of cocaine use disorder 
Serials of reviews published by Dr. Koob and Dr. Volkow have demonstrated the 
brain regions and neurocircuits involved in different stages of substance use disorders using 
evidence from animal models and human imaging studies (57-60). Neuroadaptive changes 
induced by chronic cocaine use in these brain circuits responsible for reward, memory and 
learning, emotion, motivation, and executive function are underlying the transition from 
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recreational use to compulsive cocaine use disorder (60). A better understanding of these 
fundamental mechanisms shed light on the discovery and development of medicines for 
cocaine use disorder. 
1.3.2.1.1. Reward circuit – VTA and striatum  
The initial reward (reinforcing) effect of cocaine is mediated by its action in the 
mesolimbic dopamine pathway, which is composed of dopaminergic neurons located in 
the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) in ventral 
striatum. Most neurons (up to 95%) in the striatum are GABAergic medium spiny neurons 
(MSN), typically segregated into those expressing D1 dopamine receptors (D1R) and those 
expressing D2 dopamine receptors (D2R) (61). This circuit plays important roles in 
processing the reward-related stimuli, including natural rewards (e.g. food and sex) and 
drugs of abuse (62).  
A human imaging study demonstrated that intoxicating doses of cocaine increase 
the level of dopamine in the ventral striatum and this is associated with the subjective effect 
of cocaine (60). This fast and steep increase in dopamine level mimics or even exceeds the 
dopamine changes induced by the phasic dopamine cell firing (fast burst firing > 30 Hz) 
associated with natural reward at the normal condition (63). Studies further showed that 
the activation of low-affinity D1R by the DA increase from phasic firing is necessary to 
produce the reinforcing (reward) effect (64), whereas, activation of D2R alone by DA 
release from tonic firing is not sufficient (65).  
It has been found in human imaging studies that the subjects with a history of drug 
abuse have long-lasting decreases in the numbers of D2R compared with non-drug users 
(66). Moreover, cocaine abusers show reduced DA release in response to intravenous 
methylphenidate injection, indicating decreased DA activity (67). These changes are 
proposed to be reasons for anhedonia reported by addicted individuals (60). 
Animal studies enable us to learn the adaptive changes in a more detailed level. It 
has been shown that one exposure to cocaine induced long-term potentiation (LTP) of 
AMPA-mediated currents at excitatory synapses onto dopamine cells in the VTA for at 
least 5 days (68). Later, it was found that self-administration of cocaine, but not passive 
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cocaine infusions, produced a persistent potentiation of VTA excitatory synapses, which 
was resistant to behavioral extinction and was present after 3 months abstinence (69). 
Using whole-cell synaptic physiology in NAc brain slices, Kourrich et al. demonstrated a 
progression of bidirectional changes in glutamatergic synaptic strength after repeated in 
vivo exposure to cocaine. NAc neurons from cocaine-experienced mice first developed a 
robust potentiation of AMPA-mediated synaptic transmission during a protracted drug-free 
period. A single re-exposure to cocaine during extended withdrawal became a potent 
stimulus for synaptic depression, abruptly reversing the initial potentiation (70). Additional 
evidence indicated dysregulated glutamate transmission in the NAc following chronic 
cocaine exposure and during withdrawal (71, 72), an effect is hypothesized to lead to a 
drive to engage in drug-seeking (73).  
There is evidence demonstrating the gradual engagement of dorsal striatum along 
the development of habitual and compulsive cocaine use (57). Microdialysis studies have 
shown that prolonged cocaine-seeking increased dopamine release in the dorsal striatum 
but not ventral striatum (74). In addition, disconnection of the ventral striatum from dorsal 
striatum led to deficits in rats with compulsive intake but not in rats that recently acquired 
cocaine self-administration under the second-order schedule (75).  
Overall, based animal studies, the neuroadaptive changes in the mesolimbic 
pathway begins with one administration of the drug, develops into LTP first in the VTA 
then NAc, and via feedback loops subsequently engages the dorsal striatum (57).  
1.3.2.1.2. Memory and learning – Hippocampus 
The connection between addiction and learning/memory is based on the fact that 
an environment, a person, or a cue associated with previous experience of cocaine use can 
trigger an intense desire for cocaine and, thereafter, induce relapse (60). Declarative 
memory, which is mediated by the hippocampus and related areas, is believed to be 
involved in learning and linking the affective conditions or circumstances with drug-taking 
experience (57).  Human studies with PET and fMRI have revealed that regions linked with 
memory are activated during acute cocaine intoxication (76), and cue-elicited cocaine 
craving (77). In addition, animal studies demonstrated that excitotoxic lesion of ventral 
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subiculum of the hippocampus caused moderately impaired acquisition of cocaine self-
administration in rats (78). There are also evidences indicating the involvement of a 
dysregulated hippocampus in the transition to cocaine addiction. In one animal study, rats 
allowed extended access, but not limited access, to cocaine showed impaired object 
recognition, which is sensitive to hippocampal function (79).   
1.3.2.1.3. Impulsivity and executive function – Prefrontal cortex 
The prefrontal cortex (PFC), including anterior cingulate (ACC), orbitofrontal 
cortex (OFC), and dorsolateral prefrontal cortex, plays important roles in executive 
function and motivation driven behavior. It has projections into the motor and sensory 
cortex as well as to subcortical areas including striatum and amygdala and VTA. It is 
widely believed that the prefrontal cortical dysfunction is crucial to the addiction process 
(80). As demonstrated in human studies and clinical observations, chronic drug users, 
including cocaine addicts, always show augmented impulsivity, deficits in executive 
function and impairment inhibitory control (57, 60).  
Moreover, a large body of evidence implied that the malfunction of PFC plays an 
important role in relapse. It has been found in human imaging studies that the OFC appears 
to be hypoactive in the detoxified cocaine abuser (tested during withdrawal) (81) and this 
is associated with the reductions in striatal D2R (82). In addition, activation of OFC has 
been reported during intoxication in drug addicts, but not native subjects, and the level of 
activation predicted the intensity of drug-induced craving (83). Based on this, it has been 
hypothesized that drug or drug-associated cue reactivates OFC during withdrawal, 
resulting in compulsive drug taking (60). Evidences from rodent studies also suggests that 
drug and cue-induced reinstatements are mediated by glutamate projection that links the 
PFC to the NAc (58, 84).  
1.3.2.1.4. Emotion – Extended amygdala 
One remarkable feature of cocaine addiction is the presence of emotional or 
motivational withdrawal syndrome, including states of irritability, dysphoria and stress, 
when the rewarding effects of cocaine wear off (85). This state is not only attributed to the 
loss of function in the brain reward system, but also the activation of brain stress system in 
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extended amygdala. It is a region composed of several basal forebrain structures, including 
the bed nucleus of the stria terminalis (BNST), the central nucleus of the amygdala (CeA), 
and a transition zone in the medial part of the nucleus accumbens (e.g., shell) (86).  
Both the hypothalamic-pituitary-adrenal (HPA) axis and brain stress system 
mediated by corticotropin-releasing factor (CRF) are dysregulated by the chronic 
administration of cocaine (58). During withdrawal, elements of brain stress systems, such 
as CRF, norepinephrine, dynorphin, hypocretin, and substance P are elevated, producing 
aversive or stress-like states (87). Meanwhile, elements involved in brain anti-stress 
systems, such as neuropeptide Y, nociception, and endocannabinoids, are downregulated 
(87). It has been shown in a rodent self-administration model that CRF antagonists 
selectively blocked the increased cocaine intake with extended access (88). 
1.3.3. Preclinical models to evaluate medications for cocaine use disorder 
Animal models are useful to study the physiological effects and abuse associated 
properties of cocaine. They are also widely used to evaluate medications to treat cocaine 
use disorder. Locomotor activity tests and drug discrimination tests are commonly used as 
high throughput methods to screen candidate agents. Whereas, self-administration, as a 
direct method measuring the reinforcing effects of cocaine, serves as a gold standard to 
assess the potential therapeutic value of promising agents. 
1.3.3.1. Locomotor activity 
Cocaine as a psychostimulant, when entering the brain, could cause increased 
extracellular levels of monoamines by blocking monoamine reuptake transporters. One 
remarkable physiological consequence in rodents is elevated psychomotor behaviors. 
Moreover, repeated exposure to such psychostimulants leads to a progressive and enduring 
enhancement in the motor stimulant effect elicited by a subsequent drug challenge, which 
is called behavioral sensitization. This experiment has been proposed to model the drug-
induced plastic changes which underlie the transition to drug addiction (89). However, 
assessment of cocaine-induced locomotor activity after cocaine self-administration training 
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showed that extended access to cocaine fails to produce locomotor sensitization (90) but 
does produce a sensitized stereotyped behavior response (91).  
1.3.3.2. Drug discrimination 
Drug discrimination (DD) techniques have been widely used to classify and 
characterize the interoceptive effects of abused drugs. It can be viewed as analogues to the 
measurement of the subjective effects induced by drugs in humans (92). In this paradigm, 
pressing one lever (e.g. left) is reinforced when the training drug is injected before the 
session, while responding on the other lever (e.g. right) is reinforced when vehicle is 
injected. During test session, lever choice reveals whether the rat perceives the test 
compound as training drug-like or vehicle-like (92).  
Based on the hypothesis that the ability to perceive and identify the particular 
subjective effects of drugs and their withdrawal syndromes promotes drug-seeking 
behaviors (93), it is believed that attenuation of such effects might serve as a useful 
indicator of therapeutically beneficial actions during preclinical evaluation of candidate 
medications for drug addiction treatment (94). Naltrexone, which is an FDA-approved 
medication for management of opioid (and alcohol) abuse and addiction, has been well 
characterized in preclinical drug discrimination studies and approved to be effective for 
modulating the subjective effects of abused opioids (95, 96).  
The discriminative stimulus effects of cocaine have been comprehensively studied. 
It has been found that this effect of cocaine can be fully substituted by other indirectly 
acting dopamine receptor agonists (e.g. methamphetamine, methylphenidate) (97), 
partially substituted by dopamine D1R and D2R receptor agonists, and surmountably 
antagonized by D1R and D2R blockers (97, 98). 
1.3.3.3. Self-administration 
Drug intravenous self-administration (IVSA) in laboratory animals has repeatedly 
proven to be a reliable model and direct measurement of the reinforcing effects of drugs 
with substantial predictive validity. It has been widely used in preclinical evaluation of 
pharmacotherapies for the treatment of drug abuse (99). Modifications of this model could 
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be used to directly test the reinforcing properties of the drug and may be linked to different 
symptoms associated with addiction as described in DSM-V. 
1.3.3.3.1. Maintenance 
Preclinical evaluation of anti-addiction treatment is based in part on the assumption 
that an effective treatment medication should be able to make the abused drug more like 
saline or a lower dose by antagonizing its reinforcing properties (99). However, cocaine 
self-administration is featured by an inverted U-shaped dose-response curve relating unit 
dose (dose per infusion) to number of infusions per session (or response rate) (100). 
Reduced reinforcing effects may not be manifested as decrease in self-administration. The 
results would be difficult to interpret, if only a single dose is tested. Therefore, it is always 
important to assess the dose-response curve (DRC) under a fixed-ratio schedule. A shift 
(e.g, right, left, up, down) in the DRC for a drug of abuse indicates change in the efficacy 
of reinforcing effects of the drug.   
1.3.3.3.2. Escalation 
The transition from causal to compulsive drug consumption is critical to the 
development of addiction. An extended access paradigm has been developed to model this 
feature of drug addiction (101, 102). In this model, rats are trained to self-administer 
cocaine initially on a FR1 schedule across daily one-hour sessions. After stable responding 
is reached, they are assigned to two groups with differential cocaine access. Rats in long 
access group (LgA) are allowed to self-administer cocaine daily in a six-hour session, 
whereas rats in short access group (ShA) are maintained in one-hour sessions (101). The 
LgA rats exhibit a gradual escalation in cocaine intake and the elevated intake usually 
persists later when short-access is resumed. 
1.3.3.3.3. Motivation 
Progressive ratio (PR) schedules are been used to evaluate the reinforcing efficacy 
of a drug (103), as well as the motivation to obtain drug by rats via self-administration. In 
this model, the number of responses required to receive one infusion of drug is increased 
progressively within the self-administration session until responses cease. A “breaking 
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point” could be determined as the final ratio completed, which presumably reflects the 
maximal effort that a rat will expend to get a drug infusion (103). 
1.3.3.3.4. Reinstatement 
The most difficult clinical problem in the treatment of human drug addiction is high 
rates of relapse, which is defined as the resumption of drug use after a period of abstinence 
(104, 105). Clinical and laboratory studies have demonstrated that, in addition to 
withdrawal symptoms, exposure to the abused drug, stress, and drug-associated cue can 
serve as triggers to induce relapse (106), in which re-exposure to abused drug itself is the 
most powerful one in both human and animals. In 1981, de Wit and Stewart reported that 
non-contingent priming injections of cocaine or re-exposure to cocaine-paired cues 
reinstates lever-pressing behavior following extinction of drug-reinforced behavior (107). 
Later, they proposed this reinstatement model could be used to study factors involved in 
relapse to drug use (106). In the between-session procedure, training for drug self-
administration, the extinction of drug-reinforced behavior, and tests for reinstatement are 
conducted during sequential daily sessions (106).  
1.4. Small molecules under development for cocaine use disorder 
Most small-molecule drug candidates under development for cocaine use disorder 
are aiming to modulate the disrupted neurochemistry caused by chronic cocaine use in 
order to resemble those of healthy individuals (108). The primary targets for modulation 
include dopaminergic pathway and other neurotransmitter systems involved in the 
development and relapse of cocaine use disorder.  
1.4.1. Dopaminergic system 
The intuitive mechanism of a pharmacotherapy to treat cocaine use disorder is to 
block cocaine’s action on the dopamine reuptake transporter (109). Naltrexone, the µ-
opioid receptor antagonist, is one example of an antagonist medication approved for the 
treatment of opioid-use disorder. However, as the cocaine binding site in its primary target 
- dopamine reuptake transporter (DAT) - overlaps with dopamine’s (DA) binding site (110), 
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it is difficult to directly block the action of cocaine without interrupting the essential 
function of dopaminergic system. “Agonist therapy” is a pharmaceutical strategy that 
works the opposite way. Candidate small molecules share the pharmacodynamics 
mechanisms of action of cocaine, but usually have distinct pharmacokinetic characteristics, 
like bioavailability associated administration route, slow onset of action, long duration of 
action, to lower their abuse liability (109). Several FDA-approved medications for other 
indications, which also act as either a dopamine releaser or dopamine reuptake inhibitor, 
have been assessed in human laboratory studies and clinical trials for their efficacy to 
attenuate the reinforcing effects of cocaine and to manage cocaine dependence, including 
methylphenidate, d-amphetamine, bupropion and modafinal (108, 111). It was found that 
dopamine releasers (e.g. d-amphetamine) are more effective than dopamine reuptake 
inhibiters (e.g. methylphenidate) for reducing the use of cocaine (111). Bupropion was 
demonstrated to be effective in facilitating cognitive behavioral therapy (CBT) (112), 
although the effect was small.  
Another potential therapeutic target in the dopaminergic system is dopamine D3 
receptor (D3R) (113), which is a D2-like dopamine receptor with restricted localization to 
the ventral striatum (114) and enhanced expression in the brains of cocaine-dependent 
individuals (115, 116). During the latest decades, D3R-selective antagonists and partial 
agonists with high affinity and varying efficacies have been discovered and assessed in 
preclinical animal models of drug addiction, showing promising results in rodent models 
of relapse-like behavior (117). However, to date, no D3R-selective or preferential 
antagonists or partial agonists showed positive results in clinical trials for cocaine use 
disorder.  
1.4.2. GABAergic system 
γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the CNS 
and GABAergic neurons modulate the dopaminergic system through heavy innervation in 
the VTA and NAc. It has been proposed that facilitating the function of GABA could 
antagonist the action of cocaine in the brain. Several FDA approved GABA-A or GABA-
B agonists have been assessed in clinical trials for facilitating abstinence in cocaine-
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dependent individuals. It has been found that topiramate, a GABA-A receptor agonist, can 
apparently facilitate cognitive behavioral therapy to achieve better abstinence (118, 119). 
However, baclofen, gabapentin and tiagabine generated mixed results in clinical trials 
(108). More studies are required to determine their therapeutic efficacy.  
1.4.3. Glutamatergic system 
Glutamate is one of the primary excitatory neurotransmitters in the CNS and acts 
on two families of glutamate receptors, including inotropic glutamate receptors (iGluR, e.g. 
NMDA and AMPA) and metabotropic glutamate receptors (mGluR1-8). It has been 
hypothesized that the imbalance of glutamate homeostasis underlies the impaired 
communication between the PFC and NAc (120). There is growing preclinical evidence 
suggesting that glutamatergic neurotransmission system is essentially involved in relapse 
to drug-seeking behaviors (84).  
One therapeutic strategy based on this knowledge is to normalize glutamate 
homeostasis in order to reverse the neural maladaptive changes caused by chronic cocaine 
exposure (120). N-acetyl-cysteine (NAC), a prodrug of cysteine, has been proposed to act 
as anti-relapse agent and offer benefits for treating cocaine use disorder (121). NAC is 
oxidized into cystine within the brain and drives the glial cystine-glutamate exchanger to 
release glutamate and restore basal extracellular glutamate levels to normalize the 
compromised cortocostraiatal function. Preclinical studies have demonstrated that the 
NAC treatment could reduce cue and cocaine-primed drug seeking in formerly cocaine 
dependent rats (122, 123). In the molecular level, NAC reversed the changes in spine 
morphology and AMPA/NMDA ratio produced after withdrawal from self-administration 
of cocaine (124). A proton magnetic resonance spectroscopy (1H MRS) study in in 
cocaine-dependent patients and normal controls revealed that NAC normalizes glutamate 
levels in cocaine-dependent patients (125). In 2013, a randomized, double blinded, placebo 
controlled clinical study revealed NAC failed to show impact on cocaine abstinence (126). 
However, in subgroup of the sample that was already abstinent, NAC with high dose (2400 
mg/day) prolonged the time to relapse and reduced craving, indicating NAC may work as 
a relapse-prevention agent rather than an abstinence-promoting agent (126). 
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Among the eight subtypes of mGluRs, mGluR2/3 and mGluR5 are promising targets 
for development of anti-addiction medications (120). It has been demonstrated using 
experimental animals that both agonists (or positive allosteric modulators) of mGluR2/3 
(127) and antagonists (or negative allosteric modulators) of mGluR5 (128, 129) are able to 
reduce cocaine self-administration and reinstatement of drug-seeking. However, no agents 
in this category have been studied in their effects in facilitating cocaine abstinence in 
clinical trials so far.  
1.4.4. Others 
Medicines that modulate other neurochemical and neuroendocrine systems, 
including the serotonin system (antidepressants), endocannabinoids system (CB1/2 
receptor agonist), and neuropeptides involved in brain stress system (CRF1 antagonist), 
have been proposed and tested in preclinical and clinical studies to treat cocaine use 
disorder (130). However, none of them have been effective in clinical trials so far. 
1.5. Biologics under development for cocaine use disorder/overdose 
As discussed above, the small molecule-based medications for cocaine use disorder 
is aiming to alter the pharmacodynamics of cocaine by direct or indirect antagonizing 
cocaine’s action or correcting the disrupted neurochemistry system. However, despite the 
decades of effort, no candidate agent has been approved as an effective pharmacotherapy 
for cocaine use disorder. Therefore, new approaches using a pharmacokinetic (PK) strategy 
have been developed. These protein-based methods use either enzyme or antibody/vaccine 
to alter the PK profile of cocaine (e.g. increasing its metabolism, altering its distribution) 
in order to prevent cocaine from interacting with its major targets in the brain (131). Tables 
1-1 and 1-2 summarized the literatures reporting the results of preclinical studies and 
clinical studies of immunotherapy-based agents and enzyme-based agents, respectively.  
1.5.1. Vaccine and Anti-cocaine antibody 
1.5.1.1. Vaccine 
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Vaccines for cocaine use disorder are immunogens consisting of a hapten 
structurally similar to the cocaine conjugated to immunogenic carried protein. The 
immunogens are formulated with adjuvants to increase immunogenicity. When immunized, 
the conjugated immunogens lead to T cell-dependent B cell activation to generate 
polyclonal anti-cocaine antibody with the ability to sequester cocaine and prevent its entry 
to the brain (132).  
The first anti-cocaine vaccine (IPC-1010 or TA-CD) evaluated in clinical trials 
consisted of cocaine derivative (succinyl norcocaine) coupled to recombinant cholera toxin 
B (rCTB). In preclinical studies, TA-CD was shown to be effective in inducing cocaine 
specific antibodies and reducing cocaine intake in rats, with serum antibody concentration > 
0.05-0.07 mg/ml (133, 134). In the phase I clinical trial, the vaccine was well tolerated and 
produced specific antibodies in a dose-dependent manner (135, 136). In a phase II clinical 
trial that involved 115 outpatients addicted to opioids and cocaine undergoing substitution 
therapy with methadone, only 38% of the participants treated with TA-CD evoked antibody 
titer levels (≥ 43 µg/ml) required to significantly reduce cocaine access to the brain and to 
prevent its euphoric effects (137). In a human lab study, it has been demonstrated that 
subjects with TA-CD-induced high antibody titers had significantly reduced subjective 
ratings after smoking cocaine (138). However, in the phase III clinical trial involving 300 
cocaine dependent subjects, the results did not confirm the efficacy found in previous study 
in subjects with high antibody titer (≥ 43 µg/ml) based on retention and attaining abstinence 
(139). 
In order to deal with the insufficient immune responses in most subjects, vaccines 
based on the specific adenoviral vectors were developed. One of the novel cocaine vaccine 
(dAd5GNE), which is comprised GNE, a cocaine-like molecule that is linked to the capsid 
protein of a disrupted serotype 5 adenovirus, has shown efficacy in antagonizing cocaine 
addiction-related behaviors in rats (140) and reducing cocaine binding to dopamine 
transporter (from 62% to 20%) in non-human primate (141). Currently, a phase I trial of 
this vaccine is recruiting patients (NCT02455479).  
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1.5.1.2. Anti-cocaine monoclonal antibody 
Despite active immunization using vaccine, another method of immunotherapy for 
cocaine use disorder is passive immunization based on a monoclonal antibody (mAb) 
prepared in the laboratory (142). One apparent benefit of mAb over vaccine is immediate 
onset of action without a requirement of multiple immunization and weeks to months 
waiting time before effective titers generated.  
Passive immunization studies with murine anti-cocaine mAbs, including MO240 
(143), GNC92H2 (144, 145), have been demonstrated to attenuate the toxic and behavioral 
effects of cocaine. Later, a chimeric human/murine anti-cocaine, 2E2, was generated in 
transgenic mice engineered to produce human sequence mAb (146). This mAb has been 
demonstrated to change the in vivo distribution of cocaine in mice with a concomitant 
dramatic decrease in brain cocaine concentrations (147) and increased the level of cocaine 
required to reinstate cocaine self-administration (148). Beside regular anti-cocaine mAbs, 
catalytic antibody with the capacity to bind and degrade cocaine, were also developed (149). 
One catalytic antibody, known as mAb 15A10 (kcat = 2.3 min-1 and KM = 220 µM), has 
been demonstrated to be able to protect the animals against seizures and death in a model 
of cocaine overdose (150, 151), attenuate the cardiovascular impact of cocaine in mice 
(152), and alter the reinforcing effects of cocaine in rats (150, 151).  
However, there has been no mAb assessed in clinical trials for cocaine use disorder 
so far.  
1.5.2. Enzyme-based therapy 
Compared to immunological approaches, enzyme-based therapy has an inherent 
advantage.  Each enzyme molecule can degrade multiple drug molecules, depending on the 
catalytic parameters of the enzyme such as the turnover number (catalytic rate constant 
kcat), which is remarkably different from the well-known stoichiometric binding of an 
antibody with drug. 
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1.5.2.1. Bacterial cocaine esterase and mutants 
Bacterial cocaine esterase (CocE) is isolated from a strain of Rhodococcus 
bacterium, which grows in the soil surrounding the roots of the coca plant (153). It has 
been characterized that it breaks down cocaine at benzoyl ester bond (kcat = 468 min-1, KM 
= 0.64 μM), producing ecgonine methyl ester (EME) and benzoic acid (154).  In addition, 
native CocE hydrolyzes cocaine with an 800-fold improved catalytic efficiency compared 
to wild-type human BChE (155).  
However, native CocE has a very short half-life of 12.2 min in vivo due to its poor 
stability at physiological temperature (37) (156). This drawback largely limits its potential 
to be developed as a therapeutic agent. Based on rational computational approach, a new 
CocE form with double mutations (RQ-CocE), T172R-G173Q, has been designed and 
validated to display enhanced stability at 37 without compromising its catalytical 
efficiency (kcat = 3204 min-1, KM = 17 μM) (157). RQ-CocE has been tested in cocaine self-
administration models in rats to show a dose-dependent effect on reinforcing responding 
(158). In addition, its effects in amelioration of cocaine-induced cardiovascular effects has 
been tested in rodents (159) and in rhesus monkeys (160).  
A phase IIa trial (NCT01846481) conducted by Reckitt Benckiser Pharmaceuticals 
Inc. has demonstrated that RBP-8000 (RQ-CocE) with dose of 100 mg or 200 mg was safe 
and well-tolerated. It rapidly reduced cocaine level by 98% within 2 min and caused a 
blunting of physiological effects of cocaine compared with placebo (161). The sponsor 
concluded that all the evidences supported its use for the treatment of cocaine intoxication.   
1.5.2.2. Human Butyrylcholinesterase and mutants  
In human, the dominant pathway for cocaine metabolism is BChE-catalyzed 
hydrolysis at the benzoyl ester group (162). All the metabolites of this metabolic pathway 
are considered as non-psychoactive. A lot of evidences based on animal studies or human 
clinical use supported that BChE is devoid of toxic effects. The safety of human BChE was 
evaluated in mice and guinea pigs (163, 164). They demonstrated that no sign of toxicity 
was found as measured by general observation, serum chemistry, hematology, and 
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histological tissue changes. Purified human plasma BChE has been used in clinical for 
treatment of organophosphate (OP) pesticide poisoning, succinylcholine apnea, or 
mivacurium apnea for more than 50 years. Based on case reported from 1953 to 2005, 
BChE has been used to treat about 150 patients with one of such conditions (165). However, 
no adverse events were reported (165). Therefore, hBChE is an optimal candidate enzyme 
for designing cocaine hydrolases (CocHs).  
Given that the catalytic activity of wild-type BChE against naturally occurring, 
biologically active (-)-cocaine is very low (kcat = 4.1 min-1, KM = 4.5 μM) (166), studies 
were carried out in our lab to identify CocHs (hBChE mutants) with high catalytic activity 
against (-)-cocaine based on computational modeling and simulations of the enzyme-
substrate binding and transition state. Several CocHs have been identified to have more 
than 1000-fold improved catalytic activity (167-169) selectively against (-)-cocaine. The 
kinetic parameters of wild-type BChE and selective CocHs for enzymatic hydrolysis of (-)-
cocaine and acetylcholine (ACh) summarized from literatures are displayed in Table 1-3. 
A series of experiments have been done to characterize their in vitro enzymatic properties 
(170-172) and in vivo effectiveness for cocaine detoxification (167, 173). 
1.5.2.3. Long-lasting CocHs 
Besides the catalytic efficacy, the circulatory half-life of CocH is also a critical 
factor for achieving desired therapeutic outcome. The original forms of high-activity 
CocHs have half-lives around 7.3 hours in rats (173). By modifying amino-acid residues 
to specifically increase the thermal stability of one of the therapeutically valuable CocHs, 
its biological half-life has been extended to ~13 hours in rats (174). In order to further 
extend the biological half-lives of CocHs and obtain prolonged therapeutic effects suitable 
for long-term cocaine addiction treatment, most promising CocHs were fused with one of 
stabilizing protein carriers, including human serum albumin (HSA), Fc domain of human 
IgG (Fc), and their mutants designed by our laboratory. HSA or Fc fusion could prevent 
CocH from intracellular degradation via neonatal Fc receptor (FcRn) mediated recycling 
(175).  
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Albu-CocH (Albu-CocH1 or TV-1380) is a chimeric protein by fusing wild-type 
human serum albumin (HSA) to the C-terminal of early discovered BChE mutant (E14-3) 
in our lab (168). Experiments have been carried out to confirm its effectiveness in 
attenuating the reinforcing effects of cocaine in rats (176, 177) and squirrel monkeys (178). 
It has been known that TV-1380 has a half-life of 8 hours in rats (IV) (179), 28 hours in 
squirrel monkeys (IV) (178). Phase I and Phase II clinical trials of TV-1380 have been 
completed by Teva Pharmaceutical Industries Ltd. In the phase I study, normal volunteers 
received up to four weekly intramuscular doses of TV1380. It has shown that, at doses of 
up to 300 mg, TV-1380 is safe and well-tolerated. The plasma half-life is determined to be 
43-77 hours in health human subjects (IM) (180). In a small study with recreational users, 
subjects were administered single doses of TV-1380 and challenged with an intravenous 
dose of cocaine 1, 4, and 7 days later. The results showed that TV-1380 dramatically 
reduced the Cmax and t1/2 of cocaine in a dose-dependent manner (181). In the recent Phase 
II clinical trial, the ability of TV-1380 to safely and effectively increase abstinence in 
treatment-seeking individuals with cocaine dependence was evaluated (182). With the 
enzyme dose (150 mg or 300 mg) and injection regime (once per week) used in this clinical 
trial, TV-1380 failed to meet the primary endpoint (abstinence) in the study. Obviously, 
the half-life of 43-77 hours is not sufficiently long for each dose of TV-1380 to be effective 
for an entire week. Nevertheless, there was a dose-related increase in the percentage of 
negative urines during the last two months of treatment (182). The results suggested it 
might be beneficial for abstinence maintenance if the plasma levels of TV-1380 could stay 
higher during the study by higher doses or more frequent administration (e.g. twice a week). 
However, this would not be feasible due to the consideration of costs and acceptable 
administration frequency. Based on a survey of treatment providers before the clinical 
study, it is not acceptable if one injection product requires administration more than once 
weekly (182). Overall, the current results positively to justify the development of an 
enzyme form with both higher catalytic efficiency and longer biological half-life.  
The fragment crystallizable (Fc) region of IgG is the important part to ensure the 
long biological half-lives of antibodies. It can bind with the neonatal Fc receptor (FcRn) in 
the acidic environment of the endosome to avoid lysosomal degradation (183). When it is 
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transported to the cell surface and exposed to a neutral pH, IgG is released back in to the 
main blood stream. The development of carrier protein technology enabled the usage of 
the Fc region of human IgG to prolong the biological half-lives of other therapeutic proteins, 
leading to fusion proteins with average biological half-lives up to 17 days (184, 185). In 
our laboratory, this strategy has been recruited to design a long-acting CocH form that has 
both the long biological half-life of an antibody and the high catalytic activity of a CocH 
against (-)-cocaine.  
The first published Fc-fused CocH form is CocH3-Fc (186), in which the C 
terminus of CocH3 was fused with the N terminus of the hinge region linked with Fc. As 
shown in Table 1-3, CocH3 has a significantly higher catalytic efficiency against (-)-
cocaine than does CocH1 or TV-1380. It has been confirmed that the CocH3-Fc not only 
has a high catalytic efficiency against cocaine but also, like an antibody, has a considerably 
longer biological half-life (e.g., ∼107 h in rats). A single dose of CocH-Fc was able to 
accelerate cocaine metabolism in rats even after 20 days and thus block cocaine-induced 
hyperactivity and toxicity for a long period of time. Based on the preclinical and clinical 
performance of TV-1380, the CocH3-Fc was proposed to allow dosing once every 2–4 
weeks, or longer, for treatment of cocaine addiction in humans.  
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Table 1-1. Preclinical and clinical studies of major immunotherapy for cocaine use disorder 
 
 
Biologic Description Preclinical study (specie/Reference) Clinical study 
 
Toxicity Addiction-related behavior Company/Sponsor Phase/ 
NCT/Reference 
Vaccine TA-CD 
 
  Self-administration 
(Rat (133, 134)) 
Celtic Pharmaceutical; 
Baylor College of 
Medicine 
I-IIa-IIb-III 
NCT00969878 
(137, 139) 
 
New York State 
Psychiatric Institute 
NCT00965263 
(138) 
dAd5GNE  Behavioral sensitization 
Reinstatement 
(140) 
Weill Medical College 
of Cornell University 
I 
NCT02455479 
Antibody MO240   Self-administration 
(Rat (134)) 
  
GNC92H2  Lethality 
 Convulsion/seizures 
(Mice (145)) 
Reinstatement 
(Rat (144)) 
  
2E2  Reinstatement 
(Rat (148)) 
  
Catalytic 
antibody  
mAb 15A10  Lethality 
 Convulsion/seizures 
(Rat (150)) 
 Cardiovascular 
(Mice (152)) 
 Self-administration 
(Rat (150, 151)) 
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Table 1-2. Preclinical and clinical studies of major enzyme-based therapy for cocaine use disorder 
 
Biologic Description Preclinical study (specie/Reference) Clinical study 
 
Toxicity Addiction-related behavior Company/Sponsor Phase/ 
NCT/Reference 
Mutants 
of CocE 
Double mutant 
CocE 
(RQ-CocE; 
RBP-8000) 
 Lethality 
 Convulsion/seizures 
(Rat (158, 187)) 
 Cardiovascular 
(Rat (188);  
Rhesus monkey (160)) 
 Self-administration 
(Rat (158)) 
 
Indivior Inc. I-II 
NCT01846481 
(161) 
 PEGylated 
CCRQ-CocE  
 Lethality 
(Rat (189)) 
 Cardiovascular 
(Rhesus monkey (189) ) 
 Self-administration 
(Rat (189, 190)) 
 Drug-discrimination 
(Rat (190)) 
  
Mutants 
of BchE 
AlbuBChE 
(TV-1380, 
Albu-CocH1) 
 Convulsion/seizure 
(Rat (176)) 
 Blood pressure 
(Rat (176)) 
 Cardiovascular 
(Cynomolgus monkeys (191)) 
 Self-administration  
 (Rat (177);  Squirrel monkeys 
(178) ) 
 Drug-discrimination 
 (Squirrel monkeys (178)) 
 Reinstatement 
(Rat (176);  Squirrel monkeys 
(178)) 
Teva 
Pharmaceutical 
Industries 
I-II 
NCT01887366 
(181, 182, 192) 
 
CocH3  Lethality 
(173) 
 Locomotor activity 
(173) 
  
CocH3-Fc   Locomotor activity 
(186) 
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Table 1-3. Kinetic parameters of wild-type BChE and selective CocHs for enzymatic hydrolysis of (-)-cocaine and 
acetylcholine (ACh) 
 
 
Enzyme 
(-)-cocaine ACh 
kcat  
(min-1) 
KM(µM) kcat /KM 
(M-1min-1) 
RCEa kcat  
(min-1) 
KM(µM) kcat /KM 
(M-1min-1) 
RCEa 
Wild-type BChE b 4.1 4.5 9.1 × 105 1 61,200 148 4.1 × 108 1 
CocH1 (E14-3) c 
A199S/S287G/A328W/Y332G 
(168) 
3,060 3.1 9.9 × 108 1080 5,320 36 1.5 × 108 0.37 
CocH2 c 
A199S/F227A/S287G/A328W/E441D 
(193) 
1,730 1.1 1.6 × 109 1730 10,400 27 3.9 × 108 0.95 
CocH3 (E12-7) c 
A199S/F227A/S287G/A328W/Y332G 
(169) 
5,700 3.1 1.8 × 109 2020 11,900 37 3.2 × 108 0.78 
E30-6 d  
A199S/F227A/P285A/S287G/A328W/Y332G 
(167) 
14,600 3.65 4.0 × 109 4395 8,710 54.7 1.6 × 108  0.39 
a RCE refers to the relative catalytic efficiency (kcat/KM), i.e. the ratio of the kcat/KM value of the mutant to that of wild-type 
BChE against the same substrate. 
b Data of wild-type BChE against (-)-cocaine is from the reference (166). Data of wild-type BChE against ACh is from the 
reference (176). 
c Date from the reference (172). 
d Data from the reference (167). 
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1.6. Hypotheses and Specific aims 
The long-term goal of our laboratory is to develop the enzyme-based 
pharmacotherapies for cocaine overdose and cocaine use disorder. Based on the therapeutic 
outcomes shown in phase II clinical trial of TV-1380 (Albu-CocH1), we believe the 
second-generation fusion CocH, Fc-fused CocH, which has longer biological half-life and 
higher catalytic efficacy, is desirable for further development for cocaine overdose and 
cocaine use disorder treatment. 
In order to identify and characterize most promising enzyme form for further 
development, Fc-fused CocHs were screened by in vitro binding affinity assays first. 
Enzyme forms that have improved binding affinity with FcRn at pH 6 were further studied 
in rats to characterize the biological half-lives via two administration routes (IV and IM).  
The overall hypotheses of this dissertation are (1) fusion CocHs will have improved 
performance on cocaine detoxification; (2) a single dose, which is translatable to bedside, 
of the Fc-fused CocH will be long-term effective to block or attenuate abuse related effects 
of cocaine.  
In chapter two, fusion CocH and its corresponding unfused enzyme were compared 
based on their effectiveness in facilitating recovery form toxic effects of a lethal dose of 
cocaine in rodent rescue model.  
In chapter three, Albu-CocH1 (TV-1380) served as an example to investigate the 
clinical potential of enzyme-based therapy for cocaine overdose treatment.  
In chapter four, selected Fc-fused CocHs were accessed on their effectiveness and 
duration in blocking physiological and subjective effects of cocaine in rats. 
In chapter five, the most promising forms of Fc-fused CocHs were chosen to study 
their effects in blocking and attenuating the reinforcing effects of cocaine using self-
administration model in rats.  
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2. Chapter Two 
Compare the Potency of CocHs and Fusion CocHs in Rodent Rescue Models 
2.1. Enzyme-based treatment for cocaine overdose 
The toxicity induced by cocaine in animals and humans is attributed to its multiple 
physiological effects in central nervous system and cardiovascular system, among others 
(11). Like other commonly abused substances, cocaine use leads to neurological 
impairments due to its neurotoxic effects mediated by dopaminergic and glutamatergic 
neurotransmitter systems (30, 34). In severe cases, the acute toxicity associated with 
cocaine overdose could cause life-threatening events including seizures, cardiovascular 
failure, or respiratory depression (11). Practical emergency treatment for cocaine 
intoxication includes initial administration of a benzodiazepine anticonvulsant agent (e.g. 
diazepam) and/or physical cooling, followed by interventions aimed to relieve the other 
symptoms (194). 
The inherent difficulties of antagonizing physiological effects of drugs in the 
central nervous system have led to exploring protein-based pharmacokinetic approaches 
using biologics like vaccines, monoclonal antibodies, and enzymes (195, 196). In principle, 
among various pharmacokinetic approaches, a drug-metabolizing enzyme should be the 
most efficient for drug overdose treatment (196-199). In particular, each enzyme molecule 
can degrade multiple drug molecules, depending on the catalytic parameters of the enzyme 
such as the turnover number (catalytic rate constant kcat), which is remarkably different 
from the well-known stoichiometric binding of an antibody with drug. Based on our 
structure-and-mechanism-based computational design, efficient and thermally stable 
cocaine-metabolizing enzymes have been discovered and developed recently as potential 
candidates of therapies for cocaine overdose and addiction (157, 168, 169, 174, 200, 201). 
These computationally designed enzymes, which are mutants of human 
butyrylcholinesterase (BChE) or bacterial cocaine esterase (CocE), can rapidly convert 
cocaine to non-psychoactive metabolites: ecgonine methyl ester (EME) and benzoic acid. 
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Previously, several enzyme forms have been tested in rodent models of cocaine 
toxicity. A thermostable CocE with double mutants (RQ-CocE or RBP-8000) (157) could 
reverse hypertension and bradycardia caused by 5.6 mg/kg (IV) cocaine, when 
administered 1 min prior to cocaine injection. Similarly, administrations of RQ-CocE 
following doses of cocaine that are sufficient to produce convulsions in rats (180 mg/kg; 
IP) can completely reverse the neurological and cardiovascular effects in rats (187). Albu-
CocH1 (Albu-CocH or TV-1380), a chimeric protein by fusing wild-type human serum 
albumin to the C-terminal of the early discovered BChE mutant (E14-3), was shown to be 
able to protect and rescue both male and female rats from a lethal dose of cocaine (176). 
Importantly, in the rodent models, Albu-CocH1 treatment remained fully protective for 12 
hr (176), but the bacterial enzyme lost its ability to protect in 30 min or less. This is 
consistent with the observation in the clinical trial of RBP-8000 that a rebound of cocaine 
concentration was seen at later time points when the plasma concentration of PBR-8000 
had declined (161). This indicated that the half-life of the therapeutic protein also plays an 
important role influencing its performance in the cocaine detoxification treatment.  
Besides RQ-CocR and Albu-CocH1, several other CocHs with higher catalytic 
efficiency and their corresponding fusion proteins with extended biological half-lives have 
been designed and characterized in our lab. CocH3 is a BChE mutant has ~2,020-fold 
improved catalytic efficiency against naturally occurring (-)-cocaine (169, 171, 173). 
CocH3-HSA and CocH3-Fc were made by fusing CocH3 with human albumin protein 
(HSA) or the Fc region of human IgG (202), respectively. They have the similar catalytic 
efficiency as CocH3, but distinct PK profiles. E30-6 is the most efficient CocH among all 
published BChE mutants, which has ~4000-fold improved catalytic efficiency against 
naturally occurring (-)-cocaine (167). E20-7 is an unpublished BChE mutant, which has 
similar catalytic efficiency as E30-6. E20-7-Fc was made by fusion E20-7 with the Fc 
region of human IgG. Therefore, E20-7-Fc has both higher catalytic efficiency and longer 
biological half-life compared to CocH3. The enzymatic parameters and biological half-life 
of each enzyme form are listed in Table 2-1. 
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In the studies described this chapter, we are aiming to compare fusion CocHs and 
their corresponding unfused enzyme based on their effectiveness in facilitating recovery 
from toxic effects of a lethal dose of cocaine in rodent rescue model.  
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Table 2-1. Enzyme kinetic parametersa and biological half-lifeb of CocHs 
 
Enzyme  kcat  (min-1) KM(µM) kcat /KM  
(M-1min-1) 
Half-life (hr) 
In rats 
CocH3 5700 3.1 1.8 × 109 7.3 
CocH3-Fc 5700 3.1 1.8 × 109 ~ 110 
CocH3-Albu 5700 3.1 1.8 × 109 8 
E30-6 14600 3.65 4.0 × 109 7.3 
E20-7 ~14600 ~3.65 ~4.0 × 109 7.3 
E20-7-Fc ~14600 ~3.65 ~4.0 × 109 ~ 110 
 
a Enzyme kinetic parameters for enzymatic hydrolysis against naturally occurring (-)-
cocaine.  
b T1/2 of slow phase calculated from the two-phase exponential decay model. 
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2.2. Materials and methods 
2.2.1. Materials 
The enzymes used in this study were prepared using the methods described in our 
previous study (202, 203). Briefly, all the proteins were expressed in stable CHO-S cells 
(developed in our lab using a lentivirus-based method). The protein production was 
performed in an agitated bioreactor BioFlo/CelliGen 115 (Eppendorf, Hauppauge, NY). 
Unfused CocHs (CocH3, E30-6, and E20-7) were purified using ion-exchange 
chromatography (Q Sepharose® Fast Flow) followed by affinity chromatography 
(hydroxyapatite column). HSA fused protein (CocH3-HSA) was purified using AlbuPure 
affinity chromatography. Fc fused proteins (CocH3-Fc, E30-6-Fc, and E20-7-Fc) were 
purified using protein A affinity chromatography. The processes of protein purification 
were performed on an ÄKTA Avant 150 system (GE Healthcare Life Sciences, Pittsburgh, 
PA).  
(−)-Cocaine was provided by the National Institute on Drug Abuse (NIDA) Drug 
Supply Program (Bethesda, MD). 
2.2.2. Animals 
A total of 30 female Wistar rats (220–250 g) and 30 male NIH Swiss mice were 
used in this study. They were ordered from Harlan (Harlan, Indianapolis, IN), and housed 
initially as two rats or five mice per cage. All rodents were allowed ad libitum access to 
food and water and maintained on a 12 h light/12 h dark cycle, with the lights on at 8:00 
a.m. at a room temperature of 21–22 °C. The animal protocol was approved by the IACUC 
(Institutional Animal Care and Use Committee) at the University of Kentucky. 
2.2.3. Rescue experiment in mice.  
Mice received IP injection of 100 mg/kg (~ LD50) cocaine. After convulsion onset, 
mice were rapidly moved into a restrainer to facilitate IV injection through tail vein. Rescue 
treatment (vehicle or enzyme) were required to introduce within 1 min after the convulsion 
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onset.  Then, mice were returned to the chambers or containers for observation. Time from 
treatment injection to the occurrence of death, righting reflex, or walk (free movement with 
four limbs) were recorded. All the mice survived after the experiment were housed in their 
home cages for one-week follow-up observation. 
2.2.4. Rescue experiment in rat. 
Rats received IP injection of 100 mg/kg (~ LD100) cocaine. Rescue treatment 
(vehicle or enzyme) was IV injected immediately after the obvious sign indicating the onset 
of cocaine-induced convulsion through a temporary catheter placed in the tail vein before 
cocaine administration. 200 µl (the dead volume of the catheter) of saline was administered 
after the enzyme to complete the enzyme injection. It generally took around 20s to finish 
this procedure. Then, rats were immediately returned to the chambers or containers for 
observation. Time from treatment injection to the occurrence of death, righting reflex, or 
normal walk (free movement with four limbs) were recorded.  
2.2.5. Statistical analysis 
Incidence of death is reported as overall percentage for each group. Time was 
presented as mean  SD (min) in the tables. Time comparison among all treatments were 
preformed using one-way ANOVA with individual comparison made by Turkey’s post hoc 
test when appropriate. Time comparison involving only two groups was made by un-paired 
t-test. 
2.3. Experiments and results 
2.3.1. Mice study 
In this experiment, we compared the effects four CocH forms when used as an agent 
to rescue the cocaine intoxicated mouse and to facilitate their recovery. All the mice were 
randomly assigned to five groups, receiving different recue intervention within 1 minute 
after the start of cocaine-induced tonic-colonic activity (convulsion). The treatments were 
vehicle, CocH3, CocH3-Albu, CocH3-Fc, and E20-7-Fc at a dose of 0.4 mg/kg. CocH3 at 
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this dose was able to achieve 100% rescue rate in a preliminary pilot study. The time of 
convulsion onset, the incidence of death, the time of occurrence of righting reflex and 
voluntary walk, with various rescue treatment are shown in Table 2-2.  
In mice, IP administration of 100 mg/kg cocaine rapidly evoked convulsion, a 
seizure related behavior, with an incidence of 100% in each group. The time to convulsion 
onset had no significant difference among five groups, determined by one-way ANOVA 
(F (4, 25) = 0.521, p = 0.721). Without any effective intervention, half of mice (3/6) in 
control group died within 10 minutes after cocaine injection. Half of them barely survived. 
However, it took them around 20 minutes to complete righting reflex and more than half 
hour to be able to move voluntarily. Although they were able to move, they showed signs 
of profound motor weakness. Two of the three survivors were found dead in their home 
cages one or two days after the experiment.  
Rescue intervention with any one of the CocHs, at a dose of 0.4 mg/kg, increased 
the survival rate from 50% to 100%. The effects for facilitating recovery, evaluated as the 
time to occurrence of righting reflex or voluntary movement after treatment injection, 
showed differences among groups (F (3, 20) = 9.585, p < 0.001 for the time to righting 
reflex, F (3, 20) = 10.75, p < 0.001 for the time to voluntary move). Result of Tukey’s post 
hoc test indicated mice treated with CocH3 took significantly longer time to show a 
righting reflex and voluntary move than the other three groups (Table 2-2). Once they were 
able to move, no sign of discomfort could be identified. All the mice behaved as normal as 
untouched mice 2 hours after the experiment and no death was found during one-week 
follow-up observation.  
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Table 2-2. Rescue study with male mice 
 
Treatment Number 
of mice 
Timea to 
convulsion 
% Death Timea to 
death 
Timeb to 
righting reflex 
Timeb to walk 
Vehicle 6 2.52 ± 0.86 50 6.93 ± 2.11 19.60 ± 2.96 29.94 ± 7.17 
CocH3 (0.4 mg/kg) 6 2.33 ± 0.50 0 N.A. 4.38 ± 1.90 6.16 ± 2.42 
CocH3-Fc (0.4 mg/kg) 6 2.03 ± 0.41 0 N.A. 2.13 ± 0.67* 3.30 ± 0.84** 
CocH3-HSA (0.4 mg/kg) 6 2.63 ± 0.76 0 N.A. 1.37 ± 0.83*** 2.71 ± 0.77*** 
E20-7-Fc (0.4 mg/kg) 6 2.54 ± 1.27 0 N.A. 1.31 ± 0.52*** 2.04 ± 0.45*** 
 
a Minutes (Mean  SD) from injection of cocaine to convulsion or death, for those mice that demonstrated these characteristics. 
b Minutes (Mean  SD) from injection of treatment to occurrence of righting reflex and movement, for those mice that demonstrated 
these characteristics. 
*p  .05, ** p  .01, *** p  .001 compared to CocH3 group using one-way analysis of variance (ANOVA) followed by the Tukey 
post hoc tests.   
N.A. = not applicable  
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2.3.2. Rat study 
In this experiment, we studied the effects of CocHs when used as an agent to rescue 
the cocaine intoxicated female rats and to facilitate their recovery. All female rats were 
randomly assigned to five groups, receiving different rescue intervention within 1 minute 
after the start of tonic-colonic activity caused by a lethal dose of cocaine. The treatments 
were vehicle, 0.3 mg/kg E30-6, 0.8 mg/kg E30-6, 0.3 mg/kg E20-7, and 0.3 mg/kg E20-7-
Fc. The time of convulsion onset, the incidence of death, the time of occurrence of righting 
reflex and voluntary walk with various rescue treatments are shown in Table 2-3.  
In female rats, IP administration of 100 mg/kg cocaine results in an incidence of 
convulsion of 100% in each group. The time to convulsion onset had no significant 
difference among five groups, determined by one-way ANOVA (F (4, 25) = 1.220, p = 
0.326). Without any effective intervention, in the control group, all rats died. The mean 
time to death was 7.03 ± 2.83 min.  
Rescue intervention with E30-6 at both doses decreased the rate of cocaine induced 
death from 100% to 0%. Rats treated with the high dose (0.8 mg/kg) of enzyme took 
significantly shorter time to show righting reflex and movement compared to the rats 
rescued by low dose (0.3 mg/kg) of enzyme.  
Rescue intervention with E20-7 and E20-7-Fc at the dose of 0.3 mg/kg also 
decreased the rate of cocaine induced death from 100% to 0%. The time to occurrence of 
righting reflex had no significant difference between these two groups, however, rats 
treated with the E20-7-Fc took significantly shorter time to have movement compared to 
the rats rescued by E20-7.
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Table 2-3. Rescue study with female rats 
Treatment 
(dose) 
Number 
of rats 
Timea to 
convulsion 
% Death Timeb to 
death 
Timeb to righting 
reflex 
Timeb to walk 
Vehicle  6 4.04 ± 1.62 100 7.03 ± 2.83 N.A. N.A. 
E30-6  
(0.3 mg/kg) 
6 6.80 ± 5.05 0 N.A. 1.24 ± 0.47 2.33 ± 1.01 
E30-6  
(0.8 mg/kg) 
6 4.18 ± 1.18 0 N.A. 0.62 ± 0.27* 1.23 ± 0.26* 
E20-7  
(0.3 mg/kg) 
6 3.98 ± 1.47 0 N.A. 0.88 ± 0.79 2.57 ± 0.86 
E20-7-Fc  
(0.3 mg/kg) 
6 3.91 ± 2.53 0 N.A. 0.37 ± 0.20 1.09 ± 0.49## 
a Minutes (Mean  SD) from injection of cocaine to convulsion or death, for those mice that demonstrated these characteristics. 
b Minutes (Mean  SD) from injection of treatment to occurrence of righting reflex and movement, for those mice that demonstrated 
these characteristics. 
* p  .05 compared to E30-6 (0.3 mg/kg) group using un-paired t-test. 
## p  .01 compared to E20-7 (0.3 mg/kg) group using un-paired t-test. 
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2.4. Discussion and conclusion 
In the experiments presented in this chapter, we compared the effects of fusion 
CocHs and unfused CocHs on their performance in acute cocaine detoxification using 
rodent cocaine overdose model. In both rat and mouse rescue models, animals rescued by 
a fusion CocH recovered significantly faster than the rats rescued by the corresponding 
unfused enzyme form with the same dose. 
In the mice rescue study, all the enzyme interventions at a dose of 0.4 mg/kg were 
able to effectively rescue the mice in each group, but those mice rescued by fusion CocHs 
(CocH3-Fc, CocH3-Albu, E20-7-Fc) had significantly shorter recovery time, indicating 
better therapeutic outcomes. This effect is largely due to the improved pharmacokinetic 
characteristics of fusion CocHs provided by the carrier protein (HSA or Fc region of human 
IgG). We did not find differences between the groups treated with CocH3-Fc and CocH3-
HSA, indicating this effect is not completely correlated with the biological half-life of each 
fusion CocH. The carrier protein not only prolonged the slow phase half-lives of fused 
CocHs, but also slowed down the sudden enzyme loss in the circulation system due to 
distribution or degradation within 10 min after enzyme administration. Interestingly, 
despite the fact that E20-7-Fc has two-fold improved catalytic efficiency compared to that 
of CocH3-Fc and CocH3-HSA, we did not find significant differences in both indicators 
between fusion version of E20-7 and fusion versions of CocH3 (only p<0.05 for time to 
walk E20-7-Fc vs. CocH3-Fc). This may due to the small sample size or a ceiling effect 
caused by fusion CocHs at this dose. If they are compared under a lower dose, the catalytic 
efficacy will be more likely to serve as an important parameter influencing the recovery 
rate.  
In the female rat study, the different recovery rates between groups treated with 
E20-7 and E20-7-Fc confirmed the results of the mice study. In addition, the two groups 
treated with different doses of E30-6 indicated the contribution of dose in the recovery rate. 
The higher the dose was, the faster the animals recovered. This is consistent with the results 
found using Albu-CocH1 (176). However, in their study, 1 out of 5 female rats died even 
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after rescue with Albu-CocH1 at a dose of 3 mg/kg. In our study, all female rats survived 
after rescue by 0.3 mg/kg and 0.8 mg/kg E30-6, indicating improved catalytic efficacy of 
CocHs could effectively lower the enzyme dose needed for cocaine detoxification in 
clinical treatment. Moreover, E20-7-Fc at dose of 0.3 mg/kg enabled rats to recover as 
faster as rats treated with 0.8 mg/kg E30-6. Considering the fact that E30-6 and E20-7 have 
similar catalytic efficiency, this further suggested that fusion CocHs will provide the 
similar therapeutic outcome at a lower dose.  
Overall, these data showed that fusion CocHs with improved pharmacokinetic 
characteristics would exhibit better performance in cocaine detoxification treatment. 
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3. Chapter Three 
Clinical Potential of an Enzyme-based Novel Therapy for  
Cocaine Overdose Treatment 
3.1. Model the cocaine overdose treatment in a clinically relevant manner 
Preclinical studies on Albu-CocH1 and other mutants of BChE or CocE for cocaine 
toxicity treatment in mice or rats reported so far included the protection and rescue 
experiments. In the protection experiment, the animals were pretreated intravenously (i.v.) 
with an enzyme before intraperitoneal (i.p.) injection of a lethal dose of cocaine (e.g. 180 
mg/kg, LD100) (157, 158, 169, 200, 204, 205). In the rescue experiment, the enzyme was 
administered right after the onset of cocaine-induced convulsion (which usually occurred 
within first three minutes after i.p. injection of a lethal dose of cocaine) (159, 199, 206). In 
the Chapter two of this thesis, we also used the similar rodent model to compare the effects 
of CocH3 and its corresponding long-lasting versions (CocH3-Albu, CocH3-Fc) in 
facilitating the recovery of the subjects after challenged with a lethal dose of cocaine. 
However, the timing of the interventions introduced in these animal models raised concerns 
about the clinical irrelevance; it was regarded as “a difficult transition to the bedside” (207). 
In fact, more than 40% of patients present to the emergency department with cocaine 
toxicity more than 1 hour after cocaine use (207). The protection and rescue experiments 
reported so far have no indication concerning whether the enzyme therapy will be effective 
in these late presenters.  
For an appropriate use of animal models with clinically relevant timing, one first 
needs to understand the general features of pharmacokinetic (PK) profiles of cocaine in the 
body. It should be noted that the elimination half-life of cocaine in the blood is dependent 
on the dose used in the PK study (26, 208), because all endogenous cocaine-metabolizing 
enzymes are saturated when cocaine concentration is sufficiently high in plasma. A 
pharmacological dose (50 mg or ~1 mg/kg) of cocaine had an average elimination half-life 
of ~93 min in humans, and significant blood cocaine concentrations were detected at 12 
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hours after cocaine infusion (209). Significantly higher doses of cocaine under the overdose 
conditions are expected to have longer elimination half-lives and physiological/toxic 
effects for a much longer period of time in humans. With the dose-dependence of cocaine 
elimination half-life in mind, it is not very difficult to understand why many patients 
suffered acute myocardial infarction at an average of 18 hours after cocaine use (210).  
Rats metabolize cocaine in the same pathways as humans, although rats can 
eliminate cocaine more rapidly than humans. Thus, cocaine generally has a significantly 
shorter elimination half-life in rats compared to humans. For example, 5 mg/kg cocaine 
(administered i.v.) had an elimination half-life of only ~23 min and did not show significant 
concentration of cocaine after 60 min following the cocaine administration according to 
our previously reported study (203). So, a period of 30 min for cocaine detoxification in 
rats might be corresponding to a few hours for cocaine detoxification in humans.  
In the research (211) described in this chapter, we used animal behavior studies 
combined with blood sample analyses, aiming to investigate whether the enzyme Albu-
CocH1 can be effective in relieving the toxic effects of cocaine when administered at 
different time points after cocaine intoxication.  In addition, the effects of Albu-CocH1 in 
each model was compared with that of diazepam. 
3.2. Materials and methods 
3.2.1. Materials 
The purified Albu-CocH1 protein was prepared in our previous study (202).  Briefly, 
the Albu-CocH1 protein was expressed in stable CHO-S cells (developed in our lab using 
a lentivirus-based method) that can stably produce the Albu-CocH1 protein. The protein 
production was performed in an agitated bioreactor BioFlo/CelliGen 115 (Eppendorf, 
Hauppauge, NY). Albu-CocH1 in the culture medium was purified by using AlbuPure 
affinity chromatography on an ÄKTA Avant 150 system (GE Healthcare Life Sciences, 
Pittsburgh, PA). AlbuPure was ordered from ProMetic (Rockville, MD). The purified 
protein was dialyzed in a storage buffer (50 mM HPEPS, 20% Sorbitol, 1 M Glycine, pH 
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7.4) and stored at −80°C before the use. (−)-Cocaine was provided by the National Institute 
on Drug Abuse (NIDA) Drug Supply Program (Bethesda, MD); and [3H](−)-Cocaine (50 
Ci/mmol) was ordered from PerkinElmer (Waltham, Massachusetts). Diazepam (Valium®) 
injectable was from Hospira (Lake Forest, IL). All other chemicals were purchased from 
Thermo Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). 
3.2.2. Animals  
A total of one hundred and thirty seven (137) male Sprague-Dawley rats (220–250 
g) were ordered from Harlan (Harlan, Indianapolis, IN), and housed initially as one or two 
rats per cage. All rats were allowed ad libitum access to food and water and maintained on 
a 12 h light/12 h dark cycle, with the lights on at 8:00 a.m. at a room temperature of 21–22 
C°. Experiments were performed in a same colony room in accordance with the Guide for 
the Care and Use of Laboratory Animals as adopted and promulgated by the National 
Institutes of Health. The animal protocol was approved by the IACUC (Institutional 
Animal Care and Use Committee) at the University of Kentucky. 
3.2.3. Determination of pharmacokinetic profiles of Albu-CocH1 in rats 
Rats were injected with the purified Albu-CocH1 protein via tail vein (5 mg/kg). 
Blood samples were taken from saphenous vein puncture using a needle. Approximately 
40-75 µl blood was collected into a heparin-treated capillary tube at various time points 
after enzyme administration. Collected blood samples were centrifuged for 15 min at a 
speed of 5000 g to separate the plasma, which was kept at 4oC before analysis. A sensitive 
radiometric assay using 100 μM (−)-cocaine was used to measure the enzyme 
concentration in plasma (202).   
3.2.4. Characterization of cocaine clearance in rats 
Blood samples (40-75 μl) were collected from saphenous vein into a heparin-treated 
capillary tube at various time-points after the (−)-cocaine administration, and mixed 
immediately with 100 µl of 25 µM paraoxon (in 0.1% formic acid). Blood samples were 
stored at −80 until analysis by using our previously developed LC-MS/MS method(212) 
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for simultaneously detecting the concentrations of (−)-cocaine and metabolites in blood 
samples.   
3.2.5. Locomotor activity assay 
Cocaine-induced hyperactivity was monitored by using a video-tracking system in 
our lab. The locomotor activity tests were performed in high-density, non-porous plastic 
chambers measuring 50 cm (L) × 50 cm (W) × 38 cm (H) in a light- and sound-attenuating 
behavioral test enclosure (San Diego Instruments, San Diego, CA). Cumulative distance 
traveled was recorded by ANY-maze video tracking system (San Diego Instruments, San 
Diego, CA) to represent the locomotor activity. Before cocaine or saline administration, 
rats were allowed to acclimate to the test chambers for 1 h. The distance traveled was 
collected in 5-min bins. After cocaine or saline administration, rats were immediately 
returned to the test chamber for activity monitoring for 6 hours with or without 
administration of 5 mg/kg Albu-CocH1 or diazepam at 30 min or 60 min after the cocaine 
administration.  
3.2.6. Protection study in rats 
Cocaine-induced acute toxicity was characterized in this study by the occurrence 
of convulsion and/or death. Cocaine-induced convulsion was defined as loss of righting 
posture for at least 5 seconds with the simultaneous presence of clonic limb movements 
(213). Protection experiment was performed by pretreatment of rats with 5 mg/kg Albu-
CocH1 (i.v.) or diazepam (i.p. or i.v.) 1 min (if i.v.) or 5 min (if i.p.) before administration 
of 180 mg/kg cocaine (i.p.). Following the cocaine administration, rats were immediately 
placed in containers for observation. The presence or absence of convulsion/death was 
recorded for 6 hours following cocaine administration. 
3.2.7. Rescue experiment in rats 
Rats were treated with 60mg/kg (~ LD75), 180 mg/kg cocaine ( > LD100) (i.p.). 5 
mg/kg CocH1-HSA (i.v.) or diazepam (i.p. or i.v.) were administered 30 min after cocaine 
injection (for rats received 60 mg/kg cocaine) or within 1 min after the onset of cocaine-
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induced convulsion (for rats received 180 mg/kg cocaine). Then, rats were immediately 
returned to the chambers or containers for observation.  
3.2.8. Statistical analysis 
The Chi-squared contingency test was used to determine the overall significance of 
the incidence of convulsions and deaths against control group in protection and rescue 
experiments. The two-way repeated measures analysis of variance (ANOVA) was used to 
determine the significance of treatment effect on the cocaine induced locomotor activity. 
Cocaine PK data were analyzed by using two-way analysis of variance (ANOVA) method 
and post hoc Dunnett’s test. All of the statistical analyses were carried out using the 
SigmaPlot software (Systat Software, San Jose, CA). 
3.3. Experiments and results 
3.3.1. Cocaine PK profile and cocaine-induced hyperactivity 
As mentioned above, the elimination half-life of cocaine is dependent on the actual 
dose. In this study, we first studied the PK profile of 60 mg/kg cocaine administered via 
intraperitoneal (i.p.) injection. According to our PK data depicted in Figure 3-1 A, 60 
mg/kg cocaine had an elimination half-life of ~56 min and still showed a significant 
concentration of cocaine (~0.6 μM) at four hours after the cocaine injection.  
A significant blood concentration of cocaine is associated with various 
physiological/toxic effects. In rat models, it is convenient to observe cocaine-induced 
hyperactivity, convulsion (a symptom of seizure), and death. We carried out locomotor 
activity tests in rats using various i.p. doses of cocaine (10, 20, 40, 60, 100, and 180 mg/kg, 
n = 8 per dose). As shown in Figure 3-2, changing the dose of cocaine from 10 to 60 mg/kg, 
the duration of cocaine-induced hyperactivity became longer and longer, roughly ~1 hour 
for 10 mg/kg, ~2 hours for 20 mg/kg, ~3 hours for 40 mg/kg, and ~4 hours for 60 mg/kg. 
The ~4-hours hyperactivity (Figure 3-2 C) induced by 60 mg/kg cocaine is consistent with 
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the observed significant blood cocaine concentrations within the four hours after the 
cocaine administration.  
3.3.2. Correlation between blood concentration and lethality of cocaine  
In addition to the hyperactivity, 60 mg/kg cocaine induced convulsion in six out of 
eight rats, and two rats died after convulsion (one at ~18 min and the other at ~24 min). 
The average time for the onset of cocaine-induced convulsion was ~10.3 min after 
administration. As shown in Figure 3-1 A, cocaine concentration in the blood reached a 
peak of ~7 M (or ~7000 nM) at ~10 min after i.p. administration of 60 mg/kg cocaine. 
Comparison of the animal behavior data in Figure 3-2 C with the cocaine PK data in Figure 
3-1 A suggests that ~7 M is close to the threshold blood cocaine concentration leading to 
convulsion in rats. When the blood cocaine concentration is around 7 M, the effects 
caused by cocaine in the central nervous system could induce seizure, which manifests as 
convulsions in the behavior of rats. This is also a critical period since persistent seizure is 
most likely to cause sudden death. Since rats would not have free movement during 
convulsion and/or after death, the observed average locomotor activity in Figure 3-2 C first 
reached a peak at ~10 min and then dropped sharply due to the occurrence of convulsions 
in several rats. Data from Figure 3-1 A also showed that the blood cocaine concentration 
maintained above 5 M from 10 min to 60 min after cocaine administration. During this 
period, the behavioral effects of cocaine varied over a large range in rats, which is the 
reason for the big error bars in the figure when plotting the locomotion data. In some rats, 
a blood concentration in this range mainly produced hyperactivity. However, in the other 
rats, the blood concentration was high enough to maintain stereotyped behaviors, showing 
as fast repetitive head and/or foreleg movement when remaining in the corner of the test 
chamber (214). After an hour, the blood cocaine concentration dropped gradually to a level 
below 5 M. Majority of the rats recovered from the restricted component of cocaine’s 
effects and manifested hyperactivity as the behavioral effects of cocaine. 
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Figure 3-1. Time-dependent blood concentrations of cocaine, cocaine metabolites, and 
Albu-CocH1 in rats. (n=5 for each group) (A) – (C): Cocaine pharmacokinetics after i.p. 
administration of 60 mg/kg cocaine without (A) and with i.v. administration of 5 mg/kg 
Albu-CocH1 (B) or i.p. administration of 60 mg/kg cocaine (C) at t=30 min. Black arrows 
indicate the time point when the intervention was introduced. (D) Cocaine 
pharmacokinetics in protection experiment. (E) Cocaine pharmacokinetics in rescue 
experiment (blood samples were taken only after the Albu-CocH1 administration). (F) 
Albu-CocH1 pharmacokinetics after i.v. administration of 5 mg/kg Albu-CocH1. p < 0.001 
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and p < 0.05 indicates the significant differences in the pharmacokinetic data between the 
treated group and the untreated group (panel A).   
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Figure 3-2. Cocaine-induced locomotor activity in rats. For each group of rats (n=8), 
rats were first allowed to acclimate to the test chambers for 60 min before i.p. 
administration of cocaine or saline. Cocaine dose: (A) 180 mg/kg; (B) 100 mg/kg; (C) 60 
mg/kg; (D) 40 mg/kg; (E) 20 mg/kg; (F) 10 mg/kg. Data are plotted as the mean ± s.e.m. 
meters traveled in 5-min bin during 7-hour tests. With the lethal doses in (A) to (C), the 
recording was terminated after the occurrence of death. 
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3.3.3. Rescue effects of Albu-CocH1 and diazepam on the toxicity of a lethal dose (60 
mg/kg, i.p.) of cocaine 
Since the blood cocaine concentration reached the peak at ~30 min after i.p. 
administration of 60 mg/kg cocaine (Figure 3-1 A), in this set of experiments, we wanted 
to see whether administration of 5 mg/kg Albu-CocH1 or diazepam at 30 min after cocaine 
administration can help to reverse the cocaine toxicity, as shown in Figure 3-3. As 
mentioned above, most of rats had convulsion after i.p. administration of 60 mg/kg cocaine, 
and about 25% rats died before 30 min after cocaine injection. Rescue procedures were 
only performed on rats that had convulsion but were still alive at 30 mn or 60 min after 
cocaine administration. 
The enzyme dose of 5 mg/kg used in our experiments is comparable to human dose 
of 300 mg per person, assuming that the body weight of an adult is around 60 kg. This dose 
has been proven safe for humans in the clinical trials for Albu-CocH1 which has an 
elimination half-life of ~8 hours in rats as shown in Figure 1F and an elimination half-life 
of 43-77 hours in humans (197, 198). For the sake of comparison, diazepam was expected 
to be administered intravenously (i.v.) as the same as the administration route for Albu-
CocH1. However, in our pilot study, 5 mg/kg diazepam administered i.v. caused strong 
sedative effects in control group (without cocaine administration) with all rats lost righting 
reflex and muscle tone immediately after injection and lasted for at least one hour. In the 
other group, rats received 5 mg/kg diazepam (i.p.) exhibited drowsiness with slow and deep 
respiration within 3 min. In addition, i.p. injection of diazepam was more commonly used 
in the other studies and has been approved to be able to prevent the cocaine-induced 
convulsion in the rats (215).Therefore, we chose i.p. injection as the appropriate route to 
administer diazepam in this experiment. 
According to data depicted in Figure 3-3B, i.p. administration of 5 mg/kg diazepam 
significantly attenuated cocaine-induced hyperactivity. This behavioral result is largely 
attributed to the central inhibitory effects of diazepam, rather than acceleration of cocaine 
metabolism. On the contrary, according to data shown in Figure 3-1 C, diazepam actually 
slowed down elimination of cocaine and its metabolites (p = 0.049 for cocaine, p = 0.046 
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for benzoylecgonine, and p < 0.001 for norcocaine, according to statistical analysis using 
the two-way ANOVA). Due to the sedative effects of diazepam, rats generally had slower 
heart and breathing rates than normal during consciousness. This led to changed speed of 
hepatic blood flow, which could be the factor altering the clearance rate of cocaine in the 
rats. In comparison, i.v. administration of 5 mg/kg Albu-CocH1 immediately and 
completely eliminated cocaine-induced convulsion and hyperactivity (Figure 3-3 A), 
which is consistent with the cocaine PK data depicted in Figure 3-1B showing that cocaine 
was metabolized rapidly after the enzyme administration. In particular, blood cocaine 
concentration dropped from ~8 M to ~0.06 M in 2 minutes after enzyme administration.    
Overall, Albu-CocH1 was able to completely and rapidly remove cocaine from the 
blood stream and relieve all of the physiological effects caused by cocaine. Therefore, 
Albu-CocH1 was much more effective than diazepam in cocaine toxicity treatment, if 
Albu-CocH1 or diazepam was given when the blood cocaine concentration reached the 
peak at 30 min after the 60 mg/kg cocaine administration. 
In order to further study the effective window for Albu-CocH1 intervention, we 
tested the effects of 5 mg/kg Albu-CocH1 when Albu-CocH1 was administered (i.v.) at 60 
min after the 60 mg/kg cocaine administration (Figure 3-3 C). Due to the individual 
differences discussed above, the average behavioral effects induced by 60 mg/kg cocaine 
(i.p.) in the first hour after administration differed from the control group. In fact, there 
were more rats in this treatment group showing prolonged stereotyped behaviors in the first 
hour after cocaine administration, resulting in relatively lower average locomotor activity 
shown in the figure. After i.v. administration of Albu-CocH1 at 60 min, all behavioral 
effects caused by cocaine, including elevated locomotor activity and stereotyped behaviors, 
were eliminated.  
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Figure 3-3. Effects of 5 mg/kg Albu-CocH1 and diazepam on cocaine-induced 
locomotor activity and toxicity in rats. (A) – (C): Rats (n=8 per group) were allowed to 
acclimate to the test chambers for 60 min before i.p. administration of saline or 60 mg/kg 
cocaine. (A) 5 mg/kg Albu-CocH1 (i.v.) or (B) 5 mg/kg diazepam (i.p.) was administered 
at t=30 min or (C) t=60 min (Albu-CocH1 only) after the cocaine administration. Vertical 
red dashed lines indicate the time points when the interventions were introduced. Data are 
plotted as the mean ± s.e.m. meters traveled in 5-min bin during 7-hour tests. (D) 
Occurrence of convulsions and death in protection and rescue experiments. p < 0.001 (or 
***) indicates the significant difference in the cocaine-induced 
hyperactivity/convulsion/lethality between the treated group and the corresponding 
untreated group.  
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3.3.4. Rescue effects of Albu-CocH1 and diazepam on the lethality of an extremely 
high dose (100 or 180 mg/kg, i.p.) of cocaine  
As shown in Figure 3-2 A, increasing the lethal dose of cocaine from 60 mg/kg to 
100 mg/kg, all rats started convulsion at ~6.3 min and died at ~18.1 min. This indicated 
that 100 mg/kg (i.p.) was LD100 for rats. Using 180 mg/kg cocaine, all rats had convulsion 
onset at ~2.8 min and died at ~4.1 min. Apparently, the higher the lethal dose of cocaine, 
the sooner the convulsion and death will occur. Hence, it would be a bigger challenge to 
detoxify subjects administered with further higher doses of cocaine in time.  
Although the dose of 60 mg/kg examined above has already been sufficiently toxic, 
we would still like to further test the effectiveness of Albu-CocH1 and diazepam in 
protection and rescue rats from an even higher dose (180 mg/kg, LD100) of cocaine.  
As shown in Figure 3-1 D, pretreatment of rats with 5 mg/kg Albu-CocH1 (i.v.) 1 
min before i.p. administration of 180 mg/kg cocaine was able to rapidly and completely 
convert cocaine to EME, a physiologically inactive metabolite, once cocaine diffused into 
the blood. Blood cocaine concentrations (as well as the concentrations of cocaine 
metabolites including benzoylecgonine  the dominant metabolite shown in Figure 3-1 A 
in the absence of Albu-CocH1) at all time-points of blood sampling were negligible 
compared to the corresponding EME concentrations. As a result, in the presence of Albu-
CocH1, 180 mg/kg cocaine did not induce convulsion or death in any rats tested, as shown 
in Figure 3-3 C and Table 3-1. The enzyme fully protected all of the rats from the acute 
toxicity of 180 mg/kg cocaine. For comparison, rats were injected with 5 mg/kg diazepam 
(i.p. or i.v.) 5 min (if i.p.) or 1 min (if i.v.) before i.p. administration of 180 mg/kg cocaine. 
Due to the anticonvulsant effects of diazepam, all rats (except one out of 14) did not show 
convulsion, but all rats died at ~9-10 min (Figure 3-3 C and Table 3-1), later than the death 
of the control rats at ~4.1 min after cocaine administration. In conclusion, under the 
condition of 180 mg/kg cocaine, diazepam was only able to extend the time between the 
cocaine administration and death, without improving the survival.  
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In further rescue experiments, rats were given 180 mg/kg cocaine (i.p.) first, and 
then given 5 mg/kg Albu-CocH1 (i.v.) or diazepam (i.p. or i.v.) within 1 min after the onset 
of cocaine-induced convulsion. As shown in Figure 3-3 D and Table 3-1, diazepam did not 
rescue any rat. In comparison, the enzyme successfully rescued all rats; all rats survived 
and recovered (i.e. have righting posture and move normally) at ~4.2 ± 1.9 min after the 
cocaine administration (or ~1 min after the enzyme administration). The rescue effects of 
the enzyme are consistent with cocaine PK data depicted in Figure 3-1 E showing the time 
course of blood cocaine concentration after the enzyme administration. As seen in Figure 
3-1 E, immediately after the enzyme administration, cocaine in the blood was converted to 
physiologically inactive metabolite EME, which explains why all rats can recover so 
rapidly.   
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Table 3-1. Effects of diazepam and Albu-CocH1 on cocaine (180 mg/kg, i.p.) induced 
convulsion and lethality in rats. 
 
Drugs used Expt. 
method 
Number 
of rats 
Time after cocaine injection (min) 
Convulsion Death Recoveryf 
Cocaine (180 
mg/kg) 
Controla 10 2.78 ± 1.03 4.07 ± 1.87 N.A. 
Cocaine (180 
mg/kg) and 
Diazepam 
(5 mg/kg) 
 
Protectionb 
10 (i.p.) N.O. 9.10 ± 2.11 N.A. 
4 (i.v.) 9.10 (one rat) 9.91 ± 5.55 N.A 
 
Rescuec 
10 (i.p.) 2.75 ± 1.95 4.13 ± 2.76 N.A. 
4 (i.v.) 2.84 ± 1.91 4.14 ± 2.17 N.A. 
Cocaine (180 
mg/kg) and 
Albu-CocH1 
(5 mg/kg) 
Protectiond 10 N.O. N.O. N.A. 
Rescuee 10 2.82 ± 1.92 N.O. 4.2 ± 1.91 
 
a Control experiment was performed by administration of 180 mg/kg cocaine (i.p.). 
b Protection experiment was performed by pretreatment of rats with 5 mg/kg diazepam (i.p. 
for 10 rats and i.v. for 4 rats) 5 min (if i.p.) or 1 min (if i.v.) before administration of 180 
mg/kg cocaine (i.p.). 
c Rescue experiment was carried out by first administration of 180 mg/kg cocaine (i.p.). 
Then, in 1 min after the onset of cocaine-induced convulsion, rats were given 5 mg/kg 
diazepam (i.p. for 10 rats and i.v. for 4 rats). 
d Protection experiment was performed by pretreatment of rats with 5 mg/kg Albu-CocH1 
(i.v.) 1 min before administration of 180 mg/kg cocaine (i.p.). 
e Rescue experiment was carried out by first administration of 180 mg/kg cocaine (i.p.). 
Then, in 1 min after the onset of cocaine-induced convulsion, rats were given 5 mg/kg 
Albu-CocH1 (i.v.). 
f The clock time (starting from the cocaine administration) when the rats were fully 
recovered (occurrence of righting reflex and normal walk) from cocaine-induced 
convulsion.  
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3.4. Discussion and Conclusion 
Cumulative evidence from animal tests and clinical studies have consistently 
demonstrated that the elimination half-life of cocaine is dependent on the cocaine dose in 
both rats and humans. The higher the dose, the longer the elimination half-life of cocaine. 
In addition, cocaine generally has a significantly shorter elimination half-life in rats 
compared to that in humans. Based on the animal data, whenever Albu-CocH1 is given to 
a living subject (no matter whether blood cocaine concentration has reached the peak or 
not), the remaining cocaine in the body will be converted rapidly to physiologically 
inactive EME and, thus, reverse the cocaine toxicity and help the subject to recover.  
Further, according to our results, when the cocaine dose exceeds LD100, the time 
window for rescue is relatively narrow. However, the lower the cocaine dose, the wider the 
window for rescue. Our study has demonstrated that the rescue window associated with a 
lethal dose of 60 mg/kg (i.p.) is very reasonable. It should be noted that, for human with a 
60 kg body weight, 60 mg/kg would be equivalent to 3.6 g, much higher than commonly 
used oral doses of 50-300 mg (216). The minimum lethal dose of cocaine was estimated to 
be 1.2 g (http://drug.addictionblog.org/cocaine-overdose-how-much-amount-of-cocaine-
to-overdose/). With a significantly lower dose of cocaine, the time window for rescue will 
be much wider, as in the cases of most cocaine overdose caused emergency department 
visits. In addition, 30 min for rats may correspond to hours for humans because rats can 
eliminate cocaine much more rapidly than humans.  
It should also be noted that Albu-CocH1 is an investigational new drug (IND), 
known as TV-1380 (197, 198, 217) approved by the FDA for clinical trials in cocaine 
addiction treatment, rather than cocaine overdose treatment. The Phase I clinical trials have 
consistently shown that Albu-CocH1 (or TV-1380) in a single dose or repeated doses of 
300 mg is safe for use in humans.(197, 198) The Phase II clinical trial results “argue for 
development of improved enzymes with greater catalytic activity”(217) in order to be 
effective with the desirable once-weekly dosing schedule for cocaine addiction treatment. 
The present study has demonstrated for the first time that Albu-CocH1 (or TV-1380) is 
likely more appropriate for cocaine overdose treatment, and all of the animal data discussed 
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above consistently indicate that Albu-CocH1 is much more effective than diazepam in 
cocaine overdose treatment. As Albu-CocH1 has been proven safe for use in humans, one 
may go ahead to conduct further clinical trials for the efficacy of CocH1 (or TV-1380) in 
cocaine overdose treatment. 
In general, all of the animal data discussed above suggest that the key to cocaine 
toxicity treatment is to accelerate cocaine metabolism and rapidly convert cocaine to 
physiologically inactive metabolite EME. Once cocaine is completely converted to EME, 
the toxicity of cocaine will be reversed for the subjects. The general concept of enzyme 
therapy approach may also be used to develop other drug-specific enzymes for effective 
treatment of the toxicity of other abused substances. 
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4. Chapter Four 
Effectiveness and Duration of Fc-Fused CocHs in Blocking and Attenuating 
Psychomotor Stimulant Effects and Discriminative Stimulus Effects of Cocaine in 
Male Rats 
4.1. The psychostimulant and discriminative stimulus effects of cocaine 
As a potent inhibitor of monoamine reuptake transporters, administration of 
cocaine induces series of physiological effects in both rodents and humans. Due to the role 
of dopaminergic pathway in motor control, cocaine exhibits psychomotor stimulant effects 
when injected into rodents. In addition, psychomotor sensitization occurs after repeated 
cocaine treatment. This phenomenon is considered to play an important role in the 
incentive-sensitization theory of addiction (218). Some studies suggested that the 
neuroadaptations underlying these behavioral changes are related to the development of 
cocaine addiction. Thus, cocaine-induced hyperactivity and development of behavioral 
sensitization in rodents could be used as a behavioral endpoint to predict the effect of a 
medicine on blocking or attenuating the physiological effects of cocaine. The 
discriminative stimulus effects of cocaine are mediated by its interoceptive property 
(subjective effects in human), which has been suggested to contribute to the relapse of 
cocaine use in human. It has been well established to use drug discrimination techniques 
to classify and characterize the discriminative stimulus effects of abuse drugs, which can 
be viewed as analogues to the measurement of the subjective effects induced by drugs in 
humans (92). Therefore, the discriminative stimulus effects of cocaine in rodents could also 
be used as a behavioral endpoint to evaluate the effects of a medicine on blocking or 
attenuating the relapse-related property of cocaine. 
In a previous study, it has been shown that pretreatment of CocH3 could block the 
hyperactivity induced by cocaine in mice (173). In addition, we have shown that one early 
version of CocH3-Fc, CocH3-Fc(M3), could provide long-term blockade effect on cocaine 
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induced hyperactivity in mice with a single dose and the duration of this protection was 
dose dependent (186). 
In order to further extend the biological half-life of Fc-fused CocH, more mutations 
were induced to the carrier protein, Fc region, according to computational design and in 
vitro studies. A new version of CocH3-Fc containing 6 mutations in the Fc region was 
generated and selected based on the pharmacokinetic profile with IV and IM routes of 
administration (unpublished data). Following that, fusion proteins E30-6-Fc and E20-7-Fc 
were produced using the same Fc region.  
In the studies demonstrated in this chapter, we used cocaine-induced hyperactivity 
and discriminative stimulus effects as endpoints to characterize the effectiveness and 
duration of long-lasting CocHs (CocH3-Fc, E30-6-Fc, and E20-7-Fc) in elimination or 
attenuation of the physiological effects and subjective effects of cocaine. 
4.2. Materials and methods 
4.2.1. Materials 
The method to prepare the fusion protein (e.g. CocH3-Fc, E30-6-FC) used in this 
study was previously reported in a study [118].  Briefly, the protein was expressed in stable 
CHO-S cells (developed in our lab using a lentivirus-based method) that can stably produce 
the fusion protein. The protein production was performed in an agitated bioreactor 
BioFlo/CelliGen 115 (Eppendorf, Hauppauge, NY). Fc fusion protein in the culture 
medium was purified by using protein A affinity chromatography, which was performed 
on an ÄKTA avant 150 system (GE Healthcare Life Sciences). The purified protein was 
dialyzed in a storage buffer (50 mM HPEPS, 20% Sorbitol, 1 M Glycine, pH 7.4) and 
stored at −80°C before the use. 
(−)-Cocaine was provided by the National Institute on Drug Abuse (NIDA) Drug 
Supply Program (Bethesda, MD); and [3H](−)-Cocaine (50 Ci/mmol) was ordered from 
PerkinElmer (Waltham, Massachusetts). (+/-)-Methamphetamine was purchased from 
Sigma-Aldrich (St. Louis, MO). 
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4.2.2. Animals 
Seventy-two male Sprague-Dawley rats (220–250 g) were used in the experiments 
described in this chapter. They were ordered from Harlan (Harlan, Indianapolis, IN), and 
housed initially as two rats per cage. All rats were allowed ad libitum access to food and 
water and maintained on a 12 h light/12 h dark cycle, with the lights on at 8:00 a.m. at a 
room temperature of 21–22 °C. The animal protocol was approved by the IACUC 
(Institutional Animal Care and Use Committee) at the University of Kentucky. 
4.2.3. Determination of pharmacokinetic profiles of fusion CocHs in rats 
Rats were injected with the purified fusion CocH proteins (CocH3-Fc, E30-6-Fc, 
E20-7-Fc) via tail vein. Approximately 40-75 µl blood was collected into a heparin-treated 
capillary tube from saphenous vein at various time points after enzyme administration. 
Collected blood samples were centrifuged for 15 min at a speed of 5000 g to separate the 
plasma, which was kept at 4°C before analysis. A sensitive radiometric assay using 100 
μM (−)-cocaine was used to measure the enzyme concentration in plasma (202).   
4.2.4. Locomotor activity assay 
Locomotor apparatus 
The locomotor activity tests were performed in high-density, non-porous plastic 
chambers measuring 50 cm (L) × 50 cm (W) × 38 cm (H) (San Diego Instruments, San 
Diego, CA). Cumulative distance traveled was recorded by ANY-maze video tracking 
system (San Diego Instruments, San Diego, CA) to represent the locomotor activity.  
Locomotor activity tests  
One week after arriving in the animal facility, rats were allowed to stay in the test 
chamber for 3 hours on 3 consecutive days to acclimate to the environment. On each test 
day, each rat was placed in a square plastic chamber. After 1 hour, rats were injected (IP) 
with saline or cocaine. Locomotion was recorded throughout the habitation period and 2 
hours (1 hour for cocaine dose 10 mg/kg) after injection. 
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4.2.5. Drug discrimination assay 
Operant conditioning chamber 
The experiment sessions were conducted in an operant conditioning chamber with 
interior size of 30.5 cm (L) × 24.1 cm (W) × 21 cm (H) placed in a sound attenuating 
cubicle (Med Associates, Fairfax, VT). Each chamber was equipped with two retractable 
levers and a pellet dispenser which delivered 45 mg sucrose pellets (Bio-Serv, Frenchtown, 
NJ) into a pellet cup between the two levers. In the chamber, a house light was mounted 
on the wall facing the levers and pellet cup and a white light was located above each of the 
levers. 
Drug discrimination training 
The rats are maintained at 80% of their free-feeding weights for the period of the 
study. They were trained to respond for sucrose pellets under an FR1TO5 schedule with 
only one lever available (left or right during alternating sessions) initially. The fixed ratio 
was gradually increased to FR10TO5. Once rats consistently earned 10 pellets in 10 min 
session, they were trained to discriminate 10.0 mg/kg (IP) cocaine from saline using a 
double-alternation (SSCCSSCC…), two-lever discrimination procedure described in 
standard protocol (92) and related literature (190). The position (right/left) of the cocaine-
appropriate lever was counterbalanced across rats.  
During each training session, following cocaine or saline administration, rats were 
placed into an operant chamber, illuminated by the house light, for a 15-min pretreatment 
period. The start of the session was signaled by the EXT of the house light, insertion of the 
levers, and the illumination of the white light above each of the levers. Completion of 10 
presses (FR10) on the injection-appropriate lever resulted in sucrose pellet delivery 
followed by a 5-second time-out (TO) during which the white lights above the levers were 
extinguished. Responding on the alternate lever was recorded but had no scheduled 
consequence. Sessions terminated after 10 pellets had earned or 10 min had elapsed, 
whichever came first. When session ended, levers were retracted, white lights were 
extinguished, and the house light was illuminated.  
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Upon acquisition of the discrimination, defined as three consecutive sessions with 
>80% injection-appropriate responding during the first ratio and entire session, the number 
of components was gradually increased to 5, with each component identical to the initial 
discrimination training session. Daily sessions comprising 1–5 components (randomized 
across days), with each component preceded by the administration of either saline or 10.0 
mg/kg IP cocaine. Training continued until rats were allocating at least 80% of their 
responding on the injection appropriate during the first ratio of each component, as well as 
for components as a whole. 
Drug discrimination testing  
Briefly, after acquisition of discrimination, a substitution study was conducted first, 
in which the generalization gradients of cocaine (e.g. 0.32, 1.0, 3.2, and 10.0 mg/kg; IP) 
and (+/-)-methamphetamine (METH) (e.g. 0.032, 0.1, 0.32, and 1.0 mg/kg: IP) after PBS 
pretreatment was examined. Percentage of responses on the drug appropriate lever and the 
rate of responding was recorded during the test of each dose. The ED50 (dose that produces 
50% cocaine- appropriate responding) was calculated using non-linear regression analysis 
to show the potency to produce cocaine-appropriate responding.  
Following that, rats were subjects for pretreatment tests, in which a single dose of 
1 mg/kg CocH3-Fc was administered. Ten times higher dose gradient of cocaine (e.g. 10.0, 
32.0, 56.0, 100.0 mg/kg, IP) was evaluated on the same day and daily after CocH3-Fc 
injection until rats allocate at least 80% of their responding on the cocaine-appropriate 
lever following the training dose of cocaine (10.0 mg/kg, IP). Blood samples were collected 
after each test session for enzyme concentration analysis. 
4.2.6. Statistical analysis 
All data reported in the texts and figures are mean ± s.e.m. The number of rats of 
each group were indicated in the figure legend. Overall, within-group comparison was done 
by one-way ANOVA with repeated tests over time. Between-group comparison was done 
by two-way ANOVA (with repeated measurements over time) with pretreatment and time 
as factors. Comparison on individual day (pretreatment group vs. control group) was 
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conducted by t-test. Detailed statistical methods were addressed in the texts and the notes 
under the figures when p value was reported. All statistical analysis were performed using 
GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA). 
4.3. Experiments and Results 
4.3.1. Experiment 1a, 1b, 1c, 1d. Locomotor activity and behavioral sensitization 
induced by repeated cocaine IP injection 
In this set of experiments, locomotor activity induced by repeated cocaine IP 
injection at various doses (10 mg/kg, 20 mg/kg, and 40 mg/kg) was tested. On the last day 
of acclimation (-1 day noted in the figures below), baseline of saline induced locomotor 
activity of each rat was tested. All rats were randomly assigned to four groups. In order to 
serve as the control groups in the following experiments, all rats were shortly restrained 
and IV injected with vehicle (1 ml/kg) before the habitation period of locomotor test on 
Day 0. Rats in Exp. 1a, 1b, and 1c were tested under the same injection paradigm with 10 
mg/kg, 20 mg/kg and 40 mg/kg cocaine, respectively. During the repeated cocaine training 
phase, rats received two times of cocaine injections on consecutive days (Day 0 and Day 
1) followed by five times on every other day (Day 3, Day 5, Day 7, Day 9, and Day 11; 
See Figure 4-1A). Locomotor activity was monitored for each cocaine injection. After the 
training phase, cocaine (with group dose) induced locomotor activity was tested three times 
with a week of withdrawal time between tests (Day 18, Day 25, and Day 32). Rats assigned 
to Exp. 1d were injected with 20 mg/kg cocaine on Day 0 and every other day to Day 32 
(See Figure 4-1B). Total distance moved per hour after cocaine injection on each training 
day and test day are displayed in Figure 4-2.  
In Exp. 1a, although the injection paradigm is slightly different from the commonly 
used cocaine-sensitization procedure, which includes cocaine injections (10 mg/kg) on 8 
consecutive days, the group revealed the similar results. The repeated cocaine treatment 
produced locomotor sensitization as shown by a significant greater locomotor response to 
the last injection (7th) of cocaine compared with the first (Figure 4-2A, one-way ANOVA). 
This sensitized response lasted at least for 3 weeks indicated by the significant increased 
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locomotor response to the test cocaine injections on Day 18, Day 25, and Day 32 
(individually compared with response to the first injection by paired t-test). The time course 
of cocaine-induced locomotor activity on training days and test days are displayed in figure 
4-3. 
The two groups treated with 20 mg/kg cocaine (Exp. 1b and 1d) showed the similar 
pattern with first 7 repeated cocaine injections (no effect of injection regime, F (1, 14) = 
2.77, p = 0.118 by two-way ANOVA with repeated measures over time). The locomotor 
response to cocaine injection increased at the beginning, reaching a peak at 3rd injection, 
and then gradually decreased. Unlike the low dose group (Exp. 1a), the response induced 
by the 7th injection was not significantly increased compared to the first injection (Figure 
4-2B, C; within group one-way ANOVA with Dunnett’s post hoc). In Exp. 1b, among the 
three test days, only the response to cocaine test on Day 18 was significantly greater than 
the response to first cocaine exposure (paired t-test, p = 0.45). Responses on Day 18, Day 
25, and Day 32 were significant decreased compared to the peak response induced by 3rd 
cocaine injection (paired t-test). Comparing the later phase in Exp. 1b and 1d, cocaine 
induced locomotor response on Day 18 and Day 32 were significantly lower in Exp. 1d 
than in Exp. 1b, indicating a contribution of cocaine exposures to the suppression on 
cocaine-induced locomotor activity. By review the video recording, we found the reduced 
locomotor response was associated with increased rate and duration of stereotyped 
behaviors (fast repetitive head and/or foreleg movement when remaining in the corner of 
the test chamber) commonly inducing by cocaine injection at a higher acute dose (eg. 40 
mg/kg, 60 mg/kg). The time course of cocaine-induced locomotor activity after each 
cocaine injection is displayed in Figures 4-4 and 4-6, respectively. 
In Exp1c, the 1st injection of 40 mg/kg cocaine evoked the highest locomotor 
response during 1st hour after injection among all three doses. Then the response dropped 
significantly with repeated injections. Cocaine with a dose at 40 mg/kg also led to 
significantly increased locomotor activity at the 2nd hour after cocaine injection compared 
to the saline baseline. The locomotor response during this period remained stable with 
repeated injections. The responses to cocaine tests on Day 18, Day 25, and Day 32 were 
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similar to the responses of last three injection in the training phase. In fact, 40 mg/kg 
cocaine induced stereotyped behaviors in a subset of rats since the 1st injection. The time 
course of locomotor activity showed two peaks with a trough at around 30 min after cocaine 
injection (Figure 4-5). With repeated injections, the first peak became sharp and the time 
between the two peaks was significantly prolonged. From the 5th injection (on Day 7), 
almost all of the rats exhibited stereotyped behaviors from 10 min to 60 min after cocaine 
injection, leading to a minimal lever distance moved during 1st hour after cocaine injection 
(Figure 4-2D). This behavioral pattern was maintained during cocaine tests on Day 18, Day 
25, and Day 32. The time course of cocaine-induced locomotor activity after each cocaine 
injection are displayed in Figure 4-5. 
Interestingly, in Exp. 1d, starting from 8th cocaine injection at a dose of 20 mg/kg, 
the time course of locomotor activity showed this two-peak pattern as well (Figure 4-6). 
This may indicate repeated cocaine exposures at a lower dose eventually lead to similar 
sensitized stereotyped behaviors as those rapidly induced by higher dose of cocaine.  
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Figure 4-1. Schedule of cocaine injection or enzyme injection. (A) and (B) present 
schedules for cocaine injection used in experiments 1, 2, and 3 for cocaine-induced 
locomotor activity tests. (C) and (D) present schedules for single enzyme injection (C) and 
multiple enzyme injections. 
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Figure 4-2. Total distance moved per hour after cocaine (saline) injection. Mean ± 
SEM total distance moved in first hour after each cocaine injection in Exp. 1a (A), Exp. 1b 
(B), Exp. 1d (C). Mean ± SEM total distance moved in the first hour (D) and the second 
hour (E) in Exp. 1c. *: vs. 1st cocaine injection in the same group by one-way ANOVA 
with Dunnett’s multiple comparisons test; $: vs. 1st cocaine injection in the same group by 
paired t-test; &: vs. 3rd cocaine injection (peak response) in the same group by paired t-test; 
#: vs. 3rd cocaine injection (peak response) in the same group by paired t-test; %: vs. 
response on the same day in exp.1b by t-test. Applied to all the labels: *, p<0.05; **, p<0.01; 
***, p<0.001 
 
74 
 
 
Figure 4-3. Time course of locomotor activity induced by 10 mg/kg cocaine on training 
days and test days in Exp. 1a. Data are displayed as mean distance (s.e.m.) moved in 5 
min during 15 min before and 60 min after cocaine injection (t=0 min). 
  
 
75 
 
 
Figure 4-4. Time course of locomotor activity induced by 20 mg/kg cocaine on training 
days and test days in Exp. 1b. Data are displayed as mean distance (s.e.m.) moved in 5 
min during 15 min before and 120 min after cocaine injection (t=0 min). 
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Figure 4-5. Time course of locomotor activity induced by 40 mg/kg cocaine on training 
days and test days Exp. 1c. Data are displayed as mean distance (s.e.m.) moved in 5 min 
during 15 min before and 120 min after cocaine injection (t=0 min). 
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Figure 4-6. Time course of locomotor activity induced by 20 mg/kg cocaine on every 
other days in Exp. 1d. Data are displayed as mean distance (s.e.m.) moved in 5 min during 
15 min before and 120 min after cocaine injection (t=0 min).  
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4.3.2. Experiment 2. Long-term effects of CocH3-Fc on blocking psychostimulant 
effects of cocaine – single IV injection and multiple IV injection 
This experiment tested the effects of a single injection and multiples injections of 
CocH3-Fc on blocking psychostimulant effects caused by repeated cocaine injections. 
After saline baseline test, rats were randomly assigned to two groups. One group of rats 
(CocH3-Fc-Single) received a single dose of 3 mg/kg CocH3-Fc (IV) pretreatment before 
the habitation period of the locomotor test on Day 0 (Figure 4-1C). Another group of rats 
(CocH3-Fc-Multiple) received the same enzyme pretreatment on Day 0 and a repeated dose 
every 10 days (Figure 4-1D). Blood samples were withdrawn from rats in these two groups 
every day to track the plasma enzyme concentration. The injection regime and dose of 
cocaine is as same as used in Exp. 1b. Thus, Exp. 1b served as control group for this set of 
experiments. Total distance moved per hour after cocaine injection on each training day 
and test day and a plot of plasm enzyme concentration are shown in Figure 4-7. Time 
course of locomotor activity of all groups on cocaine training days and test days are 
displayed in Figure 4-8. 
There were no significant group differences in spontaneous locomotor activity 
emerged during the acclimation sessions nor saline-induced locomotor response (F (2, 21) 
= 1.19, p = 0.323) before the cocaine training phase. Across the cocaine-training period, 
during the first hour recording preceded by cocaine injection, there was a main effect of 
treatment (F (2, 21) = 102.5, p < 0.0001), day (F (6, 126) = 10.72, p < 0.0001), and 
treatment-by-day interaction (F (12, 126) = 7.395, p < 0.0001) (Figure 4-4A). Tukey’s post 
hoc comparisons revealed no difference between CocH3-Fc-Single group and CocH3-Fc-
Multiple group, but significant lower locomotor activity in both groups compared to the 
control group (p < 0.0001).  Apparently, CocH3-Fc pretreatment completed blocked 20 
mg/kg cocaine-induced elevation in locomotor activity in both groups during the cocaine 
training phase (Day 0 to Day 11) (Figure 4-5), when plasma enzyme concentration was 
above 10 mg/L (Figure 4-4B). During tests on Day 18, Day 25, and Day 32, as the plasma 
enzyme concentration was decreased, cocaine injection was able to gradually trigger 
locomotor response in the CocH3-Fc-Single group (Figure 4-5). However, compared to the 
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control group, the locomotor response was still significantly attenuated. This was attribute 
to blockade of the development of behavioral sensitization during training phase and the 
significant reduction of cocaine exposure time under the protection of residual enzyme 
(Figure 4-7), rather than exhibition of stereotyped behaviors (confirmed with video). In the 
CocH3-Fc-Multiple group, plasma enzyme concentration was maintained above 10 mg/L 
during the month of the experiment. Cocaine injection was not able to trigger apparent 
elevation on locomotor activity on all test days.  
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Figure 4-7. Plasma enzyme concentration and cocaine-induced locomotor activity in 
rats following CocH3-Fc single dose or multiple doses. (A) The mean (s.e.m.) distance 
traveled for 1 hour immediately following cocaine or saline injection of each group. (B) 
Daily plasma enzyme concentration in CocH3-Fc Single group and CocH3-Fc Multiple 
group. ****: p<0.0001 control group vs. both enzyme treatment groups by post-
comparison after two-way ANOVA (training phase) or one-way ANOVA (on each test 
day); #:  p< 0.05 vs. saline baseline of the same group by paired t-test. 
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Figure 4-8. Time course of locomotor activity induced by cocaine on training days 
and test days following CocH3-Fc single dose or multiple doses.  
 
82 
 
4.3.3. Experiment 3a, 3b. Long-term effects of E30-6-Fc and E20-7-Fc on blocking 
psychostimulant effects of cocaine 
In this set of experiments, we studied the long-lasting effects of E30-6-Fc and 20-
7-Fc on blocking and attenuating the psychostimulant effects caused by more intensively 
repeated cocaine injections. After saline baseline test, rats were randomly assigned to two 
groups (E30-6-Fc and E20-7-Fc). Each group of rats received a single dose of 3 mg/kg 
E30-6-Fc (IV) or E20-7-Fc (IV) pretreatment before the habitation period of the locomotor 
test on Day 0, respectively (Figure 4-1C). Blood samples were withdrawn from rats 1 hour 
after enzyme injection and then daily after behavioral test to track the plasma enzyme 
concentration. The injection regime and dose of cocaine is as same as used in Exp. 1d. 
Thus, Exp. 1d served as control group for this set of experiments. Total distance moved in 
first hour after each cocaine injection and a plot of plasm enzyme concentration are shown 
in Figure 4-9.  Time course of locomotor activity induced by cocaine on each day of E30-
6-Fc group and E20-7-Fc group in Figures 4-10 and 4-11, respectively.  
There were no significant group differences in spontaneous locomotor activity 
emerged during the acclimation sessions nor saline-induced locomotor response (F (2, 21) 
= 2.07, p = 0.151) before the cocaine training phase. Across all 17 cocaine tests in a month, 
during the first hour recording preceded by cocaine injection, there was a main effect of 
treatment (F (2, 21) = 98.7, p < 0.0001), day (F (16, 336) = 5.12, p < 0.0001), and treatment-
by-day interaction (F (32, 336) = 13.34, p < 0.0001) (Figure 4-4A). Tukey’s post hoc 
comparisons revealed no difference between E30-6-Fc group and E20-7-Fc group, but 
significant lower locomotor activity in both groups compared to the control group (p < 
0.0001). Mean plasma enzyme concentration during the time of the study in both E30-6-
Fc group and E20-7-Fc group are displayed in Figure 4-9 B. The pharmacokinetic profile 
of each enzyme was similar as the data obtained from previous PK studies without cocaine 
treatments (unpublished data). 
Due to the locomotor response induced by cocaine were still significantly 
attenuated on Day 32 with the presence of E30-6-Fc and E20-7-Fc, we conducted 4 more 
tests to Day 40 in E30-6-Fc group and E20-7-Fc group. The locomotor responses induced 
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by 21st cocaine injection on Day 40 in both groups with enzyme pretreatment were still 
significantly lower than the initial response (1st cocaine injection) and the peak response 
(3rd cocaine injection) in the control group (Figure 4-12 A and B). 
A detailed analysis of distance moved in first 15 min of locomotor test is shown in 
Figure 4-12 C-E.  A single dose of E30-6-Fc was able to completely block psychostimulant 
effects of cocaine (at a dose of 20 mg/kg) for 12 to 14 days (no significant increase in 
locomotor activity in 0-5 min after cocaine injection compared to response to saline Figure 
4-12 C). After that, enzyme could rapidly eliminate cocaine’s effects in 5 min and 10 min 
for more than 20 days and 30 days, respectively (Figure 4-12 D and E).  
The relation between cocaine-induced locomotor activity in 15 min and plasm 
enzyme level was tested by correlation analysis. A negative correlation (R2 = 0.914) was 
found between the behavioral response and enzyme level from Day 16 to Day 40 (Figure 
4-12 F).  
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Figure 4-9. Plasma enzyme concentration and cocaine-induced locomotor activity in 
rats following a single dose of E30-6-Fc or E20-7-Fc. (A) The mean (s.e.m.) distance 
traveled for 1 hour immediately following cocaine or saline injection of each group. (B) 
Daily plasma enzyme concentration in E30-6 Single group and E20-7 Single group. # :  p< 
0.05 compared to saline baseline of the same group by one-way ANOVA with Dunnett’s 
multiple comparisons test 
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Figure 4-10. Time course of locomotor activity induced by cocaine on every other day 
following E30-6-Fc single dose. 
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Figure 4-11. Time course of locomotor activity induced by cocaine on every other day 
following E20-7-Fc single dose. 
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Figure 4-12. Locomotor activity in 15 min after each cocaine administration in rats 
pretreated with a single dose of E30-6-Fc. (A)-(B): Locomotor activities (total distance 
moved in an hour (A) and time course of movement (B)) induced by 1st & 3rd cocaine in 
control group and by 21st cocaine on 40th day in enzyme treated group (30-6-Fc and 20-7-
Fc). (C)– (E): Scatter plot of distance moved in 0-5 min (C), 5-10 min (D), 10-15 min (E) 
by individual rat after cocaine (or saline) injection on each test day. (ns: not significantly 
higher compared to saline baseline using one-way ANOVA with Dunnett’s post hoc 
comparison) (F) Regression slopes between plasma concentration of E-30-6-Fc (presented 
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as average of 8 rats on each day) and distance moved in first 15 min after cocaine injection 
(presented as average of 8 rats on each day) from Day 16 to Day 40.   
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4.3.4. Experiment 4. Pilot study: Long-term effects of CocH3-Fc on blocking 
discriminative stimulus effects of cocaine.  
In a pilot study, we evaluated the duration of CocH3-Fc’s effects on blocking the 
discriminative stimulus effects of cocaine. A group of rats was trained to discriminate 
cocaine from saline using a two-lever drug discrimination task.   
As shown in Figure 4-13 A and B, cocaine produced dose-dependent increases in 
the selection of the cocaine-associated level, with 99.86 ± 0.36% of presses occurring on 
the cocaine-appropriate lever following the training dose of cocaine (10 mg/kg, IP). 
Methamphetamine also produced similar dose-dependent increases in the selection of 
cocaine-associated level in rat pre-trained to discriminate cocaine from saline, with a full 
generalization to the discriminative stimulus effects of cocaine at 1 mg/kg.   
Pretreatment with 1.0 mg/kg CocH3-Fc produced rightward shifts in the dose–
response curve for cocaine-induced increases in cocaine-appropriate responding (Figure 4-
13 C and D). The ED50 of cocaine was significantly increased from 2.22 mg/kg (95% C.I. 
= 1.40 - 3.30 mg/kg) to 44.59 mg/kg (95% C.I. = 32.72 - 66.77 mg/kg) after Fc-CocH3 
treatment (24 hours). The discriminative effect induced by 10.0 mg/kg cocaine was 
completely blocked by single dosing of Fc-CocH3 for 10 days (Figure 4-9 E). The minimal 
plasma enzyme concentration to achieve this blockade effect was determined to be 0.99 ± 
0.65 mg/L (mean ± S.D.). 
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Figure 4-13. Effects of pretreatment with CocH3-Fc in rats trained to discriminate 
cocaine from saline.  
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4.4. Discussion and conclusion  
4.4.1. Effects of cocaine dose and injection regime on development of behavioral 
sensitization. 
In this chapter, we first studied the behavioral sensitization induced by repeated 
cocaine injection at multiple-dose (10 mg/kg, 20 mg/kg, and 40 mg/kg, IP) conditions. In 
consistent with literature, repeated IP administration of 10 mg/kg resulted in increase in 
total distance moved captured by video tracking system, which met the general definition 
of behavioral sensitization – progressively increased locomotion with repeated cocaine 
exposure. However, for the groups with cocaine dose at 20 mg/kg and 40 mg/kg, the 
patterns of behavioral change caused by repeated cocaine administration are distinct. In 20 
mg/kg group, the locomotor response induced by cocaine initially increased and reached 
peak with 3 to 4 injections, then, decreased gradually. In 40 mg/kg group, the locomotor 
response decreased steeply starting from the second injection. Later, we found the 
decreased locomotor response (horizontal movement) was due to increased time spending 
on stereotyped behavior response. This observation is consistent with the assessments of 
cocaine-induced locomotor activity after cocaine self-administration training. It has been 
shown that extended access to cocaine fails to produce locomotor sensitization (90) but 
does produce a sensitized stereotyped behavior response (91). As stated in the early 
literature focusing on behavioral responses of psychostimulant (219-221), the behavioral 
sensitization does not involve simply quantitative changes in a given behavior (e.g. 
increased locomotion), but complex qualitative changes in patterns of behavior that vary 
as a function of many factors, including dose, number of treatments, and so on (91). Our 
results supported the statement that the typical pattern of behavioral sensitization induced 
by repeated cocaine exposure involves a transition from behaviors dominated by locomotor 
hyperactivity to behavior dominated by progressively more stereotyped activity (91). In 
addition, the higher the cocaine dose is, the sooner the transition occurs, indicating a 
contribution of cumulative cocaine exposure in this process. The comparison between Exp. 
1b and Exp. 1d revealed the frequency and intensity of the cocaine exposure also played a 
role in accelerating the transition.  
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4.4.2. Long-lasting effects of Fc-fused CocHs on cocaine induced physiological and 
subjective effects. 
In this part, we first studied the long-lasting effects of a single dose and multiple 
doses of CocH3-Fc using a standard animal model for behavioral sensitization, which was 
used to evaluate the efficacy of CocH gene therapy and anti-cocaine vaccine combination 
treatment (222) and cocaine vaccine (dAd5GNE) (223) in antagonizing cocaine-induced 
locomotion in rats (as demonstrated in Exp. 2b). Based on the mechanism of action of 
biologics developed using PK strategy, the dose of cocaine using in a model plays an 
important role in determining the results. In order to induce more challenges to our enzyme, 
we used cocaine dose at 20 mg/kg, rather than 10 mg/kg and 15 mg/kg used in two previous 
studies. Even with the elevated cocaine dose, a single injection of CocH3-Fc (3 mg/kg) 
was able to show significantly more effective in antagonizing cocaine-induced locomotion 
and behavioral sensitization in rats compared to the other innervations. Rather than 
attenuated locomotor responses exhibited during the cocaine training phase (development 
of behavioral sensitization) in the other two studies, repeated administration of 20 mg/kg 
cocaine failed to trigger any apparent increase in locomotion with the presence of CocH3-
Fc. In addition, the multiple-dose group demonstrated the possibility of eliminating 
cocaine’s effects for a long term (e.g. a month, three months, six months…) by repeated 
enzyme administration. However, we have not carried out further studies to produce 
evidence from the cellular and molecular levels to show the long-term protective effects 
provided by CocH3-Fc on the rodent nervous system. 
In the next study, we introduced a more intensive repeated cocaine administration 
regime at dose of 20 mg/kg (as demonstrated in Exp. 2d) to test the effectiveness and 
duration of action with a single dose of E30-6-Fc and E20-7-Fc. These two enzyme forms 
represent the top performing enzymes we had produced in terms of both in vitro catalytic 
efficiency and in vivo biological half-life. Using this animal model, we were able to study 
the relationship between behavioral responses of rats and concurrent plasma enzyme 
concentration. As shown in the results section, E30-6-Fc and E20-7-Fc overall exhibited 
equivalent efficacy during the one-month tests in blocking or attenuating the physiological 
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effects induced by cocaine. Detailed analysis was performed using E30-6-Fc as an example. 
It has been found that with a plasma enzyme concentration above 5.19 ± 0.52 mg/L, which 
is up to 14 days after the single-dose enzyme administration, rats failed to show significant 
elevated locomotor responses within 5 min (as well as within the 2-hour recording) after 
20 mg/kg cocaine administration. From Day 16 to Day 22 after enzyme administration, 
when the plasma enzyme concentration was within the range from 4.57 ± 0.60 mg/L to 
3.13 ± 0.38 mg/L, physiological effects induced by cocaine, which lasts more than 80 min 
in rats of control group, was eliminated within 5 min. Moreover, a negative correlation 
found between the behavioral response within 15 min after cocaine injection and plasma 
enzyme level during the later phase of the study (Day 16 to Day 40) confirmed the major 
role of enzymatic activity on attenuation of behavioral responses. 
Finally, in a pilot study using drug discrimination paradigm, it has been shown that 
a single dose of 1 mg/kg CocH3-Fc was able to block the subjective effects induced by 10 
mg/kg cocaine (IP) for up to 10 days. Although, the studies using higher CocH3-Fc dose 
(3 mg/kg) was not included as part of this dissertation, the results revealed a dose-
dependent increase in the duration of blockade effects (unpublished data).  
 
In conclusion, the results presented in this chapter strongly support the hypothesis 
that the Fc fusion CocHs with significantly extended biological half-lives are able to 
maintain long-term effectiveness in blocking or attenuating the psychological and 
subjective effects of cocaine in vivo in a plasma enzyme concentration dependent manner. 
Based on these results, CocH3-Fc and E30-6-Fc were picked to be assessed in intravenous 
cocaine self-administration model for further evaluation.  
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5. Chapter Five 
Effectiveness and Duration of Fc-fused CocHs in Blocking and Attenuating 
Reinforcing Effects of Cocaine in Male and Female Rats 
5.1. The reinforcing effects of cocaine 
Cocaine’s reinforcing stimulus effects, which are mediated by its action on the 
mesolimbic dopaminergic pathway, are the key factors leading to cocaine’s abuse liability. 
Intravenous self-administration (IVSA) using laboratory animal is a reliable model and 
direct measurement of the reinforcing effects of drugs with substantial face validity and 
predictive validity. It has been widely used as a gold standard in preclinical evaluation of 
pharmacotherapies for the treatment of drug abuse. Generally, in preclinical evaluation, an 
effective anti-cocaine treatment should be able to make the cocaine more like saline or a 
lower dose by antagonizing its reinforcing properties.  
It has been shown that enzyme Albu-CocH1 was able to block or attenuate the 
reinforcing effects of cocaine in rats (176, 177) by accelerating the metabolism of cocaine 
in the peripheral circulation system. However, the enzyme required daily injection (with 
dose of 2 or 4 mg/kg) right before the test session to achieve the desired effects due to its 
short half-life in the rats (~8 hour). The only reported long-lasting effects of a single 
enzyme injection was produced by PEG-CCRQ CocE (190). However, the effects on 
attenuating the reinforcing effects of cocaine only lasted for 3 days with a dose as high as 
32 mg/kg, which is not possible to be translated to clinic use.  
As shown in Chapter three, the Fc-fused CocHs newly developed in our lab were 
able to block or attenuate the physiological effects of cocaine for at least 40 days with a 
clinically translatable dose of 3 mg/kg. In the studies described in this chapter, two 
promising Fc-fused CocHs (CocH3-Fc and E30-6-Fc) for further development were tested 
on their effectiveness and duration in blocking and attenuating the reinforcing effects of 
cocaine. The effects of E30-6-Fc were investigated in both male and female rats. In addition, 
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the minimal plasma enzyme concentrations needed to completely block the reinforcing 
effects induced by each cocaine unit doses (0.1, 0.32, and 1 mg/kg/inf.) were determined. 
5.2. Materials and methods 
5.2.1. Materials 
The method to prepared fusion protein (e.g. CocH3-Fc, E30-6-FC) used in this 
study was previously reported in a study (202).  Briefly, the protein was expressed in stable 
CHO-S cells (developed in our lab using a lentivirus-based method) that can stably produce 
the fusion protein. The protein production was performed in an agitated bioreactor 
BioFlo/CelliGen 115 (Eppendorf, Hauppauge, NY). Fc fusion protein in the culture 
medium was purified using protein A affinity chromatography, which was performed on 
an ÄKTA avant 150 system (GE Healthcare Life Sciences). The purified protein was 
dialyzed in a storage buffer (50 mM HPEPS, 20% Sorbitol, 1 M Glycine, pH 7.4) and 
stored at −80°C before the use. 
(−)-Cocaine was provided by the National Institute on Drug Abuse (NIDA) Drug 
Supply Program (Bethesda, MD); and [3H](−)-Cocaine (50 Ci/mmol) was ordered from 
PerkinElmer (Waltham, Massachusetts). (+/-)-Methamphetamine was purchased from 
Sigma-Aldrich (St. Louis, MO). 
5.2.2. Animals 
Thirty-eight male and sixteen female Sprague-Dawley rats (300–350 g) were used 
in the experiments described in this chapter. They were ordered from Harlan (Harlan, 
Indianapolis, IN), and housed initially as two rats per cage. All rats were allowed ad libitum 
access to food and water and maintained on a 12 h light/12 h dark cycle, with the lights on 
at 8:00 a.m. at a room temperature of 21–22 °C. The animal protocol was approved by the 
IACUC (Institutional Animal Care and Use Committee) at the University of Kentucky. 
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5.2.3. Blood collection and measurement of plasma CocH concentration  
At the time for treatment, rats were injected with the purified fusion CocH proteins 
(CocH3-Fc or E30-6-Fc) via tail vein. Approximately 40-75 µl blood was collected into a 
heparin-treated capillary tube from saphenous vein at 1 hour after enzyme administration 
and daily after behavioral testing. Collected blood samples were centrifuged for 15 min at 
a speed of 5000 g to separate the plasma, which was kept at 4°C before analysis. A sensitive 
radiometric assay using 100 μM (−)-cocaine was used to measure the enzyme 
concentration in plasma (202).   
5.2.4. Surgery and apparatus for self-administration 
Preparation and catheter implantation surgery 
After one-week acclimation period in the new animal facility, rats were introduced 
to the operant conditioning chambers for food reinforced lever press training for a 10 min 
session daily. Once rats were able to earn 10 food pellets within 10 min under FR5 on 3 
consecutive days, they were considered as well-trained and subjects to the catheter 
implantation surgery. 
All the rats passed the initial food training were implanted with polyurethane 
catheters (C30PU-RFV1418, Instech Laboratories, PA) in the left femoral vein under 
isoflurane anesthesia according to the method described in literature (224). The opposing 
end of the catheters were passed under the skin to the rats’ back to emerge between the 
scapular where they were attached to a rat VAH harness (VAH95AB, Instech Laboratories, 
PA). Rats were allowed to recover for 6-7 days before all the experiment. Catheters were 
flushed daily with 0.2 ml of heparinized saline (100 U/ml) before the start, and after the 
completion of operant sessions. 
Apparatus  
All experiment sessions were conducted in an operant conditioning chamber with 
interior size of 30.5 cm (L) × 24.1 cm (W) × 21 cm (H) placed in a sound attenuating 
cubicle (Med Associates, VT). Each chamber was equipped with two retractable levers. In 
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the chamber, a house light was mounted on the wall facing the levers and a white light was 
located above each of the levers. A VTA spring tether (VAH95T, Instech Laboratories, PA) 
was held above the chamber by a counterbalanced arm to connecting the syringe and 
external port on the harness. The syringe pumps (PMH-100; Med Associates) were used to 
deliver solutions under the control of Med-PC IV Software (SOF-735, Med Associates).  
5.2.5. Intravenous self-administration training 
5.2.5.1. Acquisition and maintenance of cocaine self-administration under fixed-
ratio reinforcement 
Rats were initially trained to press one lever (defined as the active level) for 
injection of 0.4 mg/kg/inf. cocaine during a 2-hour session daily under a FR1TO5 schedule 
of reinforcement with active lever counterbalanced across rats. At the beginning of the 
session, the house light and fan were turned on. Illumination of the white light above the 
active lever signaled drug availability. The press on the active lever resulted in unit cocaine 
injection. During the 5-s time out (TO) period, the white light located on the active level 
was turned off and responses were recorded but had no scheduled consequence. Once they 
were able to acquire 20 infusions per session, the ratio requirement was gradually increased 
(1, 3, 5) until rats were responding under an FR5TO5 schedule of reinforcement. Upon 
stabilization of the cocaine intake under this schedule, rats were allowed to get access to 
cocaine for at least 7 sessions for maintenance training.  
5.2.5.2. Multiple-dose cocaine self-administration 
Upon stabilization of responding, daily 2-hour sessions were replaced by a multi-
component, 5-dose procedure. Under this procedure, increasing unit doses of cocaine (0, 
0.032, 0.1, 0.32, and 1.0 mg/kg/inf.) were available during five sequential 30 min 
components (modified from (190, 225)). Each component was initiated by the non-
contingent delivery of the unit dose of the drug available for responding and separated by 
a 2-min inter-component interval during which time the house light was turned off and the 
levers were retracted. During the long-term multiple-dose testing after enzyme (or vehicle) 
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administration, only 4 cocaine doses (0, 0.1, 0.32, and 1.0 mg/kg/inf.) were included in this 
test. 
5.2.5.3. Cocaine self-administration under progressive-ratio reinforcement 
After the dose–response function of cocaine self-administration was determined, 
the rats were tested for cocaine self-administration under a progressive-ratio (PR) schedule. 
Under the PR reinforcement, the response requirement began at one response per injection 
and increased according to the following equation: responses/injection=(5 × e(injection number × 
0.2))−5 (103). When a rat failed to get the next infusion within 1 hr, the session ended.  
5.2.5.4. Methamphetamine self-administration under fixed-ratio reinforcement 
For the last step during self-administration training, methamphetamine self-
administration at unit dose of 0.06 mg/kg/inf. under same fixed-ratio reinforcement 
(FR5TO5) were tested on the cocaine dependent rats for at least 3 days. In order to match 
the total session time and drug availability condition during multiple-cocaine self-
administration test in the following experiments, there was a 30 min extinction period 
(equivalent to 0 mg/kg/inf. during multiple dose test) before the 90 min methamphetamine 
self-administration session. The drug available session was initiated by the non-contingent 
delivery of 0.06 mg/kg/inf. methamphetamine.  
5.2.6. Statistical analysis 
All data reported in the texts and figures are mean ± s.e.m. The number of rats of 
each group was indicated in the figure legend. Between-group comparison was done by 
two-way ANOVA (with repeated measurements over time) with pretreatment and time as 
factors. Detailed statistical methods were addressed in the texts and the notes under the 
figures when p value was reported. All statistical analyses were performed using GraphPad 
Prism 7.0 (GraphPad Software, La Jolla, CA). 
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5.3. Experiments and results 
5.3.1. Experimental 1: Establishment of a long-term testing model in rats 
In this experiment, we first compared the sex differences in the intravenous self-
administration (IVSA) of cocaine and methamphetamine. Under a FR schedule of 
reinforcement, we found that female rats took significantly more infusions of cocaine at a 
unit dose of 0.4 mg/kg/inf. per session (120 min) compared to male rats in the maintenance 
phase of cocaine IVSA (p < 0.0001 by t-test) (Figure 5-1 A). Whereas, there was no sex 
difference on the methamphetamine intake at a unit dose of 0.06 mg/kg/inf. (Figure 5-1 B). 
Two-way ANOVA analysis of cocaine dose response curves in both sexes revealed a 
significant main effect of unit dose (F (4, 56) = 95.46, p < 0.001), a main effect of sex (F 
(1, 14) = 89.12, p < 0.001), and a dose × sex interaction (F (4, 56) = 35.72, p < 0.001) 
(Figure 5-1 C). Comparison of total cocaine intake during sessions with various unit doses 
showed that female rats had a tendency to take more cocaine compared to male rats at the 
low to medium unit dose range (0.032 mg/kg/inf. to 0.32 mg/kg/inf.), but similar amount 
of cocaine as male rats at a higher unit dose (1 mg/kg/inf.) (Figure 5-1 D).  
In order to study the sex differences in motivation for cocaine, male and female rats 
were assessed under a PR schedule of reinforcement at two unit-doses (Figure 5-1 E, F, 
and G). Two-way ANOVA revealed a significant main effect of unit dose (F (1, 14) = 
66.92, p < 0.0001), a main effect of sex (F (1, 14) = 44.02, p < 0.0001), but no dose × sex 
interaction (F (1, 14) = 0.027, p = 0.872). Bonferroni’s post hoc comparison showed that 
both male and female rats earned significantly more infusions of cocaine at higher unit 
dose (1 mg/kg/inf.) compared to lower unit dose (0.4 mg/kg/inf.). In addition, female rats 
eared significantly more infusions of cocaine compared to male rats at both unit doses. 
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Figure 5-1. Comparison between male and female rats in cocaine and 
methamphetamine self-administration. (A) and (B): Mean number (s.e.m.) of cocaine 
(A) and methamphetamine (B) infusions under a FR schedule of reinforcement (****: p < 
0.0001 by t-test). (C) and (D): Dose response curve of cocaine self-administration (C) and 
corresponding cocaine intake per session (30 min) at each unit dose (D) (**: p < 0.01, ***: 
p < 0.001, ****: p < 0.0001 by post hoc tests of two-way ANOVA). (E) – (G): Mean 
number (s.e.m.) of cocaine earned (E), break point (F), and total active level presses (G) 
under a PR schedule of reinforcement. (###: p < 0.001, ####: p < 0.0001 comparison 
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between unit dose in the rats of the same sex; ****: p < 0.0001 comparison between sex 
under same unit dose by post hoc tests of two-way ANOVA). 
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In order to test the long-term effects of a single injection of enzyme on cocaine 
IVSA and methamphetamine IVSA, we designed a 5-week testing schedule. This schedule 
included weekly cocaine IVSA testing under a PR schedule, weekly methamphetamine 
IVSA testing, and multiple-dose cocaine IVSA tests on the rest days (Figure 5-2 B). 
Methamphetamine (0.06 mg/kg/inf.) IVSA under a FR schedule of reinforcement was 
tested on Day 2, Day 9, Day 16, Day 23, and Day 30 after enzyme or vehicle injection. 
Cocaine (1 mg/kg/inf.) IVSA under a PR schedule of reinforcement was tested on Day 5, 
Day 12, Day 19, Day 26, and Day 33 after enzyme or vehicle injection. On the rest days 
from Day 0 to Day 35 after enzyme or vehicle injection, multiple-dose cocaine (0.1, 0.32, 
1 mg/kg/inf.) tests were conducted. The test on each day was preceded by a 30-min 
extinction component. Each test was initiated by the non-contingent delivery of the unit 
dose of the drug available for responding. At the minimal cost of time and materials, this 
model enabled us to learn how a single-time enzyme treatment, depending on its PK profile, 
changes the reinforcing efficacy of cocaine, pattern of cocaine intake at various doses, and 
IVSA reinforced by methamphetamine. 
We first tested this model in female and male rats treated with vehicle to study how 
the rats behave under this long-term testing schedule. After IVSA training and baseline 
acquisition showing in Figure 5-2 A, eight female rats and eight male rats received IV 
injection of vehicle on Day 0 (denoted as Male Control and Female Control in contexts and 
figures). Then, they were subjects of the 5-week testing schedule. As seen in Figures 5-3 
and 5-4, both male and female rats maintained stable baseline-level drug intake under each 
test condition. Therefore, the long-term testing schedule had no significant impact on 
cocaine intake with each unit dose, cocaine infusions earned under FR schedule, and 
methamphetamine intake in both male and female rats.  
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Figure 5-2. Experimental design. (A) Timeline of the whole experiment, including 
surgery, cocaine self-administration training, baseline acquisition, treatment, and post-
treatment tests. (B) Detailed schedule of 5-week post-treatment self-administration tests. 
(CMDT: cocaine multiple dose tests; METH: methamphetamine IVSA test; CPR: cocaine 
progressive ratio test) 
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Figure 5-3. Effects of long-term tests on multiple-dose cocaine self-administration 
under a FR schedule of reinforcement in male and female rats. Mean number (s.e.m.) 
of cocaine infusions per session (30 min) at unit dose of 0.1 mg/kg/inf. (A: male; B: 
Female), 0.32 mg/kg/inf. (C: male; D: Female), and 1 mg/kg/inf. (E: male; F: Female) 
before (Baseline) and daily (0 Day – 35 Day) after a single time vehicle treatment. (ns: no 
effects of time by repeated measurements of one-way ANOVA) 
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Figure 5-4. Effects of long-term tests on cocaine self-administration under a PR 
schedule of reinforcement and methamphetamine self-administration under a FR 
schedule of reinforcement in male and female rats.  
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5.3.2. Experimental 2: Effects of a single dose of CocH3-Fc on cocaine and 
methamphetamine IVSA in male rats 
Six male rats were used to study the long-term effects of a single dose of CocH3-
Fc on cocaine and methamphetamine IVSA. Upon cocaine IVSA training and baseline 
acquisition, rats were IV injected 3 mg/kg CocH3-Fc on Day 0 (denoted as Male CocH3-
Fc in the contexts and figures). Then, they were tested daily following the 5-week testing 
schedule. 
As shown in Figure 5-5, there were no group difference on the baseline-level 
performance between Male Control and Male CocH3-Fc. However, the single-time 
enzyme treatment significantly changed the number of drug infusions in the sessions 
reinforced by cocaine under a FR schedule (Figure 5-6). At unit dose of 0.1 mg/kg/inf., 
mean number of cocaine infusions were significantly reduced in the Male CocH3-Fc group 
for the period of all 5 weeks with infusion number close to 0 during first 3 weeks (Figure 
5-6 A). At unit dose of 0.32 mg/kg/inf., mean number of cocaine infusions were 
significantly changed in the Male CocH3-Fc group for 22 days with infusion number 
decreased (close to 0) in the first 8 days and increased from Day 11 to Day 22 (Figure 5-6 
B). At unit dose of 1 mg/kg/inf., mean number of cocaine infusions were significantly 
changed in the Male CocH3-Fc group for 20 days with infusion number decreased (close 
to 0) in the first 3 days and increased from Day 6 to Day 20 (Figure 5-6 C). 
Male CocH3-Fc group took more cocaine in total compared to the Male Control 
group during 3-4 weeks after enzyme treatment. However, it was noticed that Male CocH3-
Fc group stayed calm down after test sessions. They had no significant behavioral sign of 
“high” when compared to the Male Control group.  
With a PR schedule of reinforcement, rats in Male CocH3-Fc group earned 
significantly less cocaine (1 mg/kg/inf.) infusions compared to Male Control in all tests 
conducted (Figure 5-7 A-C). For IVSA reinforced by methamphetamine, two-way 
ANOVA revealed no main effect of treatment (vehicle vs. CocH3-Fc) nor time (Figure 5-
7 D).  
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Figure 5-5. Baseline comparison between male control group and male CocH3-Fc 
group. (A) Mean number (s.e.m.) of cocaine infusion (0.4 mg/kg/inf.) in last 7 sessions of 
maintenance training under schedule of FR5TO5; (B) Cocaine dose response curve tested 
in daily multiple-component session; (C) Mean number (s.e.m.) of cocaine infusion (1 
mg/kg/inf.) earned under a PR schedule of reinforcement; (D) Mean number (s.e.m.) of 
methamphetamine infusion (0.06 mg/kg/inf.) in the last methamphetamine test.  
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Figure 5-6. Long-term effects of CocH3-Fc on multiple-dose cocaine self-
administration under a FR schedule of reinforcement in male rats. Mean number 
(s.e.m.) of cocaine infusions per session (30 min) at unit dose of 0.1 mg/kg/inf. (A), 0.32 
mg/kg/inf. (B), and 1 mg/kg/inf. (C) before (Baseline) and daily (Day 0 – Day 35) after a 
single time treatment (vehicle or 3 mg/kg CocH3-Fc). (&: Significantly higher infusion 
number vs. control group @: Significantly lower infusion number vs. control group) 
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Figure 5-7. Long-term effects of CocH3-Fc on cocaine self-administration under a PR 
schedule of reinforcement and methamphetamine self-administration under a FR 
schedule of reinforcement in male rats.  (A) – (C): Cocaine self-administration under a 
PR schedule before (Baseline) and weekly after the single-dose treatment (vehicle or 3 
mg/kg CocH3-Fc). Data are expressed as (A) Mean number (s.e.m.) of cocaine infusions 
earned (**: p < 0.01; ***: p < 0.001; ***: p < 0.0001 vs. control group by post hoc tests of 
two-way ANOVA), (B) Break point, defined as the final ratio completed before session 
ceased, (C) Total active lever presses. (D) Methamphetamine self-administration under a 
FR schedule before (Baseline) and weekly after the single-dose treatment.  
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5.3.3. Experimental 3: Effects of a single dose of E30-6-Fc on cocaine and 
methamphetamine IVSA in male and female rats 
Eight male rats and eight female rats were used to study the long-term effects of a 
single dose of E30-6-Fc on cocaine and methamphetamine IVSA in both sexes. Upon 
cocaine IVSA training and baseline acquisition, rats were IV injected 3 mg/kg E30-6-Fc 
on Day 0 (named as Male E30-6-Fc and Female E30-6-Fc in the contexts and figures). 
Then, they were tested daily following the 5-week testing schedule. 
For male rats, as shown in Figure 5-8, there were no group difference on the 
baseline-level performance between Male Control and Male E30-6-Fc. However, the 
single-time enzyme treatment significantly changed the number of drug infusions in the 
sessions reinforced by cocaine under a FR schedule (Figure 5-9). At unit dose of 0.1 
mg/kg/inf., the mean number of cocaine infusions was significantly reduced in the Male 
E30-6-Fc group for the period of all 5 weeks with infusion number close to 0 during first 
3 weeks (Figure 5-9 A). At unit dose of 0.32 mg/kg/inf., the mean number of cocaine 
infusions was significantly changed in the Male E30-6-Fc group for 22 days with infusion 
number decreased (close to 0) in the first 11 days and increased from Day 17 to Day 22 
(Figure 5-9 B). At unit dose of 1 mg/kg/inf., the mean number of cocaine infusions was 
significantly changed in the Male E30-6-Fc group for 24 days with infusion number 
decreased (close to 0) in the first 4 days and increased from Day 10 to Day 24 (Figure 5-9 
C).  
Male E30-6-Fc group took more cocaine in total compared to the Male Control 
group during 3-4 weeks after enzyme treatment. However, it was noticed that Male E30-
6-Fc group stayed calm down after test sessions. They had no significant behavioral sign 
of “high” when compared to the Male Control group.With a PR schedule of reinforcement, 
rats in Male E30-6-Fc group earned significantly less cocaine (1 mg/kg/inf.) infusions 
compared to Male Control in all tests conducted (Figure 5-10 A-C). For IVSA reinforced 
by methamphetamine, two-way ANOVA revealed no main effect of treatment (vehicle vs. 
E30-6-Fc) nor main effect time (Figure 5-10 D). 
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Figure 5-8. Baseline comparison between male control group and male E30-6-Fc 
group. (A) Mean number (s.e.m.) of cocaine infusion (0.4 mg/kg/inf.) in last 7 sessions of 
maintenance training under schedule of FR5TO5; (B) Cocaine dose response curve tested 
in a daily multiple-component session; (C) Mean number (s.e.m.) of cocaine infusion (1 
mg/kg/inf.) earned under a PR schedule of reinforcement; (D) Mean number (s.e.m.) of 
methamphetamine infusion (0.06 mg/kg/inf.) in the last mathamphatamine test. 
  
 
112 
 
 
Figure 5-9. Long-term effects of E30-6-Fc on multiple-dose cocaine self-
administration under a FR schedule of reinforcement in male rats. Mean number 
(s.e.m.) of cocaine infusions per session (30 min) at unit dose of 0.1 mg/kg/inf. (A), 0.32 
mg/kg/inf. (B), and 1 mg/kg/inf. (C) before (Baseline) and daily (Day 0 – Day 35) after a 
single time treatment (vehicle or 3 mg/kg CocH3-Fc). (&: Significantly higher infusion 
number vs. control group @: Significantly lower infusion number vs. control group) 
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Figure 5-10. Long-term effects of E30-6-Fc on cocaine self-administration under a PR 
schedule of reinforcement and methamphetamine self-administration under a FR 
schedule of reinforcement in male rats. (A) – (C): Cocaine self-administration under a 
PR schedule before (Baseline) and weekly after the single-dose treatment (vehicle or 3 
mg/kg E30-6-Fc). Data are expressed as (A) Mean number (s.e.m.) of cocaine infusions 
earned (**: p < 0.01; ***: p < 0.001; *** : p < 0.0001 vs. control group by post hoc tests 
of two-way ANOVA), (B) Break point, defined as the final ratio completed before session 
ceased, (C) Total active lever presses. (D) Methamphetamine self-administration under a 
FR schedule before (Baseline) and weekly after the single treatment. 
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For female rats, as shown in Figure 5-11, there were no group difference on the 
baseline-level performance between Female Control and Female E30-6-Fc. However, the 
single-time enzyme treatment significantly changed the number of drug infusions in the 
sessions reinforced by cocaine under a FR schedule (Figure 5-12). At unit dose of 0.1 
mg/kg/inf., mean number of cocaine infusions were significantly reduced in the Female 
E30-6-Fc group for the period of all 5 weeks with infusion number close to 0 during first 
3 weeks (Figure 5-12 A). At unit dose of 0.32 mg/kg/inf., mean number of cocaine 
infusions were significantly changed in the Female E30-6-Fc group for 21 days with 
infusion number decreased (close to 0) in the first 8 days and increased from Day 15 to 
Day 21 (Figure 5-12 B). At unit dose of 1 mg/kg/inf., mean number of cocaine infusions 
were significantly changed in the Female E30-6-Fc group for 25 days with infusion number 
decreased (close to 0) in the first 4 days and increased from Day 7 to Day 25 (Figure 5-9 
C).  
Female E30-6-Fc group took more cocaine in total compared to the Female Control 
group during 3-4 weeks after enzyme treatment. However, it was noticed that Female E30-
6-Fc group stayed calm down after test sessions. They had no significant behavioral sign 
of “high” when compared to the Female Control group. 
With a PR schedule of reinforcement, rats in Female E30-6-Fc group earned 
significantly less cocaine (1 mg/kg/inf.) infusions compared to Female Control in all tests 
conducted (Figure 5-10A-C). For IVSA reinforced by methamphetamine, two-way 
ANOVA revealed no main effect of treatment (vehicle vs. E30-6-Fc) nor main effect time 
(Figure 5-10 D). 
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Figure 5-11. Baseline comparison between female control group and female E30-6-Fc 
group. (A) Mean number (s.e.m.) of cocaine infusion (0.4 mg/kg/inf.) in last 7 sessions of 
maintenance training under schedule of FR5TO5; (B) Cocaine dose response curve tested 
in daily multiple-component session; (C) Mean number (s.e.m.) of cocaine infusion (1 
mg/kg/inf.) earned under a PR schedule of reinforcement; (D) Mean number (s.e.m.) of 
methamphetamine infusion (0.06 mg/kg/inf.) in the last methamphetamine test. 
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Figure 5-12. Long-term effects of E30-6-Fc on multiple-dose cocaine self-
administration under a FR schedule of reinforcement in female rats. Mean number 
(s.e.m.) of cocaine infusions per session (30 min) at unit dose of 0.1 mg/kg/inf. (A), 0.32 
mg/kg/inf. (B), and 1 mg/kg/inf. (C) before (Baseline) and daily (Day 0 – Day 35) after a 
single time treatment (vehicle or 3 mg/kg CocH3-Fc). (&: Significantly higher infusion 
number vs. control group @: Significantly lower infusion number vs. control group) 
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Figure 5-13. Long-term effects of E30-6-Fc on cocaine self-administration under a PR 
schedule of reinforcement and methamphetamine self-administration under a FR 
schedule of reinforcement in female rats. (A) – (C): Cocaine self-administration under a 
PR schedule before (Baseline) and weekly after the single-dose treatment (vehicle or 3 
mg/kg E30-6-Fc). Data are expressed as (A) Mean number (s.e.m.) of cocaine infusions 
earned (**: p < 0.01; ***: p < 0.001; *** : p < 0.0001 vs. control group by post hoc tests 
of two-way ANOVA), (B) Break point, defined as the final ratio completed before session 
ceased, (C) Total active lever presses. (D) Methamphetamine self-administration under a 
FR schedule before (Baseline) and weekly after the single treatment. 
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5.4. Discussion and conclusion 
5.4.1. Long-lasting effects of fusion CocHs on cocaine dose-response curve - cocaine 
IVSA under a FR schedule of reinforcement 
After a single dose of pretreatment (CocH3-Fc, E30-6-Fc, or vehicle), cocaine 
dose-response curves were obtained under a multi-component FR5TO5 schedule of 
reinforcement at a frequency of five times per week for 5 weeks. The cocaine dose-
response curves before (baseline) and on the selected days after the treatment in all enzyme 
treatment groups are displayed in Figure 5-14. In general, a single dose (3 mg/kg) of Fc-
fused CocH is able to cause long-term rightward and downward shift on cocaine dose-
response curve in a time dependent manner. As the only essential variable changing with 
time is the plasma enzyme concentration. So, the alternation on dose-response curve is 
indeed plasma enzyme concentration dependent. This time-dependent change is an 
evidence showing that the impact of Fc-fused CocH on cocaine IVSA is based on its 
enzymatic activity. 
Based on the baseline study, cocaine unit dose of 0.1 mg/kg/inf. is close to the 
minimal cocaine unit dose to trigger (reinstate) and maintain continuous drug intake under 
FR5 among male rats. Pretreatment with a single dose of Fc-fused CocH was able to block 
the reinforcing effects of a priming injection of 0.1 mg/kg/inf. completely for 3 weeks. At 
the last day of the study (Day 35), when the plasma enzyme concentration was below 0.2 
mg/L, this unit dose failed to trigger and maintain continuous drug intake in all the rats. At 
cocaine unit dose of 0.32 and 1 mg/kg/inf., a single dose of Fc-fused CocH completely 
blocked the reinforcing effects of a priming injection of cocaine for various lengths of time, 
depending on the catalytic efficiency of the CocH form and sex of the rat. The length of 
blockade effect on reinforcing effects of cocaine (1 or 0.32 mg/kg/inf.) and threshold 
plasma enzyme concentration are summarized in Table 5-1. After the break day, which is 
defined as the day when individual rat completed more than 5 infusions (not included) in a 
cluster when session started, majority of the rats were able to maintain continuous drug 
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intake. However, the increased infusion number indicated they were reinforced at a lower 
dose, as cocaine IVSA is featured by an inverted U-shaped dose-response curve.  
An important argument against the therapeutic value of biologics treatment 
developed according to a PK strategy is that their antagonist effects are surmountable, 
especially when cocaine is administered via IV or SM. However, our results showed that 
it is cocaine unit dose dependent. It is feasible to find the plasma enzyme concentration 
with the ability to completely eliminate the reinforcing effects of cocaine based on the 
common cocaine dose consumed by human. To our knowledge, the antagonist effect of Fc-
fused CocH (CocH3-Fc or E30-6-Fc) is the most difficult to overcome as compared to all 
tested entities in this field, including anti-cocaine vaccine, anti-cocaine mAb, and 
AlbuCocH1. 
In addition, the methamphetamine intakes under the FR schedule of reinforcement 
were not altered by the presence of enzyme. This result is another strong evidence to 
support that the effects of Fc-fused CocHs on cocaine IVSA rely on enzymatic activity 
rather than causing problem to the rats, like health issues or inability to perform the operant 
task. 
5.4.2. Long-lasting effects of fusion CocHs on reinforcing efficacy of cocaine – 
cocaine IVSA under a PR schedule of reinforcement   
In order to learn the effects of fusion CocHs on the reinforcing efficacy of cocaine, 
as well as the motivation of rats to obtain cocaine, we recruited the assessment of cocaine 
IVSA under a PR schedule of reinforcement in the current studies. It is evident that the 
single-dose treatment was still effective to reduce the cocaine infusions (1 mg/kg/inf.) 
earned under a PR schedule in both male and female rats 33 days after the pretreatment. It 
strongly suggested that the reinforcing efficacy of cocaine and the motivation of rats to 
obtain cocaine were attenuated for at least a month after the treatment.  
By comparing the results of drug intake under a FR and a PR schedule of 
reinforcement, it is interesting to notice that rats were able to compensate for the enzyme’s 
effects by taking more infusions under a FR schedule, but not under a PR schedule. We 
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consider the PR schedule of reinforcement more relevant to the situation in real life. In 
order to compensate for the enzyme’s effects by taking more cocaine to achieve desired 
level of “high”, one needs to pay more money to get the drug. The cost and risk associated 
with this process increase progressively as the demand increases, which is not as easy as 
pressing the level at FR5. In addition, the “wrong decision” for continuing drug intake is 
always made under the intoxication of the previous drug exposure. If cocaine were 
prevented from accumulation with the presence of enzyme, the time with higher risk or 
motivation to continue drug seeking or drug taking would be shortened.  
5.4.3. Comparison of effects of Fc-fused CocH in both sexes 
As a preclinical evaluation, it is necessary to study the efficacy of the Fc-fused 
CocHs in both sexes. We investigated the effectiveness and duration of action of E30-6-Fc 
in both male and female rats.  
In order to better interpret the data, we first investigated the sex differences in 
baseline. We found (1) female rats took more cocaine infusions than male rats at lower 
cocaine unit doses; (2) the minimal cocaine unit dose to trigger and maintain continuous 
cocaine intake at FR5 in majority (~ 80%) of female is 0.032 mg/kg/inf., rather than 0.1 
mg/kg/inf. for male rats; (3) female rats earned significantly more cocaine infusions than 
male rats at both doses tested under the PR schedule of reinforcement. Most of these results 
are consistent with the finding in other studies on sex differences in cocaine IVSA (226). 
In general, female rats show more sensitivity to low cocaine unit dose and higher 
motivation to obtain cocaine.  
With the pretreatment of a single dose of E30-6-Fc, female rats showed similar 
pattern of alternation on cocaine dose-response curve as male rats did (Figure 5-14). 
However, the plasma enzyme concentration needed to block the reinforcing effects of 
cocaine at the same unit dose in female rats are higher than that in male rats (Table 5-1). 
We have shown in the cocaine overdose model that fusion CocHs share similar enzymatic 
efficiency in vivo in male and female rats (227). Based on the finding from the baseline, 
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this difference is due to female rats’ sensitivity to low unit dose and higher motivation for 
drug seeking. 
In conclusion, as demonstrated using cocaine intravenous self-administration 
model, pretreatment with a single dose of Fc-fused CocH was able to block or attenuate 
the reinforcing effects of cocaine for a long term. These results indicate Fc-fused CocHs 
might be valuable for managing cocaine abuse and addiction. 
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Table 5-1. Length of blockade effect on reinforcing effects of cocaine (1 or 0.32 mg/kg/inf.) and threshold plasma enzyme 
concentration. 
 
 
Enzyme 
 
Sex (number) 
Cocaine Unit Dose 
1 mg/kg/inf. 0.32 mg/kg/inf. 
Daya Concentrationb Daya Concentrationb 
E30-6-Fc MALE (n=8) 6.38 ± 1.30 9.35 ± 2.21 13.00 ± 2.14 3.42 ± 1.49 
FEMALE (n=8) 5.75 ± 0.46 12.56 ± 1.33 11.00 ± 2.69 6.51 ± 2.24 
CocH3-Fc MALE (n=6) 3.83 ± 1.33 21.07 ± 3.30 9.33 ± 0.52 7.63 ± 1.56 
 
Data are all presented as Mean ± s.e.m. 
a The length of blockade is defined the as the break day minus one. The break day is the day when individual rat completed more than 
five infusions (not included) in a cluster when session started.  
b The plasma enzyme concentration on the day before the break day. 
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Figure 5-14. Cocaine self-administration dose-response curves obtained under a multicomponent FR5 schedule of reinforcement 
before, and on Day 1, Day 7, Day 14, Day 21, Day 28, and Day 35 after enzyme treatment in each group.
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6. Chapter Six: Overall Discussion 
In this chapter, the results and conclusions of all experiments are summarized. In 
addition, the limitations involved in the experimental design, animal models, and 
equipment are discussed. At the last, some future perspectives for this project are stated. 
6.1. Summary of results 
The major purpose of the research presented in this dissertation is to conduct 
preclinical evaluations of Fc-fused CocHs as therapeutic agents for cocaine overdose and 
cocaine use disorder treatment. Three promising fusion enzyme forms (CocH3-Fc, E30-6-
Fc, and E20-7-Fc) have been tested in one or multiple animal models, including rodent 
rescue models and rodent models of cocaine addiction, for their effectiveness and duration 
of action provided by a single dose. The summarized results are listed below: 
Compared to their unfused enzyme forms, fusion CocHs had improved potency as 
agents to rescue rodents and facilitate recovery from the toxic effects caused by a lethal 
dose of cocaine.  
Fusion CocH (e.g. AlbuCocH1) served as effective cocaine detoxification agents 
by accelerating the metabolism of cocaine. Administration of fusion CocH was able to 
reverse manifestations of toxic effects of cocaine immediately, no matter when the 
intervention was given. 
A single dose of Fc-fused CocH resulted in long-lasting blockage or attenuation in 
cocaine-induced physiological and subjective effects in rats. The maximal length of 
blockage and extend of attenuation were dependent on the plasma enzyme concentration.   
As shown in cocaine intravenous self-administration model, a single dose (3 mg/kg) 
of Fc-fused CocH (e.g. E30-6-Fc) effectively altered the dose-response curve of cocaine 
and attenuated the reinforcing efficacy of cocaine for at least a month in both male and 
female rats. 
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Together, those results suggest that Fc-fused CocHs with higher catalytic efficiency 
and longer biological half-life are promising candidates for clinical evaluation as 
medications for cocaine overdose and cocaine use disorder.  
6.2. Future perspectives 
6.2.1. Study the PK profiles and effects on cocaine IVSA of Fc fusion CocHs in non-
human primate 
In this dissertation, the preclinical evaluations of Fc-fused CocHs were only 
conducted in rodents. To obtain more human-related results, it is interesting to study the 
PK profiles and effectiveness of Fc-fused CocHs in blocking addiction-related effects of 
cocaine in non-human primate. Previous studies using AlbuCocH1 has confirmed that 
human-derived CocH could modify pharmacokinetic and abuse-related effects of cocaine 
(178) in squirrel monkeys. Since the biological half-life of 5 mg/kg AlbuCocH1 in squirrel 
monkey is only 56.6 hours, the antagonist effects lasted less than 5 days in the study. Based 
on the estimated biological half-life of Fc-fused CocH, we would expect Fc-fused CocHs 
to show a much longer duration of effectiveness as compared to AlbuCocH1 in non-human 
primate. 
6.2.2. Look for more biomarkers to extend clinical endpoints  
Currently, the most common and primary efficacy endpoint in clinical trials for 
substrate use disorder treatments is abstinence. This endpoint has been considered as 
difficult to achieve (228), since a lot of medicines showing adequate efficacy in preclinical 
animal models failed to meet this clinical endpoint. More and more researchers have raised 
the point that developing and validating alternative outcomes could facilitate drug 
development (228, 229). Based on the unique mechanism of action of enzyme-based 
therapy, adequate enzyme activity could eliminate effects caused by cocaine. Therefore, 
more research should be conducted to find biomarkers to show the long-term protective 
effects associated with the presence of enzyme in the circulation system of cocaine addicts. 
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The alternative clinical endpoints based on these biomarkers might be more meaningful 
than “abstinence” in the evaluation of treatment efficacy of enzyme-based therapy.  
 
127 
 
REFERENCES 
1. Freye E. Cocaine: History of Use.  Pharmacology and abuse of cocaine, 
amphetamines, ecstasy and related designer drugs : a comprehensive review on their mode 
of action, treatment of abuse and intoxication. Netherlands: Springer, Dordrecht; 2009. 
2. Johanson CE, Fischman MW. The pharmacology of cocaine related to its abuse. 
Pharmacol Rev. 1989;41(1):3-52. Epub 1989/03/01. PubMed PMID: 2682679. 
3. Markel H. Uber coca: Sigmund Freud, Carl Koller, and cocaine. JAMA. 
2011;305(13):1360-1. Epub 2011/04/07. doi: 10.1001/jama.2011.394. PubMed PMID: 
21467292. 
4. Drug Enforcement Administration. Drug Schedules  [cited 2018 Mar. 29]. 
Available from: https://www.dea.gov/druginfo/ds.shtml. 
5. Food and Drug Administration. Drugs@FDA  [cited 2018 Mar. 29]. Available from: 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. 
6. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine 
transporters are related to self-administration of cocaine. Science. 1987;237(4819):1219-
23. Epub 1987/09/04. PubMed PMID: 2820058. 
7. Sharkey J, Ritz MC, Schenden JA, Hanson RC, Kuhar MJ. Cocaine inhibits 
muscarinic cholinergic receptors in heart and brain. The Journal of pharmacology and 
experimental therapeutics. 1988;246(3):1048-52. Epub 1988/09/01. PubMed PMID: 
3047364. 
8. Flynn DD, Vaishnav AA, Mash DC. Interactions of cocaine with primary and 
secondary recognition sites on muscarinic receptors. Molecular pharmacology. 
1992;41(4):736-42. Epub 1992/04/01. PubMed PMID: 1569924. 
9. Rousseaux CG, Greene SF. Sigma receptors [sigmaRs]: biology in normal and 
diseased states. Journal of receptor and signal transduction research. 2015:1-62. Epub 
2015/06/10. doi: 10.3109/10799893.2015.1015737. PubMed PMID: 26056947; PMCID: 
PMC4906365. 
10. Sharkey J, Glen KA, Wolfe S, Kuhar MJ. Cocaine binding at σ receptors. European 
Journal of Pharmacology. 1988;149(1-2):171-4. doi: 10.1016/0014-2999(88)90058-1. 
11. Heard K, Palmer R, Zahniser NR. Mechanisms of acute cocaine toxicity. Open 
Pharmacol J. 2008;2(9):70-8. Epub 2008/01/01. doi: 10.2174/1874143600802010070. 
PubMed PMID: 19568322; PMCID: PMC2703432. 
12. Crumb WJ, Jr., Clarkson CW. Characterization of cocaine-induced block of cardiac 
sodium channels. Biophysical journal. 1990;57(3):589-99. Epub 1990/03/01. doi: 
10.1016/S0006-3495(90)82574-1. PubMed PMID: 2155033; PMCID: PMC1280752. 
13. Zhang S, Rajamani S, Chen Y, Gong Q, Rong Y, Zhou Z, Ruoho A, January CT. 
Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. Molecular 
pharmacology. 2001;59(5):1069-76. Epub 2001/04/18. PubMed PMID: 11306689. 
 
128 
 
14. Premkumar LS. Selective potentiation of L-type calcium channel currents by 
cocaine in cardiac myocytes. Molecular pharmacology. 1999;56(6):1138-42. Epub 
1999/11/26. PubMed PMID: 10570040. 
15. Gorelick DA. Cocaine use disorder in adults: Epidemiology, pharmacology, 
clinical manifestations, medical consequences, and diagnosis 2017 [cited 2018 Apr. 8th]. 
Available from: https://www.uptodate.com/contents/cocaine-use-disorder-in-adults-
epidemiology-pharmacology-clinical-manifestations-medical-consequences-and-
diagnosis?search=cocaine%20use%20disorder&source=search_result&selectedTitle=1~1
48&usage_type=default&display_rank=1. 
16. Coe MA, Jufer Phipps RA, Cone EJ, Walsh SL. Bioavailability and 
Pharmacokinetics of Oral Cocaine in Humans. J Anal Toxicol. 2018;42(5):285-92. Epub 
2018/02/21. doi: 10.1093/jat/bky007. PubMed PMID: 29462364; PMCID: PMC5952935. 
17. Lewis Nelson OO. Cocaine: Acute intoxication 2018 [cited 2018 May. 28th]. 
Available from: https://www.uptodate.com/contents/cocaine-acute-intoxication. 
18. Gatley SJ, Gifford AN, Volkow ND, Fowler JS. Pharmacology of Cocaine. In: 
Tarter RE, Ammerman RT, Ott PJ, editors. Handbook of Substance Abuse. Boston, MA: 
Springer US; 1998. p. 161-85. 
19. Cone EJ. Pharmacokinetics and pharmacodynamics of cocaine. J Anal Toxicol. 
1995;19(6):459-78. Epub 1995/10/01. doi: 10.1093/jat/19.6.459. PubMed PMID: 8926741. 
20. Stewart DJ, Inaba T, Lucassen M, Kalow W. Cocaine metabolism: cocaine and 
norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther. 1979;25(4):464-
8. Epub 1979/04/01. PubMed PMID: 428191. 
21. Dean RA, Christian CD, Sample RH, Bosron WF. Human liver cocaine esterases: 
ethanol-mediated formation of ethylcocaine. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology. 1991;5(12):2735-9. Epub 
1991/09/01. PubMed PMID: 1916095. 
22. Gatley SJ, MacGregor RR, Fowler JS, Wolf AP, Dewey SL, Schlyer DJ. Rapid 
stereoselective hydrolysis of (+)-cocaine in baboon plasma prevents its uptake in the brain: 
implications for behavioral studies. J Neurochem. 1990;54(2):720-3. Epub 1990/02/01. 
PubMed PMID: 2299363. 
23. Ritz MC, Cone EJ, Kuhar MJ. Cocaine inhibition of ligand binding at dopamine, 
norepinephrine and serotonin transporters: a structure-activity study. Life Sci. 
1990;46(9):635-45. Epub 1990/01/01. PubMed PMID: 2308472. 
24. Gatley SJ, Yu DW, Fowler JS, MacGregor RR, Schlyer DJ, Dewey SL, Wolf AP, 
Martin T, Shea CE, Volkow ND. Studies with differentially labeled [11C]cocaine, 
[11C]norcocaine, [11C]benzoylecgonine, and [11C]- and 4'-[18F]fluorococaine to probe 
the extent to which [11C]cocaine metabolites contribute to PET images of the baboon brain. 
J Neurochem. 1994;62(3):1154-62. Epub 1994/03/01. PubMed PMID: 8113802. 
 
129 
 
25. Bornheim LM. Effect of cytochrome P450 inducers on cocaine-mediated 
hepatotoxicity. Toxicology and applied pharmacology. 1998;150(1):158-65. Epub 
1998/06/19. doi: 10.1006/taap.1998.8403. PubMed PMID: 9630465. 
26. Barnett G, Hawks R, Resnick R. Cocaine pharmacokinetics in humans. J 
Ethnopharmacol. 1981;3:353-66. 
27. Booze RM, Lehner AF, Wallace DR, Welch MA, Mactutus CF. Dose-response 
cocaine pharmacokinetics and metabolite profile following intravenous administration and 
arterial sampling in unanesthetized, freely moving male rats. Neurotoxicol Teratol. 
1997;19(1):7-15. Epub 1997/01/01. PubMed PMID: 9088006; PMCID: PMC4041984. 
28. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, Lockridge O. An 
Improved Cocaine Hydrolase: The A328Y Mutant of Human Butyrylcholinesterase is 4-
fold More Efficient. Molecular pharmacology. 1999;55(1):83. 
29. Ambre J. The urinary excretion of cocaine and metabolites in humans: a kinetic 
analysis of published data. J Anal Toxicol. 1985;9(6):241-5. Epub 1985/11/01. doi: 
10.1093/jat/9.6.241. PubMed PMID: 4079334. 
30. Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms 
involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev. 
2008;58(1):192-208. Epub 2008/04/29. doi: 10.1016/j.brainresrev.2008.03.002. PubMed 
PMID: 18440072. 
31. Dietrich JB, Mangeol A, Revel MO, Burgun C, Aunis D, Zwiller J. Acute or 
repeated cocaine administration generates reactive oxygen species and induces antioxidant 
enzyme activity in dopaminergic rat brain structures. Neuropharmacology. 
2005;48(7):965-74. Epub 2005/04/29. doi: 10.1016/j.neuropharm.2005.01.018. PubMed 
PMID: 15857623. 
32. Macedo DS, de Vasconcelos SM, dos Santos RS, Aguiar LM, Lima VT, Viana GS, 
de Sousa FC. Cocaine alters catalase activity in prefrontal cortex and striatum of mice. 
Neuroscience letters. 2005;387(1):53-6. Epub 2005/08/09. doi: 
10.1016/j.neulet.2005.07.024. PubMed PMID: 16085363. 
33. Lipton JW, Gyawali S, Borys ED, Koprich JB, Ptaszny M, McGuire SO. Prenatal 
cocaine administration increases glutathione and alpha-tocopherol oxidation in fetal rat 
brain. Brain research Developmental brain research. 2003;147(1-2):77-84. Epub 
2004/01/27. PubMed PMID: 14741753. 
34. Mohammad Ahmadi Soleimani S, Ekhtiari H, Cadet JL. Drug-induced 
neurotoxicity in addiction medicine: From prevention to harm reduction. Prog Brain Res. 
2016;223:19-41. Epub 2016/01/26. doi: 10.1016/bs.pbr.2015.07.004. PubMed PMID: 
26806769. 
35. Williams JM, Steketee JD. Cocaine increases medial prefrontal cortical glutamate 
overflow in cocaine-sensitized rats: a time course study. The European journal of 
neuroscience. 2004;20(6):1639-46. Epub 2004/09/10. doi: 10.1111/j.1460-
9568.2004.03618.x. PubMed PMID: 15355331. 
 
130 
 
36. Rego AC, Oliveira CR. Mitochondrial dysfunction and reactive oxygen species in 
excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative 
diseases. Neurochemical research. 2003;28(10):1563-74. Epub 2003/10/23. PubMed 
PMID: 14570402. 
37. Poon HF, Abdullah L, Mullan MA, Mullan MJ, Crawford FC. Cocaine-induced 
oxidative stress precedes cell death in human neuronal progenitor cells. Neurochem Int. 
2007;50(1):69-73. Epub 2006/09/08. doi: 10.1016/j.neuint.2006.06.012. PubMed PMID: 
16956698. 
38. Cunha-Oliveira T, Rego AC, Cardoso SM, Borges F, Swerdlow RH, Macedo T, de 
Oliveira CR. Mitochondrial dysfunction and caspase activation in rat cortical neurons 
treated with cocaine or amphetamine. Brain research. 2006;1089(1):44-54. Epub 
2006/04/28. doi: 10.1016/j.brainres.2006.03.061. PubMed PMID: 16638611. 
39. Lange RA, Hillis LD. Cardiovascular Complications of Cocaine Use. New England 
Journal of Medicine. 2001;345(5):351-8. doi: 10.1056/NEJM200108023450507. 
40. Havakuk O, Rezkalla SH, Kloner RA. The Cardiovascular Effects of Cocaine. 
Journal of the American College of Cardiology. 2017;70(1):101. 
41. Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine 
use on the heart. Circulation. 1992;85(2):407-19. Epub 1992/02/01. PubMed PMID: 
1346509. 
42. Om A. Cardiovascular complications of cocaine. Am J Med Sci. 1992;303(5):333-
9. Epub 1992/05/01. doi: https://doi.org/10.1097/00000441-199205000-00014. PubMed 
PMID: 1533749. 
43. Billman GE. Mechanisms responsible for the cardiotoxic effects of cocaine. 
FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology. 1990;4(8):2469-75. Epub 1990/05/01. doi: 
10.1096/fasebj.4.8.2185973. PubMed PMID: 2185973. 
44. Hale SL, Lehmann MH, Kloner RA. Electrocardiographic abnormalities after acute 
administration of cocaine in the rat. The American journal of cardiology. 
1989;63(20):1529-30. Epub 1989/06/15. PubMed PMID: 2729144. 
45. Administration SAaMHS. Drug Abuse Warning Network, 2011: National 
Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance 
Abuse and Mental Health Services Administration, 2013. 
46. Prevention CfDCa. Annual Surveillance Report of Drug-Related Risks and 
Outcomes. United States: Centers for Disease Control and Prevention, U.S. Department of 
Health and Human Services, 2017. 
47. NIDA. Overdose Death Rates 2017 [updated Sep. 2017; cited 2018 May 29th]. 
Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-
death-rates. 
 
131 
 
48. Daras M, Kakkouras L, Tuchman AJ, Koppel BS. Rhabdomyolysis and 
hyperthermia after cocaine abuse: a variant of the neuroleptic malignant syndrome? Acta 
neurologica Scandinavica. 1995;92(2):161-5. Epub 1995/08/01. PubMed PMID: 7484066. 
49. Richards JR, Garber D, Laurin EG, Albertson TE, Derlet RW, Amsterdam EA, 
Olson KR, Ramoska EA, Lange RA. Treatment of cocaine cardiovascular toxicity: a 
systematic review. Clinical toxicology (Philadelphia, Pa). 2016;54(5):345-64. Epub 
2016/02/27. doi: 10.3109/15563650.2016.1142090. PubMed PMID: 26919414. 
50. Forster A, Gardaz JP, Suter PM, Gemperle M. Respiratory depression by 
midazolam and diazepam. Anesthesiology. 1980;53(6):494-7. Epub 1980/12/01. PubMed 
PMID: 7457966. 
51. Michalewicz L, Messerli FH. Cardiac effects of calcium antagonists in systemic 
hypertension. The American journal of cardiology. 1997;79(10a):39-46; discussion 7-8. 
Epub 1997/05/22. PubMed PMID: 9186066. 
52. McCord J, Jneid H, Hollander JE, de Lemos JA, Cercek B, Hsue P, Gibler WB, 
Ohman EM, Drew B, Philippides G, Newby LK. Management of Cocaine-Associated 
Chest Pain and Myocardial Infarction. Circulation. 2008;117(14):1897. 
53. Ramoska E, Sacchetti AD. Propranolol-induced hypertension in treatment of 
cocaine intoxication. Annals of emergency medicine. 1985;14(11):1112-3. Epub 
1985/11/01. PubMed PMID: 4051280. 
54. Diagnostic and statistical manual of mental disorders : DSM-5. American 
Psychiatric A, American Psychiatric Association DSMTF, editors. Arlington, VA: 
American Psychiatric Association; 2013. 
55. United Nations Office on Drugs and Crime. Executive summary.  World Drug 
Report 2017: United Nations publication; 2017. 
56. Administration. SAaMHS. Key substance use and mental health indicators in the 
United States: Results from the 2016 National Survey on Drug Use and Health. Rockville, 
MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental 
Health Services Administration., 2017. 
57. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 
2010;35(1):217-38. Epub 2009/08/28. doi: 10.1038/npp.2009.110. PubMed PMID: 
19710631; PMCID: PMC2805560. 
58. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. The 
lancet Psychiatry. 2016;3(8):760-73. Epub 2016/08/01. doi: 10.1016/S2215-
0366(16)00104-8. PubMed PMID: 27475769. 
59. Volkow ND, Morales M. The Brain on Drugs: From Reward to Addiction. Cell. 
2015;162(4):712-25. Epub 2015/08/16. doi: 10.1016/j.cell.2015.07.046. PubMed PMID: 
26276628. 
60. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from 
imaging studies. J Clin Invest. 2003;111(10):1444-51. Epub 2003/05/17. doi: 
10.1172/JCI18533. PubMed PMID: 12750391; PMCID: PMC155054. 
 
132 
 
61. Tepper JM, Bolam JP. Functional diversity and specificity of neostriatal 
interneurons. Current opinion in neurobiology. 2004;14(6):685-92. doi: 
https://doi.org/10.1016/j.conb.2004.10.003. 
62. Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. 
Neurotoxicity research. 2008;14(2-3):169-83. Epub 2008/12/17. doi: 
10.1007/BF03033808. PubMed PMID: 19073424; PMCID: PMC3155128. 
63. Wightman RM, Robinson DL. Transient changes in mesolimbic dopamine and their 
association with 'reward'. J Neurochem. 2002;82(4):721-35. Epub 2002/10/03. PubMed 
PMID: 12358778. 
64. Caine SB, Thomsen M, Gabriel KI, Berkowitz JS, Gold LH, Koob GF, Tonegawa 
S, Zhang J, Xu M. Lack of Self-Administration of Cocaine in Dopamine 
D&lt;sub&gt;1&lt;/sub&gt; Receptor Knock-Out Mice. The Journal of Neuroscience. 
2007;27(48):13140. 
65. Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, 
Saiardi A, Borrelli E. Role of dopamine D2-like receptors in cocaine self-administration: 
studies with D2 receptor mutant mice and novel D2 receptor antagonists. The Journal of 
neuroscience : the official journal of the Society for Neuroscience. 2002;22(7):2977-88. 
Epub 2002/03/30. doi: 20026264. PubMed PMID: 11923462. 
66. Volkow ND, Wang GJ, Fowler JS, Thanos PP, Logan J, Gatley SJ, Gifford A, Ding 
YS, Wong C, Pappas N. Brain DA D2 receptors predict reinforcing effects of stimulants in 
humans: replication study. Synapse (New York, NY). 2002;46(2):79-82. Epub 2002/09/05. 
doi: 10.1002/syn.10137. PubMed PMID: 12211085. 
67. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, 
Dewey SL, Pappas N. Decreased striatal dopaminergic responsiveness in detoxified 
cocaine-dependent subjects. Nature. 1997;386(6627):830-3. Epub 1997/04/24. doi: 
10.1038/386830a0. PubMed PMID: 9126741. 
68. Ungless MA, Whistler JL, Malenka RC, Bonci A. Single cocaine exposure in vivo 
induces long-term potentiation in dopamine neurons. Nature. 2001;411(6837):583-7. Epub 
2001/06/01. doi: 10.1038/35079077. PubMed PMID: 11385572. 
69. Chen BT, Bowers MS, Martin M, Hopf FW, Guillory AM, Carelli RM, Chou JK, 
Bonci A. Cocaine but not natural reward self-administration nor passive cocaine infusion 
produces persistent LTP in the VTA. Neuron. 2008;59(2):288-97. Epub 2008/08/01. doi: 
10.1016/j.neuron.2008.05.024. PubMed PMID: 18667156; PMCID: PMC2593405. 
70. Kourrich S, Rothwell PE, Klug JR, Thomas MJ. Cocaine experience controls 
bidirectional synaptic plasticity in the nucleus accumbens. The Journal of neuroscience : 
the official journal of the Society for Neuroscience. 2007;27(30):7921-8. Epub 2007/07/27. 
doi: 10.1523/JNEUROSCI.1859-07.2007. PubMed PMID: 17652583. 
71. Boudreau AC, Wolf ME. Behavioral sensitization to cocaine is associated with 
increased AMPA receptor surface expression in the nucleus accumbens. The Journal of 
 
133 
 
neuroscience : the official journal of the Society for Neuroscience. 2005;25(40):9144-51. 
Epub 2005/10/07. doi: 10.1523/JNEUROSCI.2252-05.2005. PubMed PMID: 16207873. 
72. Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng LJ, Shaham Y, Marinelli M, 
Wolf ME. Formation of accumbens GluR2-lacking AMPA receptors mediates incubation 
of cocaine craving. Nature. 2008;454(7200):118-21. Epub 2008/05/27. doi: 
10.1038/nature06995. PubMed PMID: 18500330; PMCID: PMC2574981. 
73. Kalivas PW. Glutamate systems in cocaine addiction. Current opinion in 
pharmacology. 2004;4(1):23-9. Epub 2004/03/17. doi: 10.1016/j.coph.2003.11.002. 
PubMed PMID: 15018835. 
74. Ito R, Dalley JW, Robbins TW, Everitt BJ. Dopamine release in the dorsal striatum 
during cocaine-seeking behavior under the control of a drug-associated cue. The Journal 
of neuroscience : the official journal of the Society for Neuroscience. 2002;22(14):6247-
53. Epub 2002/07/18. doi: 20026606. PubMed PMID: 12122083. 
75. Belin D, Everitt BJ. Cocaine seeking habits depend upon dopamine-dependent 
serial connectivity linking the ventral with the dorsal striatum. Neuron. 2008;57(3):432-41. 
Epub 2008/02/08. doi: 10.1016/j.neuron.2007.12.019. PubMed PMID: 18255035. 
76. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, 
Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR, Hyman SE. 
Acute effects of cocaine on human brain activity and emotion. Neuron. 1997;19(3):591-
611. Epub 1997/10/23. PubMed PMID: 9331351. 
77. Grant S, London ED, Newlin DB, Villemagne VL, Liu X, Contoreggi C, Phillips 
RL, Kimes AS, Margolin A. Activation of memory circuits during cue-elicited cocaine 
craving. Proceedings of the National Academy of Sciences of the United States of America. 
1996;93(21):12040-5. Epub 1996/10/15. PubMed PMID: 8876259; PMCID: PMC38179. 
78. Caine SB, Humby T, Robbins TW, Everitt BJ. Behavioral effects of psychomotor 
stimulants in rats with dorsal or ventral subiculum lesions: locomotion, cocaine self-
administration, and prepulse inhibition of startle. Behavioral neuroscience. 
2001;115(4):880-94. Epub 2001/08/18. PubMed PMID: 11508727. 
79. Briand LA, Gross JP, Robinson TE. Impaired object recognition following 
prolonged withdrawal from extended-access cocaine self-administration. Neuroscience. 
2008;155(1):1-6. Epub 2008/07/02. doi: 10.1016/j.neuroscience.2008.06.004. PubMed 
PMID: 18590801; PMCID: PMC2523261. 
80. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: 
neuroimaging findings and clinical implications. Nature reviews Neuroscience. 
2011;12(11):652-69. Epub 2011/10/21. doi: 10.1038/nrn3119. PubMed PMID: 22011681; 
PMCID: PMC3462342. 
81. Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Wolf AP, Dewey SL, 
Handlesman L. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 
(New York, NY). 1992;11(3):184-90. Epub 1992/07/01. doi: 10.1002/syn.890110303. 
PubMed PMID: 1636149. 
 
134 
 
82. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, 
Wolf AP. Decreased dopamine D2 receptor availability is associated with reduced frontal 
metabolism in cocaine abusers. Synapse (New York, NY). 1993;14(2):169-77. Epub 
1993/06/01. doi: 10.1002/syn.890140210. PubMed PMID: 8101394. 
83. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, 
Ding YS, Pappas N. Association of methylphenidate-induced craving with changes in right 
striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. The 
American journal of psychiatry. 1999;156(1):19-26. Epub 1999/01/19. doi: 
10.1176/ajp.156.1.19. PubMed PMID: 9892293. 
84. Knackstedt LA, Kalivas PW. Glutamate and reinstatement. Current opinion in 
pharmacology. 2009;9(1):59-64. Epub 2009/01/23. doi: 10.1016/j.coph.2008.12.003. 
PubMed PMID: 19157986; PMCID: PMC2667702. 
85. Koob GF, Mason BJ. Existing and Future Drugs for the Treatment of the Dark Side 
of Addiction. Annual review of pharmacology and toxicology. 2016;56:299-322. Epub 
2015/10/31. doi: 10.1146/annurev-pharmtox-010715-103143. PubMed PMID: 26514207. 
86. Heimer L, Alheid GF. Piecing together the Puzzle of Basal Forebrain Anatomy. In: 
Napier TC, Kalivas PW, Hanin I, editors. The Basal Forebrain: Anatomy to Function. 
Boston, MA: Springer US; 1991. p. 1-42. 
87. Koob GF. A role for brain stress systems in addiction. Neuron. 2008;59(1):11-34. 
Epub 2008/07/11. doi: 10.1016/j.neuron.2008.06.012. PubMed PMID: 18614026; PMCID: 
PMC2748830. 
88. Specio SE, Wee S, O’Dell LE, Boutrel B, Zorrilla EP, Koob GF. CRF(1) receptor 
antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology. 
2008;196(3):473-82. doi: 10.1007/s00213-007-0983-9. PubMed PMID: PMC2769571. 
89. Steketee JD, Kalivas PW. Drug wanting: behavioral sensitization and relapse to 
drug-seeking behavior. Pharmacol Rev. 2011;63(2):348-65. Epub 2011/04/15. doi: 
10.1124/pr.109.001933. PubMed PMID: 21490129; PMCID: PMC3082449. 
90. Ben-Shahar O, Ahmed SH, Koob GF, Ettenberg A. The transition from controlled 
to compulsive drug use is associated with a loss of sensitization. Brain research. 
2004;995(1):46-54. Epub 2003/12/04. PubMed PMID: 14644470. 
91. Ferrario CR, Gorny G, Crombag HS, Li Y, Kolb B, Robinson TE. Neural and 
behavioral plasticity associated with the transition from controlled to escalated cocaine use. 
Biological psychiatry. 2005;58(9):751-9. Epub 2005/08/16. doi: 
10.1016/j.biopsych.2005.04.046. PubMed PMID: 16098484. 
92. Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR. Using drug-
discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. 
Nature protocols. 2006;1(3):1194-206. Epub 2007/04/05. doi: 10.1038/nprot.2006.167. 
PubMed PMID: 17406402. 
 
135 
 
93. Falk JL, Lau CE. Stimulus control of addictive behavior: persistence in the presence 
and absence of a drug. Pharmacology, biochemistry, and behavior. 1995;50(1):71-5. Epub 
1995/01/01. PubMed PMID: 7700957. 
94. Rocha BA, Bergman J, Comer SD, Haney M, Spealman RD. Development of 
medications for heroin and cocaine addiction and regulatory aspects of abuse liability 
testing. Animal and Translational Models for CNS Drug Discovery: Reward Deficit 
Disorders: Reward Deficit Disorders. 2009;3:221. 
95. Bowen CA, Fischer BD, Mello NK, Negus SS. Antagonism of the antinociceptive 
and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and 
naltrexone in rhesus monkeys. The Journal of pharmacology and experimental therapeutics. 
2002;302(1):264-73. Epub 2002/06/18. PubMed PMID: 12065726. 
96. Wessinger WD, McMillan DE. Quantitative analysis of naloxone antagonism of 
the discriminative stimulus properties of morphine in the pigeon. Pharmacology, 
biochemistry, and behavior. 1986;25(1):209-14. Epub 1986/07/01. PubMed PMID: 
3749228. 
97. Woolverton WL. Discriminative stimulus effects of cocaine. NIDA research 
monograph. 1991(116):61-74. Epub 1991/01/01. PubMed PMID: 1369682. 
98. Spealman RD, Bergman J, Madras BK, Melia KF. Discriminative stimulus effects 
of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. The Journal 
of pharmacology and experimental therapeutics. 1991;258(3):945-53. Epub 1991/09/01. 
PubMed PMID: 1679852. 
99. Mello NK, Negus SS. Preclinical evaluation of pharmacotherapies for treatment of 
cocaine and opioid abuse using drug self-administration procedures. 
Neuropsychopharmacology. 1996;14(6):375-424. 
100. LeSage M, Stafford D, Glowa J. Preclinical research on cocaine self-administration: 
environmental determinants and their interaction with pharmacological treatment. 
Neuroscience & biobehavioral reviews. 1999;23(5):717-41. 
101. Ahmed SH, Koob GF. Transition from moderate to excessive drug intake: change 
in hedonic set point. Science. 1998;282(5387):298-300. Epub 1998/10/09. PubMed PMID: 
9765157. 
102. Ahmed SH, Koob GF. Long-lasting increase in the set point for cocaine self-
administration after escalation in rats. Psychopharmacology (Berl). 1999;146(3):303-12. 
Epub 1999/12/14. PubMed PMID: 10541731. 
103. Richardson NR, Roberts DC. Progressive ratio schedules in drug self-
administration studies in rats: a method to evaluate reinforcing efficacy. Journal of 
neuroscience methods. 1996;66(1):1-11. Epub 1996/05/01. PubMed PMID: 8794935. 
104. O'Brien CP. A range of research-based pharmacotherapies for addiction. Science. 
1997;278(5335):66-70. Epub 1997/10/06. PubMed PMID: 9311929. 
105. Hunt WA, Barnett LW, Branch LG. Relapse rates in addiction programs. J Clin 
Psychol. 1971;27(4):455-6. Epub 1971/10/01. PubMed PMID: 5115648. 
 
136 
 
106. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J. The reinstatement model of drug 
relapse: history, methodology and major findings. Psychopharmacology (Berl). 
2003;168(1-2):3-20. Epub 2002/10/29. doi: 10.1007/s00213-002-1224-x. PubMed PMID: 
12402102. 
107. de Wit H, Stewart J. Reinstatement of cocaine-reinforced responding in the rat. 
Psychopharmacology (Berl). 1981;75(2):134-43. Epub 1981/01/01. PubMed PMID: 
6798603. 
108. Kim JH, Lawrence AJ. Drugs currently in Phase II clinical trials for cocaine 
addiction. Expert opinion on investigational drugs. 2014;23(8):1105-22. Epub 2014/04/30. 
doi: 10.1517/13543784.2014.915312. PubMed PMID: 24773297. 
109. Negus SS, Henningfield J. Agonist Medications for the Treatment of Cocaine Use 
Disorder. Neuropsychopharmacology. 2015;40(8):1815-25. Epub 2015/01/08. doi: 
10.1038/npp.2014.322. PubMed PMID: 25563633; PMCID: PMC4839506. 
110. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, Newman 
AH, Javitch JA, Weinstein H, Gether U, Loland CJ. The binding sites for cocaine and 
dopamine in the dopamine transporter overlap. Nat Neurosci. 2008;11(7):780-9. Epub 
2008/06/24. doi: 10.1038/nn.2146. PubMed PMID: 18568020; PMCID: PMC2692229. 
111. Stoops WW, Rush CR. Agonist replacement for stimulant dependence: a review of 
clinical research. Current pharmaceutical design. 2013;19(40):7026-35. Epub 2013/04/12. 
PubMed PMID: 23574440; PMCID: PMC3740019. 
112. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Kao UH, Wang PC, Bholat MA, 
Ling W. Bupropion hydrochloride versus placebo, in combination with cognitive 
behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis. 
2008;27(1):13-23. Epub 2008/06/17. doi: 10.1300/J069v27n01_02. PubMed PMID: 
18551884. 
113. Newman AH, Grundt P, Nader MA. Dopamine D3 receptor partial agonists and 
antagonists as potential drug abuse therapeutic agents. J Med Chem. 2005;48(11):3663-79. 
Epub 2005/05/27. doi: 10.1021/jm040190e. PubMed PMID: 15916415. 
114. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons 
in the human forebrain: comparison with D2 receptor expressing neurons. 
Neuropsychopharmacology. 1999;20(1):60-80. Epub 1999/01/14. doi: 10.1016/S0893-
133X(98)00066-9. PubMed PMID: 9885786. 
115. Matuskey D, Gallezot JD, Pittman B, Williams W, Wanyiri J, Gaiser E, Lee DE, 
Hannestad J, Lim K, Zheng MQ, Lin SF, Labaree D, Potenza MN, Carson RE, Malison 
RT, Ding YS. Dopamine D(3) receptor alterations in cocaine-dependent humans imaged 
with [(1)(1)C](+)PHNO. Drug and alcohol dependence. 2014;139:100-5. Epub 2014/04/11. 
doi: 10.1016/j.drugalcdep.2014.03.013. PubMed PMID: 24717909; PMCID: 
PMC4071607. 
 
137 
 
116. Blaylock BL, Nader MA. Dopamine D3 receptor function and cocaine exposure. 
Neuropsychopharmacology. 2012;37(1):297-8. Epub 2011/12/14. doi: 
10.1038/npp.2011.170. PubMed PMID: 22157862; PMCID: PMC3238064. 
117. Keck TM, John WS, Czoty PW, Nader MA, Newman AH. Identifying Medication 
Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. 
J Med Chem. 2015;58(14):5361-80. Epub 2015/04/01. doi: 10.1021/jm501512b. PubMed 
PMID: 25826710; PMCID: PMC4516313. 
118. Siniscalchi A, Bonci AB, Mercuri NB, Pirritano D, Squillace A, Sarro GD, Gallelli 
L. The Role of Topiramate in the Management of Cocaine Addiction: A Possible 
Therapeutic Option. Current Neuropharmacology. 2015;13(6):815-8. doi: 
10.2174/1570159X13666150729222643. PubMed PMID: PMC4759320. 
119. Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, 
Liu L. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. 
JAMA psychiatry. 2013;70(12):1338-46. Epub 2013/10/18. doi: 
10.1001/jamapsychiatry.2013.2295. PubMed PMID: 24132249. 
120. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nature reviews 
Neuroscience. 2009;10(8):561-72. Epub 2009/07/03. doi: 10.1038/nrn2515. PubMed 
PMID: 19571793. 
121. Nocito Echevarria MA, Andrade Reis T, Ruffo Capatti G, Siciliano Soares V, da 
Silveira DX, Fidalgo TM. N-acetylcysteine for treating cocaine addiction - A systematic 
review. Psychiatry research. 2017;251:197-203. Epub 2017/02/19. doi: 
10.1016/j.psychres.2017.02.024. PubMed PMID: 28213190. 
122. Reichel CM, Moussawi K, Do PH, Kalivas PW, See RE. Chronic Treatment of N-
Acetylcysteine during Abstinence or Extinction after Cocaine Self-Administration 
Produces Enduring Reductions in Drug Seeking. Journal of Pharmacology and 
Experimental Therapeutics. 2011;337(2):487. 
123. Amen SL, Piacentine LB, Ahmad ME, Li S-J, Mantsch JR, Risinger RC, Baker DA. 
Repeated N-Acetyl Cysteine Reduces Cocaine Seeking in Rodents and Craving in Cocaine-
Dependent Humans. Neuropsychopharmacology. 2011;36(4):871-8. doi: 
10.1038/npp.2010.226. PubMed PMID: PMC3052624. 
124. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, Kalivas PW. 
N-Acetylcysteine Reverses Cocaine Induced Metaplasticity. Nature neuroscience. 
2009;12(2):182-9. doi: 10.1038/nn.2250. PubMed PMID: PMC2661026. 
125. Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE. N-
Acetylcysteine Normalizes Glutamate Levels in Cocaine-Dependent Patients: A 
Randomized Crossover Magnetic Resonance Spectroscopy Study. 
Neuropsychopharmacology. 2012;37:2143. doi: 10.1038/npp.2012.66. 
126. LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. 
A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine 
 
138 
 
dependence. American Journal on Addictions. 2013;22(5):443-52. doi: 10.1111/j.1521-
0391.2013.12034.x. 
127. Cannella N, Halbout B, Uhrig S, Evrard L, Corsi M, Corti C, Deroche-Gamonet V, 
Hansson AC, Spanagel R. The mGluR2/3 Agonist LY379268 Induced Anti-Reinstatement 
Effects in Rats Exhibiting Addiction-like Behavior. Neuropsychopharmacology. 
2013;38(10):2048-56. doi: 10.1038/npp.2013.106. PubMed PMID: PMC3746689. 
128. Kenny PJ, Boutrel B, Gasparini F, Koob GF, Markou A. Metabotropic glutamate 5 
receptor blockade may attenuate cocaine self-administration by decreasing brain reward 
function in rats. Psychopharmacology. 2005;179(1):247-54. doi: 10.1007/s00213-004-
2069-2. 
129. Keck TM, Yang H-J, Bi G-H, Huang Y, Zhang H-Y, Srivastava R, Gardner EL, 
Newman AH, Xi Z-X. Fenobam sulfate inhibits cocaine-taking and cocaine-seeking 
behavior in rats: implications for addiction treatment in humans. Psychopharmacology. 
2013;229(2):253-65. doi: 10.1007/s00213-013-3106-9. 
130. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of 
cocaine abuse. Drugs. 2004;64(14):1547-73. Epub 2004/07/06. PubMed PMID: 15233592. 
131. Gorelick DA. Pharmacokinetic strategies for treatment of drug overdose and 
addiction. Future medicinal chemistry. 2012;4(2):227-43. Epub 2012/02/04. doi: 
10.4155/fmc.11.190. PubMed PMID: 22300100; PMCID: PMC3297078. 
132. Pravetoni M. Biologics to treat substance use disorders: Current status and new 
directions. Hum Vaccin Immunother. 2016;12(12):3005-19. Epub 2016/07/22. doi: 
10.1080/21645515.2016.1212785. PubMed PMID: 27441896; PMCID: PMC5215474. 
133. Kantak KM, Collins SL, Bond J, Fox BS. Time course of changes in cocaine self-
administration behavior in rats during immunization with the cocaine vaccine IPC-1010. 
Psychopharmacology (Berl). 2001;153(3):334-40. Epub 2001/03/29. PubMed PMID: 
11271406. 
134. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. Evaluation of 
anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. 
Psychopharmacology (Berl). 2000;148(3):251-62. Epub 2001/02/07. PubMed PMID: 
10755738. 
135. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B. 
Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine. 2002;20(7-
8):1196-204. Epub 2002/01/23. PubMed PMID: 11803082. 
136. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy 
for the treatment of cocaine dependence. Biological psychiatry. 2005;58(2):158-64. Epub 
2005/07/26. doi: 10.1016/j.biopsych.2005.04.032. PubMed PMID: 16038686. 
137. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR. 
Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained 
patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen 
 
139 
 
Psychiatry. 2009;66(10):1116-23. Epub 2009/10/07. doi: 
10.1001/archgenpsychiatry.2009.128. PubMed PMID: 19805702; PMCID: PMC2878137. 
138. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW. Cocaine-specific 
antibodies blunt the subjective effects of smoked cocaine in humans. Biological psychiatry. 
2010;67(1):59-65. Epub 2009/10/23. doi: 10.1016/j.biopsych.2009.08.031. PubMed PMID: 
19846066; PMCID: PMC3319755. 
139. Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, 
Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, 
Kampman K. Vaccine for cocaine dependence: a randomized double-blind placebo-
controlled efficacy trial. Drug and alcohol dependence. 2014;140:42-7. Epub 2014/05/06. 
doi: 10.1016/j.drugalcdep.2014.04.003. PubMed PMID: 24793366; PMCID: 
PMC4073297. 
140. Wee S, Hicks MJ, De BP, Rosenberg JB, Moreno AY, Kaminsky SM, Janda KD, 
Crystal RG, Koob GF. Novel cocaine vaccine linked to a disrupted adenovirus gene 
transfer vector blocks cocaine psychostimulant and reinforcing effects. 
Neuropsychopharmacology. 2012;37(5):1083-91. Epub 2011/09/16. doi: 
10.1038/npp.2011.200. PubMed PMID: 21918504; PMCID: PMC3306868. 
141. Maoz A, Hicks MJ, Vallabhjosula S, Synan M, Kothari PJ, Dyke JP, Ballon DJ, 
Kaminsky SM, De BP, Rosenberg JB, Martinez D, Koob GF, Janda KD, Crystal RG. 
Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the 
nonhuman primate CNS dopamine transporter. Neuropsychopharmacology. 
2013;38(11):2170-8. Epub 2013/05/11. doi: 10.1038/npp.2013.114. PubMed PMID: 
23660705; PMCID: PMC3773666. 
142. Zalewska-Kaszubska J. Is immunotherapy an opportunity for effective treatment of 
drug addiction? Vaccine. 2015;33(48):6545-51. Epub 2015/10/04. doi: 
10.1016/j.vaccine.2015.09.079. PubMed PMID: 26432911. 
143. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French 
TL, Thompson TL, Schad VC, Greenstein JL, Gefter ML, Exley MA, Swain PA, Briner 
TJ. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med. 1996;2(10):1129-
32. Epub 1996/10/01. PubMed PMID: 8837612. 
144. Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Cocaine 
vaccines: antibody protection against relapse in a rat model. Proceedings of the National 
Academy of Sciences of the United States of America. 2000;97(11):6202-6. Epub 
2000/05/24. PubMed PMID: 10823960; PMCID: PMC18582. 
145. Carrera MR, Trigo JM, Wirsching P, Roberts AJ, Janda KD. Evaluation of the 
anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. 
Pharmacology, biochemistry, and behavior. 2005;81(4):709-14. Epub 2005/07/12. doi: 
10.1016/j.pbb.2005.04.018. PubMed PMID: 16005948. 
146. Paula S, Tabet MR, Farr CD, Norman AB, Ball WJ, Jr. Three-dimensional 
quantitative structure-activity relationship modeling of cocaine binding by a novel human 
 
140 
 
monoclonal antibody. J Med Chem. 2004;47(1):133-42. Epub 2003/12/30. doi: 
10.1021/jm030351z. PubMed PMID: 14695827. 
147. Norman AB, Tabet MR, Norman MK, Buesing WR, Pesce AJ, Ball WJ. A chimeric 
human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the 
brain in mice. The Journal of pharmacology and experimental therapeutics. 
2007;320(1):145-53. Epub 2006/10/07. doi: 10.1124/jpet.106.111781. PubMed PMID: 
17023573. 
148. Norman AB, Norman MK, Buesing WR, Tabet MR, Tsibulsky VL, Ball WJ. The 
effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-
administration in rats. The Journal of pharmacology and experimental therapeutics. 
2009;328(3):873-81. Epub 2008/12/18. doi: 10.1124/jpet.108.146407. PubMed PMID: 
19088302; PMCID: PMC2682256. 
149. Yang G, Chun J, Arakawa-Uramoto H, Wang X, Gawinowicz MA, Zhao K, Landry 
DW. Anti-Cocaine Catalytic Antibodies:  A Synthetic Approach to Improved Antibody 
Diversity. Journal of the American Chemical Society. 1996;118(25):5881-90. doi: 
10.1021/ja953077+. 
150. Mets B, Winger G, Cabrera C, Seo S, Jamdar S, Yang G, Zhao K, Briscoe RJ, 
Almonte R, Woods JH. A catalytic antibody against cocaine prevents cocaine’s reinforcing 
and toxic effects in rats. Proceedings of the National Academy of Sciences. 
1998;95(17):10176-81. 
151. Baird TJ, Deng SX, Landry DW, Winger G, Woods JH. Natural and artificial 
enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of 
cocaine in rats. The Journal of pharmacology and experimental therapeutics. 
2000;295(3):1127-34. Epub 2000/11/18. PubMed PMID: 11082449. 
152. Briscoe RJ, Jeanville PM, Cabrera C, Baird TJ, Woods JH, Landry DW. A catalytic 
antibody against cocaine attenuates cocaine's cardiovascular effects in mice: a dose and 
time course analysis. Int Immunopharmacol. 2001;1(6):1189-98. Epub 2001/06/16. 
PubMed PMID: 11407313. 
153. Bresler MM, Rosser SJ, Basran A, Bruce NC. Gene cloning and nucleotide 
sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl 
Environ Microbiol. 2000;66(3):904-8. Epub 2000/03/04. PubMed PMID: 10698749; 
PMCID: PMC91920. 
154. Larsen NA, Turner JM, Stevens J, Rosser SJ, Basran A, Lerner RA, Bruce NC, 
Wilson IA. Crystal structure of a bacterial cocaine esterase. Nat Struct Biol. 2002;9(1):17-
21. Epub 2001/12/14. doi: 10.1038/nsb742. PubMed PMID: 11742345. 
155. Narasimhan D, Woods JH, Sunahara RK. Bacterial cocaine esterase: a protein-
based therapy for cocaine overdose and addiction. Future medicinal chemistry. 
2012;4(2):137-50. Epub 2012/02/04. doi: 10.4155/fmc.11.194. PubMed PMID: 22300094; 
PMCID: PMC3290992. 
 
141 
 
156. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen 
NA, Wilson IA, Landry DW, Woods JH. Rapid and robust protection against cocaine-
induced lethality in rats by the bacterial cocaine esterase. Molecular pharmacology. 
2006;70(6):1885-91. Epub 2006/09/14. doi: 10.1124/mol.106.025999. PubMed PMID: 
16968810. 
157. Gao D, Narasimhan DL, Macdonald J, Brim R, Ko MC, Landry DW, Woods JH, 
Sunahara RK, Zhan CG. Thermostable variants of cocaine esterase for long-time protection 
against cocaine toxicity. Molecular pharmacology. 2009;75(2):318-23. Epub 2008/11/07. 
doi: 10.1124/mol.108.049486. PubMed PMID: 18987161; PMCID: PMC2684895. 
158. Collins GT, Brim RL, Narasimhan D, Ko MC, Sunahara RK, Zhan CG, Woods JH. 
Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-
administration of cocaine in rats. The Journal of pharmacology and experimental 
therapeutics. 2009;331(2):445-55. Epub 2009/08/28. doi: 10.1124/jpet.108.150029. 
PubMed PMID: 19710369; PMCID: 2775252. 
159. Collins GT, Zaks ME, Cunningham AR, St Clair C, Nichols J, Narasimhan D, Ko 
M-C, Sunahara RK, Woods JH. Effects of a long-acting mutant bacterial cocaine esterase 
on acute cocaine toxicity in rats. Drug Alcohol Depend. 2011 118:158-65. 
160. Collins GT, Carey KA, Narasimhan D, Nichols J, Berlin AA, Lukacs NW, 
Sunahara RK, Woods JH, Ko MC. Amelioration of the cardiovascular effects of cocaine 
in rhesus monkeys by a long-acting mutant form of cocaine esterase. 
Neuropsychopharmacology. 2011;36(5):1047-59. Epub 2011/02/04. doi: 
10.1038/npp.2010.242. PubMed PMID: 21289605; PMCID: PMC3076304. 
161. Nasser AF, Fudala PJ, Zheng B, Liu Y, Heidbreder C. A randomized, double-blind, 
placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-
8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects. J 
Addict Dis. 2014;33(4):289-302. Epub 2014/10/10. doi: 10.1080/10550887.2014.969603. 
PubMed PMID: 25299069. 
162. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a 
treatment strategy. Drug and alcohol dependence. 1997;48(3):159-65. Epub 1998/02/04. 
PubMed PMID: 9449014. 
163. Saxena A, Sun W, Fedorko JM, Koplovitz I, Doctor BP. Prophylaxis with human 
serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman 
or VX. Biochemical pharmacology. 2011;81(1):164-9. Epub 2010/09/18. doi: 
10.1016/j.bcp.2010.09.007. PubMed PMID: 20846507. 
164. Saxena A, Sun W, Luo C, Doctor BP. Human serum butyrylcholinesterase: in vitro 
and in vivo stability, pharmacokinetics, and safety in mice. Chemico-biological 
interactions. 2005;157-158:199-203. Epub 2005/11/03. doi: 10.1016/j.cbi.2005.10.028. 
PubMed PMID: 16263104. 
165. Lockridge O. Review of human butyrylcholinesterase structure, function, genetic 
variants, history of use in the clinic, and potential therapeutic uses. Pharmacology & 
therapeutics. 2014. 
 
142 
 
166. Sun H, Pang YP, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase 
as a cocaine hydrolase. Molecular pharmacology. 2002;62(2):220-4. Epub 2002/07/20. 
PubMed PMID: 12130672. 
167. Zheng F, Xue L, Hou S, Liu J, Zhan M, Yang W, Zhan CG. A highly efficient 
cocaine-detoxifying enzyme obtained by computational design. Nature communications. 
2014;5:3457. Epub 2014/03/20. doi: 10.1038/ncomms4457. PubMed PMID: 24643289; 
PMCID: PMC3996704. 
168. Pan Y, Gao D, Yang W, Cho H, Yang G, Tai HH, Zhan CG. Computational 
redesign of human butyrylcholinesterase for anticocaine medication. Proceedings of the 
National Academy of Sciences of the United States of America. 2005;102(46):16656-61. 
Epub 2005/11/09. doi: 10.1073/pnas.0507332102. PubMed PMID: 16275916; PMCID: 
PMC1283827. 
169. Zheng F, Yang W, Ko MC, Liu J, Cho H, Gao D, Tong M, Tai HH, Woods JH, 
Zhan CG. Most efficient cocaine hydrolase designed by virtual screening of transition 
states. Journal of the American Chemical Society. 2008;130(36):12148-55. Epub 
2008/08/20. doi: 10.1021/ja803646t. PubMed PMID: 18710224; PMCID: PMC2646118. 
170. Yang W, Xue L, Fang L, Chen X, Zhan CG. Characterization of a high-activity 
mutant of human butyrylcholinesterase against (-)-cocaine. Chemico-biological 
interactions. 2010;187(1-3):148-52. Epub 2010/01/12. doi: 10.1016/j.cbi.2010.01.004. 
PubMed PMID: 20060817; PMCID: PMC2891156. 
171. Xue L, Hou S, Yang W, Fang L, Zheng F, Zhan CG. Catalytic activities of a cocaine 
hydrolase engineered from human butyrylcholinesterase against (+)- and (-)-cocaine. 
Chemico-biological interactions. 2013;203(1):57-62. Epub 2012/08/25. doi: 
10.1016/j.cbi.2012.08.003. PubMed PMID: 22917637; PMCID: PMC3527670. 
172. Hou S, Xue L, Yang W, Fang L, Zheng F, Zhan CG. Substrate selectivity of high-
activity mutants of human butyrylcholinesterase. Organic & biomolecular chemistry. 
2013;11(43):7477-85. Epub 2013/10/01. doi: 10.1039/c3ob41713a. PubMed PMID: 
24077614; PMCID: PMC3836059. 
173. Xue L, Hou S, Tong M, Fang L, Chen X, Jin Z, Tai HH, Zheng F, Zhan CG. 
Preparation and in vivo characterization of a cocaine hydrolase engineered from human 
butyrylcholinesterase for metabolizing cocaine. The Biochemical journal. 
2013;453(3):447-54. Epub 2013/07/16. doi: 10.1042/BJ20130549. PubMed PMID: 
23849058; PMCID: PMC4365901. 
174. Fang L, Hou S, Xue L, Zheng F, Zhan CG. Amino-acid mutations to extend the 
biological half-life of a therapeutically valuable mutant of human butyrylcholinesterase. 
Chemico-biological interactions. 2014;214:18-25. Epub 2014/03/04. doi: 
10.1016/j.cbi.2014.02.007. PubMed PMID: 24582612; PMCID: 3996703. 
175. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. 
Current opinion in biotechnology. 2011;22(6):868-76. Epub 2011/08/25. doi: 
10.1016/j.copbio.2011.06.012. PubMed PMID: 21862310. 
 
143 
 
176. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R, Zhao Q, Singh M, 
Carroll ME. A cocaine hydrolase engineered from human butyrylcholinesterase selectively 
blocks cocaine toxicity and reinstatement of drug seeking in rats. 
Neuropsychopharmacology. 2008;33(11):2715-25. Epub 2008/01/18. doi: 
10.1038/sj.npp.1301666. PubMed PMID: 18199998; PMCID: 2562914. 
177. Carroll ME, Gao Y, Brimijoin S, Anker JJ. Effects of cocaine hydrolase on cocaine 
self-administration under a PR schedule and during extended access (escalation) in rats. 
Psychopharmacology (Berl). 2011;213(4):817-29. Epub 2010/10/26. doi: 10.1007/s00213-
010-2040-3. PubMed PMID: 20972552; PMCID: 3631565. 
178. Schindler CW, Justinova Z, Lafleur D, Woods D, Roschke V, Hallak H, Sklair-
Tavron L, Redhi GH, Yasar S, Bergman J, Goldberg SR. Modification of pharmacokinetic 
and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. 
Addiction biology. 2013;18(1):30-9. Epub 2012/01/24. doi: 10.1111/j.1369-
1600.2011.00424.x. PubMed PMID: 22264200; PMCID: PMC3337883. 
179. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S. An albumin-
butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic 
properties. Chemico-biological interactions. 2008;175(1-3):83-7. Epub 2008/06/03. doi: 
10.1016/j.cbi.2008.04.024. PubMed PMID: 18514640; PMCID: 2536750. 
180. Cohen-Barak O, Wildeman J, van de Wetering J, Hettinga J, Schuilenga-Hut P, 
Gross A, Clark S, Bassan M, Gilgun-Sherki Y, Mendzelevski B, Spiegelstein O. Safety, 
Pharmacokinetics, and Pharmacodynamics of TV-1380, a Novel Mutated 
Butyrylcholinesterase Treatment for Cocaine Addiction, After Single and Multiple 
Intramuscular Injections in Healthy Subjects. Journal of clinical pharmacology. 2014. 
Epub 2014/12/20. doi: 10.1002/jcph.450. PubMed PMID: 25524052. 
181. Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, 
Eyal E, Weiss S, Gilgun-Serki Y, Sellers EM, Faulknor J, Spiegelstein O. Assessment of 
Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated 
Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine 
Users. J Clin Psychopharmacol. 2015;35(4):396-405. Epub 2015/06/18. doi: 
10.1097/JCP.0000000000000347. PubMed PMID: 26082975. 
182. Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, Cohen-Barak 
O, Hallak H, Chiang N, Gyaw S. Placebo-controlled evaluation of a bioengineered, 
cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine 
dependence. Drug and alcohol dependence. 2016;166:13-20. Epub 2016/07/11. doi: 
10.1016/j.drugalcdep.2016.05.019. PubMed PMID: 27394932. 
183. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao S-W, Lencer WI, Pierce 
GF, Blumberg RS. Fc-fusion proteins and FcRn: structural insights for longer-lasting and 
more effective therapeutics. Critical reviews in biotechnology. 2015;35(2):235-54. doi: 
10.3109/07388551.2013.834293. PubMed PMID: PMC4876602. 
 
144 
 
184. Baldo BA. Chimeric fusion proteins used for therapy: indications, mechanisms, and 
safety. Drug safety. 2015;38(5):455-79. Epub 2015/04/03. doi: 10.1007/s40264-015-0285-
9. PubMed PMID: 25832756. 
185. Strohl WR. Fusion Proteins for Half-Life Extension of Biologics as a Strategy to 
Make Biobetters. BioDrugs. 2015;29(4):215-39. Epub 2015/07/17. doi: 10.1007/s40259-
015-0133-6. PubMed PMID: 26177629; PMCID: PMC4562006. 
186. Chen X, Xue L, Hou S, Jin Z, Zhang T, Zheng F, Zhan CG. Long-acting cocaine 
hydrolase for addiction therapy. Proceedings of the National Academy of Sciences of the 
United States of America. 2016;113(2):422-7. Epub 2015/12/30. doi: 
10.1073/pnas.1517713113. PubMed PMID: 26712009; PMCID: PMC4720324. 
187. Collins GT, Zaks ME, Cunningham AR, St Clair C, Nichols J, Narasimhan D, Ko 
MC, Sunahara RK, Woods JH. Effects of a long-acting mutant bacterial cocaine esterase 
on acute cocaine toxicity in rats. Drug and alcohol dependence. 2011;118(2-3):158-65. 
Epub 2011/04/13. doi: 10.1016/j.drugalcdep.2011.03.015. PubMed PMID: 21481548; 
PMCID: PMC3150623. 
188. Wood SK, Narasimhan D, Cooper Z, Sunahara RK, Woods JH. Prevention and 
reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug and 
alcohol dependence. 2010;106(2-3):219-29. Epub 2009/10/06. doi: 
10.1016/j.drugalcdep.2009.09.001. PubMed PMID: 19800183; PMCID: PMC3349347. 
189. Narasimhan D, Collins GT, Nance MR, Nichols J, Edwald E, Chan J, Ko MC, 
Woods JH, Tesmer JJ, Sunahara RK. Subunit stabilization and polyethylene glycolation of 
cocaine esterase improves in vivo residence time. Molecular pharmacology. 
2011;80(6):1056-65. Epub 2011/09/06. doi: 10.1124/mol.111.074997. PubMed PMID: 
21890748; PMCID: PMC3228533. 
190. Collins GT, Narasimhan D, Cunningham AR, Zaks ME, Nichols J, Ko MC, 
Sunahara RK, Woods JH. Long-lasting effects of a PEGylated mutant cocaine esterase 
(CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. 
Neuropsychopharmacology. 2012;37(5):1092-103. Epub 2011/10/14. doi: 
10.1038/npp.2011.226. PubMed PMID: 21993206; PMCID: PMC3306869. 
191. Shemesh-Darvish L, Shinar D, Hallak H, Gross A, Rosenstock M. TV-1380 
attenuates cocaine-induced changes in cardiodynamic parameters in monkeys and reduces 
the formation of cocaethylene. Drug and alcohol dependence. 2018;188:295-303. doi: 
https://doi.org/10.1016/j.drugalcdep.2018.01.033. 
192. Cohen-Barak O, Wildeman J, van de Wetering J, Hettinga J, Schuilenga-Hut P, 
Gross A, Clark S, Bassan M, Gilgun-Sherki Y, Mendzelevski B, Spiegelstein O. Safety, 
pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated 
butyrylcholinesterase treatment for cocaine addiction, after single and multiple 
intramuscular injections in healthy subjects. Journal of clinical pharmacology. 
2015;55(5):573-83. Epub 2014/12/20. doi: 10.1002/jcph.450. PubMed PMID: 25524052; 
PMCID: PMC4402032. 
 
145 
 
193. Xue L, Ko MC, Tong M, Yang W, Hou S, Fang L, Liu J, Zheng F, Woods JH, Tai 
HH, Zhan CG. Design, preparation, and characterization of high-activity mutants of human 
butyrylcholinesterase specific for detoxification of cocaine. Molecular pharmacology. 
2011;79(2):290-7. Epub 2010/10/26. doi: 10.1124/mol.110.068494. PubMed PMID: 
20971807; PMCID: PMC3033707. 
194. Burnett LB, Roldan CJ, Adler J. Cocaine Toxicity Treatment & Management. 
http://emedicinemedscapecom/article/813959-treatment Updated Jun 30, 2016, (accessed 
July 28, 2017). 
195. Skolnick P, White D, Acri JB. Editorial: Emerging Targets for Stimulant Use 
Disorders: Where To Invest In An Era Of Constrained Resources? CNS & Neurological 
Disorders - Drug Targets. 2015;14:691. 
196. Zheng F, Zhan CG. Are pharmacokinetic approaches feasible for treatment of 
cocaine addiction and overdose? Future medicinal chemistry. 2012;4(2):125-8. Epub 
2012/02/04. doi: 10.4155/fmc.11.171. PubMed PMID: 22300091; PMCID: PMC4373604. 
197. Cohen-Barak O, Wildeman J, van de Wetering J, Hettinga J, Schuilenga-Hut P, 
Gross A, Clark S, Bassan M, Gilgun-Sherki Y, Mendzelevski B, Spiegelstein O. Safety, 
Pharmacokinetics, and Pharmacodynamics of TV-1380, a Novel Mutated 
Butyrylcholinesterase Treatment for Cocaine Addiction, After Single and Multiple 
Intramuscular Injections in Healthy Subjects. J Clin Pharmacol. 2015;55:573-83. 
198. Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, 
Eyal E, Weiss S, Gilgun Y, Sellers EM, Faulknor J, Spiegelstein O. Assessment of 
Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated 
Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine 
Users. J Clin Psychopharmacol. 2015 35:396-405. 
199. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, LaFleur D, Shah R, Zhao Q, Singh M, 
Carroll ME. A Cocaine Hydrolase Engineered from Human Butyrylcholinesterase 
Selectively Blocks Cocaine Toxicity and Reinstatement of Drug Seeking in Rats. 
Neuropsychopharmacology. 2008;33(11):2715-25. 
200. Xue L, Ko M-C, Tong M, Yang W, Hou S, Fang L, Liu J, Zheng F, Woods JH, Tai 
H-H, Zhan C-G. Design, preparation, and characterization of high-activity mutants of 
human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol. 
2011;79:290-7. 
201. Zheng F, Xue L, Hou S, Liu J, Zhan M, Yang W, Zhan C-G. A highly efficient 
cocaine-detoxifying enzyme obtained by computational design. Nature Commun. 
2014;5:3457. doi: 10.1388/ncomms4457. 
202. Chen X, Xue L, Hou S, Jin Z, Zhang T, Zheng F, Zhan C-G. Long-acting cocaine 
hydrolase for addiction therapy. Proc Natl Acad Sci USA. 2016;113:422-7. 
203. Xue L, Hou S, Tong M, Fang L, Chen X, Jin Z, Tai H-H, Zheng F, Zhan C-G. 
Preparation and in vivo characterization of a cocaine hydrolase engineered from human 
butyrylcholinesterase for metabolizing cocaine. Biochem J. 2013;453:447-54. 
 
146 
 
204. Brim RL, Nance MR, Youngstrom DW, Narasimhan D, Zhan CG, Tesmer JJ, 
Sunahara RK, Woods JH. A thermally stable form of bacterial cocaine esterase: a potential 
therapeutic agent for treatment of cocaine abuse. Molecular pharmacology. 
2010;77(4):593-600. Epub 2010/01/21. doi: 10.1124/mol.109.060806. PubMed PMID: 
20086035; PMCID: PMC2845945. 
205. Fang L, Chow KM, Hou S, Xue L, Chen X, Rodgers DW, Zheng F, Zhan CG. 
Rational design, preparation, and characterization of a therapeutic enzyme mutant with 
improved stability and function for cocaine detoxification. ACS chemical biology. 
2014;9(8):1764-72. Epub 2014/06/12. doi: 10.1021/cb500257s. PubMed PMID: 24919140; 
PMCID: PMC4136690. 
206. Ko MC, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Woods JH. Effects 
of cocaine esterase following its repeated administration with cocaine in mice. Drug and 
alcohol dependence. 2009;101(3):202-9. Epub 2009/02/17. doi: 
10.1016/j.drugalcdep.2009.01.002. PubMed PMID: 19217723; PMCID: PMC2693214. 
207. Connors NJ, Hoffman RS. Experimental treatments for cocaine toxicity: a difficult 
transition to the bedside. The Journal of pharmacology and experimental therapeutics. 
2013;347(2):251-7. Epub 2013/08/28. doi: 10.1124/jpet.113.206383. PubMed PMID: 
23978563. 
208. Zheng F, Zhan CG. Modeling of pharmacokinetics of cocaine in human reveals the 
feasibility for development of enzyme therapies for drugs of abuse. PLoS computational 
biology. 2012;8(7):e1002610. Epub 2012/07/31. doi: 10.1371/journal.pcbi.1002610. 
PubMed PMID: 22844238; PMCID: PMC3406004. 
209. Nasser AF, Fudala PJ, Zheng B, Liu Y, Heidbreder C. A randomized, double-blind, 
placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-
8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects. J 
Addict Dis. 2014;33:289-302. 
210. Amin M, Gabelman G, Karpel J, Buttrick P. Acute myocardial infarction and chest 
pain syndromes after cocaine use. Am J Cardiol. 1990;66:1434–7. 
211. Zhang T, Zheng X, Zhou Z, Chen X, Jin Z, Deng J, Zhan C-G, Zheng F. Clinical 
Potential of an Enzyme-based Novel Therapy for Cocaine Overdose. Scientific Reports. 
2017;7(1):15303. doi: 10.1038/s41598-017-14105-5. 
212. Chen X, Zheng X, Ding K, Zhou Z, Zhan CG, Zheng F. A quantitative LC-MS/MS 
method for simultaneous determination of cocaine and its metabolites in whole blood. J 
Pharm Biomed Anal. 2017;134:243-51. Epub 2016/12/07. doi: 10.1016/j.jpba.2016.11.024. 
PubMed PMID: 27923200; PMCID: PMC5196007. 
213. Ko MC, Bowen LD, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Cooper 
ZD, Woods JH. Cocaine esterase: interactions with cocaine and immune responses in mice. 
The Journal of pharmacology and experimental therapeutics. 2007;320(2):926-33. Epub 
2006/11/23. doi: 10.1124/jpet.106.114223. PubMed PMID: 17114567. 
 
147 
 
214. Ellinwood EH, Jr., Balster RL. Rating the behavioral effects of amphetamine. Eur 
J Pharmacol. 1974;28(1):35-41. Epub 1974/09/01. PubMed PMID: 4473346. 
215. Tseng CC, Derlet RW, Albertson TE. Acute cocaine toxicity: the effect of agents 
in non-seizure-induced death. Pharmacology, biochemistry, and behavior. 1993;46(1):61-
5. Epub 1993/09/01. PubMed PMID: 8255923. 
216. Treadwell SD, Robinson TG. Cocaine use and stroke. Postgrad Med J. 2007 
83:389-94. 
217. Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, Cohen-Barak 
O, Hallak H, Chiang N, Gyaw S. Placebo-controlled evaluation of a bioengineered, 
cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine 
dependence. Drug Alcohol Depend. 2016;166:13-20. 
218. Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory 
of addiction. The American psychologist. 2016;71(8):670-9. Epub 2016/12/16. doi: 
10.1037/amp0000059. PubMed PMID: 27977239; PMCID: PMC5171207. 
219. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by 
chronic amphetamine administration: A review and evaluation of animal models of 
amphetamine psychosis. Brain Research Reviews. 1986;11(2):157-98. doi: 10.1016/0165-
0173(86)90002-0. 
220. Segal DS. Behavioral and neurochemical correlates of repeated d-amphetamine 
administration. Advances in biochemical psychopharmacology. 1975;13:247-62. 
221. Post RM, Rose H. Increasing effects of repetitive cocaine administration in the rat. 
Nature. 1976;260(5553):731-2. doi: 10.1038/260731a0. 
222. Carroll ME, Zlebnik NE, Anker JJ, Kosten TR, Orson FM, Shen X, Kinsey B, Parks 
RJ, Gao Y, Brimijoin S. Combined cocaine hydrolase gene transfer and anti-cocaine 
vaccine synergistically block cocaine-induced locomotion. PloS one. 2012;7(8):e43536. 
Epub 2012/08/23. doi: 10.1371/journal.pone.0043536. PubMed PMID: 22912888; PMCID: 
PMC3422258. 
223. Wee S, Hicks MJ, De Bishnu P, Rosenberg JB, Moreno AY, Kaminsky SM, Janda 
KD, Crystal RG, Koob GF. Novel cocaine vaccine linked to a disrupted adenovirus gene 
transfer vector blocks cocaine psychostimulant and reinforcing effects. 
Neuropsychopharmacology. 2012;37(5):1083-91. 
224. Thrivikraman KV, Huot RL, Plotsky PM. Jugular vein catheterization for repeated 
blood sampling in the unrestrained conscious rat. Brain Res Brain Res Protoc. 
2002;10(2):84-94. PubMed PMID: 12431707. 
225. Barrett AC, Miller JR, Dohrmann JM, Caine SB. Effects of dopamine indirect 
agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-
administration and food maintained responding in rats. Neuropharmacology. 2004;47:256-
73. 
 
148 
 
226. Becker JB, Koob GF. Sex Differences in Animal Models: Focus on Addiction. 
Pharmacol Rev. 2016;68(2):242-63. Epub 2016/01/17. doi: 10.1124/pr.115.011163. 
PubMed PMID: 26772794; PMCID: PMC4813426. 
227. Zheng X, Zhou Z, Zhang T, Jin Z, Chen X, Deng J, Zhan C-G, Zheng F. 
Effectiveness of a Cocaine Hydrolase for Cocaine Toxicity Treatment in Male and Female 
Rats. The AAPS journal. 2017;20(1):3. doi: 10.1208/s12248-017-0167-4. 
228. Volkow ND, Woodcock J, Compton WM, Throckmorton DC, Skolnick P, Hertz S, 
Wargo EM. Medication development in opioid addiction: Meaningful clinical end points. 
Science translational medicine. 2018;10(434). Epub 2018/03/30. doi: 
10.1126/scitranslmed.aan2595. PubMed PMID: 29593105. 
229. Volkow ND, Boyle M. Neuroscience of Addiction: Relevance to Prevention and 
Treatment. The American journal of psychiatry. 2018:appiajp201817101174. Epub 
2018/04/25. doi: 10.1176/appi.ajp.2018.17101174. PubMed PMID: 29690790. 
 
  
 
149 
 
CURRICULUM VITAE 
 
EDUCATION 
08/2013 - Current Graduate student, Pharmaceutical Sciences 
University of Kentucky, Lexington, KY 
08/2010 - 05/2013 
 
M.S., Biology  
University of Kentucky, Lexington, KY 
09/2007 - 07/2010 
 
M.S., Cognitive Neuroscience 
Institute of Psychology, Chinese Academy of Sciences, Beijing, 
China 
09/2004 - 07/2007 
 
B.S., Life Science 
China Agricultural University, Beijing, China 
 
RESEARCH EXPERIENCE 
Advisor: Chang-Guo Zhan, Ph.D., University of Kentucky, Lexington, KY 
 Development and preclinical evaluation of enzyme-based therapies for cocaine 
overdose and cocaine use disorder 
Advisor: Bruce O’Hara, Ph.D., University of Kentucky, Lexington, KY 
 Identify Quantitative trait locus (QTLs) associated with temporal dynamics of sleep 
using expanded BXD recombinant inbred panel 
 Improve and validate the non-invasive Piezo system for sleep architecture 
screening 
Advisor: Fei Luo, Ph.D., Institute of Psychology, CAS, Beijing, China 
 The preliminary study of analgesia effect caused by deep brain stimulation on 
animal models of inflammatory and neuropathic pain 
 Study the impact of cortical outputs on formalin induced pain behavior in rats 
  
 
150 
 
 
PUBLICATION 
1. Zhang T, Su YL, Wang N, Wang JY, Luo F. Progress of basic researches and 
clinical application on deep brain stimulation-induced analgesia effect. Chinese 
Journal of Pain Medicine, 2011, 12: 752 – 756 (Review in Chinese) 
2. Wang N, Zhang T, Su YL, Wang JY, Luo F. Differential modulation of electrical 
stimulation of periaqueductal gray and thalamus on nociceptive behaviors of rats. 
Sheng Li Xue Bao, 2016,68(2):115-125. 
3. Chen X, Xue L, Hou S, Jin Z, Zhang T, Zheng F, Zhan CG. Long-acting cocaine 
hydrolase for addiction therapy. Proc Natl Acad Sci USA. 2016 Jan 12;113(2):422-
7. 
4. Zheng X, Deng J, Zhang T, Yao J, Zheng F, Zhan CG. Potential anti-obesity effects 
of a long-acting cocaine hydrolase. Chem Biol Interact. 2016 Nov 25;259(Pt B):99-
103. 
5. Wang G, Zhang T, Huang H, Hou S, Chen X, Zheng F, Zhan CG. Plant expression 
of cocaine hydrolase-Fc fusion protein for treatment of cocaine abuse. BMC 
Biotechnol. 2016 Oct 19;16(1):72. 
6. Zhang T, Zheng X, Zhou Z, Chen X, Jin Z, Deng J, Zheng F, Zhan CG.  Clinical 
potential of an enzyme-based novel therapy for cocaine overdose. Sci. Rep. 2017 
Nov 10;7(1):15303.  
7. Zheng X, Zhou Z, Zhang T, Chen X, Jin Z, Deng J, Zhan CG, Zheng F.  
Effectiveness of a cocaine hydrolase for cocaine toxicity treatment in male and 
female rats. AAPS J. 2017 Nov 27;20(1):3. 
8. Ding K, Zhou Z, Zhou S, Yuan Y, Kim K, Zhang T, Zheng X, Zheng F, Zhan CG. 
Design, synthesis, and discovery of 5-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones and related derivatives as novel 
inhibitors of mPGES-1. Bioorg Med Chem Lett. 2018 Mar 1;28(5):858-862. 
 
